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Chronic pain occurs due to a maladaptive response of the nociceptive system. As a global 
health issue, the discovery of novel pain treatments is key to reducing the substantial 
economic burden associated with this condition, as well as the myriad of co-morbid diseases. 
Data from pre-clinical mouse models of chronic pain have shown a superior analgesic effect 
when using a bispecific blocker directed against both nerve growth factor (NGF) and tumour 
necrosis factor (TNFα) compared to targeting either one alone. Here, we tested the 
hypothesis that synergistic interactions exist between these two pain-relevant mediators. In 
primary neuronal cultures and a novel co-culture system, comprising mouse adult dorsal root 
ganglia (DRG) neurones with bone-marrow derived macrophages (BMDM), we quantified 
gene expression and functional cellular responses to NGF, TNFα or a combination of the two, 
assaying for additive or synergistic actions of these two mediators.  We demonstrate robust 
responses of highly purified DRG neuronal cultures to NGF but fail to detect TNFα 
responsiveness. However, using our novel adult DRG neurone-macrophage co-culture system 
we highlight a role for NGF and TNFα in sensitising primary afferent CGRP release. We show 
a critical role for macrophages in delivering TNFα-driven sensitisation, which appears to 
summate with the direct NGF sensitisation of DRG neurones. In a mouse models of 
inflammatory chronic pain, we detect an increase in Cd14 and Itgam mRNA within pain-
relevant tissue (DRG and knee fat pad), indicative of myeloid cells (most likely macrophage) 
infiltration. Combined individual antagonism of NGF and TNFα does not prevent these 
increases in mRNA levels from occurring post intra-articular CFA (Complete Freund’s 




BMDM enhances the expression of several pain-relevant transcripts in purified DRG cultures. 
These data suggest that the mechanism(s) by which the dual blockade (of NGF and TNFα) 
regulates analgesia is not simply by an inhibition of non-neuronal cell type infiltration into 
pain-relevant tissue types, but more likely to be dependent on a combined dampening of 
neuronal sensitisation evoked by the TNFα-induced macrophage secretome and the direct 
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GPCRs G-Protein Coupled Receptors 
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GPR84 G-Protein Coupled Receptor 84 
HBSS Hank’s Balanced Salt Solution 
HIV Human Immunodeficiency Virus 
HSAN-IV Hereditary Sensory and Autonomic Neuropathy Type IV 
HTRF Homogenous Time Resolved Fluorescence 
IB4 Isolectin B4 
ICC Immunocytochemistry 
IFNβ1 Interferon Beta 1 
IFNγR1 Interferon Gamma Receptor 1 
IFNγR2 Interferon Gamma Receptor 2 
IL-1β Interleukin 1 Beta 
IL-3 Interleukin 3 
IL-6 Interleukin 6 
IL6RA Interleukin 6 Receptor Subunit Alpha 
IL10RA Interleukin 10 Receptor Subunit Alpha 
IL-11 Interleukin 11 
IL-17A Interleukin 17A 
IL-18 Interleukin 18 
ITGAM Integrin Subunit Alpha M 
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JAK2 Janus Kinase 2 
JNK c-Jun N-Terminal Kinase 
LDH Lactate Dehydrogenase 
LEP Leptin 
LIMMA Linear Model for Micro Array Data 
LLOQ Lower Limits of Quantification 
LPS Lipopolysaccharide 
LTP Long-Term Potentiation 
MACS Magnetic-Activated Cell Sorting 
MAPK Mitogen-Activated Protein Kinase 
MCSF Macrophage Colony-Stimulating Factor 
mTNFα Membrane Tumour Necrosis Factor Alpha 
NF-κB Nuclear Factor Kappa-Light-Chain Enhancer of Activated B Cells 
NGF Nerve Growth Factor 
NGFR Nerve Growth Factor Receptor 
NMDA N-Methyl-D-Aspartate 
NO Nitric Oxide 
NOS1 Nitric Oxide Synthase 1 
NOS2 Nitric Oxide Synthase 2 
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NPY Neuropeptide Y 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
NTRK1 Neurotrophic Receptor Tyrosine Kinase 1 
NTRK2 Neurotrophic Receptor Tyrosine Kinase 2 
NTRK3 Neurotrophic Receptor Tyrosine Kinase 3 
NT3 Neurotrophin 3 
NT4 Neurotrophin 4 
NT5 Neurotrophin 5 
OA Osteoarthritis 
OPRM1 Opioid Receptor Mu 1 
P2X3R P2X Purinoceptor 3 
P2X4R P2X Purinoceptor 4 
P2Y12R P2Y Purinoceptor 12 




PI3K-Akt Phosphatidylinositol-3-Kinase and Protein Kinase B 
PKC Protein Kinase C 
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PLC Phospholipase C 
PNS Peripheral Nervous System 
PTGS2 Prostaglandin-Endoperoxide Synthase 2 
RA Rheumatoid Arthritis 
RAC-1 Ras-Related C3 Botulinum Toxin Substrate 1 
RIN RNA Integrity Number 
RLT RNeasy Lysis Buffer 
RW1 and RPE RNeasy Wash Buffers 
RPMI Roswell Park Memorial Institute medium 
RT Room Temperature 
RT-qPCR Quantitative Reverse Transcription Polymerase Chain Reaction 
SCN9A Sodium Voltage-Gated Channel Alpha Subunit 9 
SCN10A Sodium Voltage-Gated Channel Alpha Subunit 10 
SCN11A Sodium Voltage-Gated Channel Alpha Subunit 11 
SEM Standard Error of the Mean 
SLFN2 Schlafen 2 
SLFN5 Schlafen 5 
SNL Spinal Nerve Ligation 
SNP Single Nucleotide Polymorphism 
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SODD Silencer of Death Domains 
SP Substance P 
Sp5C Spinal Trigeminal Nucleus Caudalis 
STAT1 Signal Transducer and Activator of Transcription 1 
STAT3 Signal Transducer and Activator of Transcription 3 
STAT6 Signal Transducer and Activator of Transcription 6 
sTNFα Soluble Tumour Necrosis Factor Alpha 
TAC1 Tachykinin Precursor 1 
TACE Tumour Necrosis Factor Alpha Converting Enzyme 
TLR4 Toll-Like Receptor 4 
TNFα Tumour Necrosis Factor Alpha 
TNFR1 Tumour Necrosis Factor Receptor 1 
TNFR2 Tumour Necrosis Factor Receptor 2 
TRAF2 Tumour Necrosis Factor Receptor-Associated Factor 2 
TrkA Tropomyosin Receptor Kinase A 
TRP Transient Receptor Potential 
TRPA1 Transient Receptor Potential Ankyrin 1 
TRPV1 Transient Receptor Potential Vanilloid 1 




VGF VGF Nerve Growth Factor Inducible 
VGSCs Voltage- Gated Sodium Channels 
WDR Wide-Dynamic Range 
YWHAZ 
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase 
Activation Protein 



























1. General Introduction 
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1.1 Historical Perspective on Pain 
Throughout history the definition of pain has been altered per the current beliefs at the time. 
The theories for the root cause of pain have ranged from an imbalance in the vital fluids of 
the human body (Sykiotis et al., 2005) to a punishment from God (Bial and Cope, 2011). The 
shift between pain being a spiritual experience to a physiological one was first described by 
René Descartes’ Treatise of Man in 1662, where the potential link between sites in the 
periphery and centres in the brain was outlined. Since then several theories have been 
proposed, these include the Specificity Theory of Pain, whereby different noxious modalities 
are transmitted via distinct pathways to the central nervous system (CNS), and the Gate 
Control Theory of Pain, the idea that non-noxious stimuli are able to close the ‘gate’ to noxious 
stimuli and therefore able to suppress pain sensations (Melzack and Wall, 1966). It is the 
amalgamation of centuries of theories that have formed the basis of the current definition of 
pain given by the International Association of Pain (IASP); Pain is ‘an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described in terms 
of such damage’ (Bonica, 1979).  
1.2 Non-Pathological Nociceptive Signalling 
In healthy individuals, acute pain functions as a protective mechanism serving as a 
physiological warning to potentially tissue-damaging stimuli and promoting avoidance of 
those same stimuli in the future. The importance of this physiological drive to avoid danger is 
highlighted in individuals who suffer from a rare autosomal recessive condition; known as 
congenital insensitivity to pain (Nagasako, Oaklander and Dworkin, 2003). These patients 
cannot perceive when they are engaging with damaging stimuli and often suffer from extreme 
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injuries resulting in a substantially reduced life-span (Nagasako, Oaklander and Dworkin, 
2003).  
1.2.1 Transmission of Pain Signals from the Peripheral Nervous System to the Central 
Nervous System  
Noxious mechanical, thermal and chemical stimuli are detected in the periphery by 
specialised nerve endings known as nociceptors; nociceptors are pseudounipolar sensory 
neurones. A single process originates from the cell body which then splits in two branches; 
one axon to innervate peripheral sensory organs (e.g. skin) and the other to synapse on 
second-order neurones in the dorsal horn of the spinal cord in the CNS (Dubin and 
Patapoutian, 2010).  
These specialised sensory neurones are responsible for converting the above stimuli into 
electrical signals that are then sent to the higher brain centres, via the spinal cord, to illicit 
the appropriate response (Figure 1). The cell bodies of the above neurones are located in the 
dorsal root ganglia (DRG), where they modulate the expression of a number of regulatory 
proteins (Dubin and Patapoutian, 2010).  
The DRG is a multicellular environment, with many other cell types being present in addition 
to the neuron cell bodies.  One such cell type is satellite glial cells which wrap completely 
around the sensory neurones (Hanani, 2005).  Given their close proximity to the neurones, it 
is perhaps not entirely surprising that this particular cell type has received growing interest in 
the context of pain.  It has emerged that satellite glial cells play an active role in the initiation 
and maintenance of neuronal changes that underlie pain mechanisms (Ohara et al., 2009).  
For example, one study demonstrated that fractalkine/CX3CR1 signalling in satellite glial cells 
is a key component of the genesis of inflammatory pain, resulting in increased production and 
29 
 
release of TNFα, IL-1β and prostaglandin E2 (Souza et al., 2013).  Additionally, in a model of 
neuropathic pain, the continuous infusion of a glial metabolism inhibitor into the injured DRG, 
was able to significantly alleviate mechanical allodynia (Liu et al., 2012).  These studies 
highlight the importance of changes occurring in non-neuronal cell types as well as the 
neurones themselves.   
The signal generated in the periphery is transmitted predominantly to laminae I, II and V of 
the dorsal horn in the spinal cord, mainly via thinly myelinated Aδ fibres or unmyelinated C 
fibres (although some Aβ fibres have been described as being nociceptive (Djouhri and 
Lawson, 2004)), the characteristics of which are specified in Table 1.  
The primary afferents terminate in the dorsal horn with a distribution pattern which is 
determined by two factors; their sensory modality and the region of the body that they 
innervate (Todd, 2010).  It is at this point that the incoming information undergoes processing 
by complex circuits involving inhibitory (GABA or glycine as their main neurotransmitter) and 
excitatory (glutamate as their main neurotransmitter) interneurons, subsequent to being 
transmitted via projection neurones, to various areas of the brain (Todd, 2010).  It is now 
widely accepted that changes in this region can contribute to chronic pain states, with the 
interneurons playing a particularly profound role (Todd, 2017).  Under normal conditions, 
inhibitory interneurons continuously release GABA to control the excitability of lamina 1 
projection neurones and modulate pain transmission.   However, it is now known that a 
reduction in this inhibitory effect (as a result of trauma or injury) can lead to both 
hypersensitivity and allodynia (Yin, Yi and Kim, 2018). 
The major ascending pathway associated with conveying information about pain is the 
spinothalamic tract (Treede, 2007). Tracing studies have demonstrated that primary 
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supraspinal targets for projection neurones (in the rat) include the caudal ventrolateral 
medulla (CVLM), the nucleus of solitary tract (NTS), the lateral parabrachial area (LPb), the 
periaqueductal grey matter (PAG) and certain nuclei in the thalamus (Gauriau and Bernard, 
2003). 
Neuronal activity in the dorsal horn is further regulated by descending modulatory pathways. 
In contrast to interneurons, the key neurotransmitters involved in the latter are noradrenaline 
and serotonin (Steeds, 2009). Under normal conditions, two important areas of the brainstem 
are involved in the reduction of pain; the PAG and the nucleus raphe magnus (NRM) (Steeds, 
2009).  However, there is growing evidence to support the hypothesis that dysregulation of 
descending pain modulation contributes to chronic pain states, for example, via diminished 





Figure 1. Nociceptive pathways from the peripheral tissues to the CNS. Schematic demonstrating the basic nociceptive 
pathway. Aδ and C fibres innervating peripheral tissues transduce and transmit pain signals initiated by noxious mechanical, 
thermal or chemical stimuli. These primary afferents terminate in the dorsal horn of the spinal cord where they synapse with 
projection neurones prior to being transmitted to the brain where an appropriate response is initiated. This pathway can be 
modulated at both the spinal cord level (involvement of interneurons) and descending pathways from the brain.  
Abbreviations: CNS: central nervous system. 
Despite often being over-simplified, the pain signalling pathway is highly dynamic, shaped by 
a number of integrative influences from both the peripheral and central nervous system, and 
therefore can be modulated and influenced at several points (Bolay and Moskowitz, 2002).  
In addition to the physiological aspect, pain is a highly subjective phenomenon influenced by 
sociological, psychological and genetic factors of the individual (Coghill, 2010). For instance, 
it has recently been suggested that neonates experiencing painful procedures, such as heel 
punctures, not only have a heightened pain response at the time due to the incomplete 
development of pain inhibition pathways, but also have increased pain responses later in life 
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(Beggs, 2015). The latter highlights how early life experiences can shape the nociceptive 
system in adulthood.   
1.2.2 Classification of Nociceptors 
Nociceptors form late during neurogenesis and are derived from neural crest stem cells 
migrated from the dorsal part of the neural tube (Anderson, 2000). This differs from larger-
diameter sensory neurones, such as proprioceptors, that develop much earlier (Anderson, 
2000). During neurogenesis all developing nociceptors in the DRG are known to express TrkA, 
the receptor for Nerve Growth Factor (NGF). However, during perinatal and postnatal periods, 
approximately 50 % will switch off their TrkA expression and start to express Ret (Golden et 
al., 2010), the receptor for glial cell-derived neurotrophic factor (GDNF)-family ligands. 
Following this pivotal change in receptor expression, the fate of these neurones diverges into 
either non-peptidergic or peptidergic nociceptors (Woolf and Ma, 2007). Classically, ret-
expressing non-peptidergic nociceptors are isolectin B4 (IB4) positive, whereas TrkA-
expressing peptidergic nociceptors are calcitonin gene-related peptide (CGRP) and substance 
P (SP) positive (Woolf and Ma, 2007). Recently, using single-cell RNA-sequencing and neurone 
size-based hierarchical clustering, it has been possible to further sub-classify the small-
diameter neurones of the mouse DRG based on their transcriptome profile (Li et al., 2016a), 
allowing for more in depth study of the sensory mechanisms associated with pain.  The 
authors showed that small diameter DRG neurones can be classified into one type of low-
threshold mechanoreceptor and five types of mechanoheat nociceptors.  In contrast, large 
diameter neurones are categorised into four separate groups.  These distinct ‘signatures’ 
provide a more comprehensive manner in which somatosensory neurones may be 
characterised (Li et al., 2016a).  
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Table 1. Properties of Different Primary Afferent Fibers Types. Information regarding the different properties of different 
nerve fibers, including the type of information conveyed, location, whether the fibre is myelinated, the conduction 
velocity at which information is transmitted and the diameter of each fiber type.  
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1.3 Chronic Pain 
While acute pain serves a physiological function, chronic pain is the result of a maladaptive 
response of the nociceptive system, and therefore no longer serves a protective purpose. It 
has been estimated that up to eight million people in the UK live with chronic pain (Fayaz et 
al., 2016). These patients often experience a detrimental impact on their quality of life, with 
chronic pain affecting the ability to maintain employment, exercise, sleep, attendance at 
social activities, and even impacting the ability to maintain and develop healthy relationships 
(Breivik et al., 2006). Chronic pain is defined as pain which lasts longer than 3-6 months and 
persists despite the initial injury or trauma having healed (Treede et al., 2015). In addition to 
suffering from chronic pain, it is not uncommon for these patients to suffer from a range of 
co-morbid conditions, such as anxiety, depression and insomnia (Nicholson and Verma, 2004), 
further adding to the economic and personal burden of this disease.   
1.3.1 Current Treatment for Chronic Pain Patients 
Current treatment for chronic pain is often based upon the ‘analgesic ladder’, a treatment 
strategy originally used for patients suffering from cancer pain (Takeda, 1990, Jadad, 1995). 
The ‘lowest rung’ of the ladder involves oral administration of non-opioid based drugs such 
as paracetamol/aspirin, with or without an adjuvant, such as cyclooxygenase-2 (COX-2) 
inhibitors (Vargas-Schaffer, 2010). Following disease progression or lack of pain relief, the 
patient moves up the ladder where the use of weak (e.g. codeine) or strong (e.g. morphine) 
opioids is employed in addition to the use of non-opioid drugs and non-steroidal anti-
inflammatory drugs (NSAIDs) (Vargas-Schaffer, 2010). The opioid dose is escalated until either 
the patient achieves adequate pain management, or the maximum dose is reached (Vargas-
Schaffer, 2010). This system fails to acknowledge any individual differences and often results 
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in poor pain-management. The primary drawback of the above system is the extensive use of 
potent opioids, treatment of which can result in both psychological and physiological 
addiction, as well as extensive adverse effects (Benyamin et al., 2008) and the development 
of tolerance (Dumas and Pollack, 2008).  
Although the above analgesic drugs account for 89 % of analgesic prescriptions (Mico et al., 
2006), antidepressants and anticonvulsants are increasingly being viewed as legitimate 
treatment options, particularly for neuropathic pain patients (Ryder and Stannard, 2005). It is 
thought that the mechanisms involved in antidepressant-induced analgesia include enhanced 
availability of noradrenaline, activation of endogenous opioid receptors, and N-methyl-D-
aspartate (NMDA) receptor inhibition, whereas anticonvulsant-induced analgesia results 
from blockade of both sodium and calcium channels in addition to the modulation of 
neurotransmitter release (Sarder et al., 2016). Although the above drugs are recognised as 
first-line treatments for several neuropathic pain conditions, these drugs are not themselves 
without extensive side effects (Maizels and McCarberg, 2005). These limitations highlight the 
need for the identification of novel and more effective pain targets and therapies.  
1.3.2 Mechanisms of Chronic Pain  
Chronic pain may be driven via both peripheral and CNS dependent mechanisms (Dray et al., 
1999), often with components of one affecting the other, resulting in a heightened sensitivity 
in pain, a phenomenon referred to as hyperalgesia. This project will primarily focus on the 
peripheral aspect of pain; however, a brief overview of CNS-dependent mechanisms will be 
outlined below.  
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1.3.2.1 CNS-Dependent Mechanisms of Pain 
Treating patients with chronic pain is a complex task partly due to the wide array of changes 
that occur in the CNS, both at a functional and structural level. These changes include 
molecular, synaptic, cellular and network level modifications (Kuner, 2010). Examples of these 
are highlighted below: 
One of the key molecular changes contributing to the development of hyperalgesia (an 
enhanced sensitivity to pain) is the recruitment of GluR1 α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) to neuronal plasma membranes at the spinal level 
(Galan et al., 2004). Studies have demonstrated that mice lacking the GluR1 subunit of the 
receptor display a loss of nociceptive plasticity in vitro and a reduction in acute inflammatory 
hyperalgesia in vivo (Hartmann et al., 2004).  
At the synaptic level there is strong evidence to implicate long term potentiation (LTP) in the 
development of hyperalgesia. LTP is defined as the long-lasting, but not irreversible, increase 
in synaptic strength (Bliss and Collingridge, 1993). The induction of activity-dependent LTP 
and the subsequent rise in Ca2+ spinal cord lamina I neurones is well established (Sandkuhler 
and Gruber-Schoffnegger, 2012). The rise in intracellular Ca2+ is indeed known to initiate a 
myriad of signalling cascades, including protein kinase C (PKC), phospholipase C (PLC) and 
Ca2+/calmodulin-dependent protein kinase II (CAMKII) activation, all of which are important 
for the development of hyperalgesia (Ikeda et al., 2006).  As a consequence, spontaneous 
activity develops at the cellular level (Latremoliere and Woolf, 2009).  
Despite the lack of nociceptive stimulus in the periphery, this spontaneous activity 
demonstrates the continued input into the central nervous system and subsequent signal 
amplification (Kuner, 2010). The consequences of unchecked nociceptive signalling include 
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modulation of neural networks; changes that can now be visualised in the brains of chronic 
pain patients. Individuals suffering from chronic back pain have been shown to display 
alterations in the spontaneous resting patterns and the brain default mode network during 
an attention task compared to control patients (Tagliazucchi et al., 2010).  
The above examples are changes occurring at the functional level, but structural 
modifications also occur. It has been found that chronic pain patients show a reduction in 
brain gray matter, in a number of brain regions, compared to healthy age-matched controls 
(Apkarian et al., 2004, Schmidt-Wilcke et al., 2005, Kuchinad et al., 2007). This effect was seen 
to be reversed in patients who were pain free following total hip replacement, suggesting this 
structural change is a response to chronic nociceptive transmission rather than one of the 
underlying causes (Rodriguez-Raecke et al., 2009). Furthermore, alterations in dendritic spine 
morphology within the spinal cord have been observed. These include dendritic spine 
dysgenesis on wide-dynamic range (WDR) neurons in lamina IV – V (Tan et al., 2008), but also 
on lamina II neurones following spinal cord injury (Cao et al., 2017). The inhibition of Ras-
related C3 botulinum toxin substrate 1 (Rac-1) activity, resulting in suppression of dendritic 
spine modifications, has been shown to be associated with the reversal of the neuropathic 
pain phenotype in rats (Zhao et al., 2016).  
1.3.2.2 PNS-Dependent Mechanisms of Pain  
Although the mechanisms produced centrally and peripherally are regularly treated as 
separate entities, often the modulation of signalling pathways in the periphery is a prelude to 
the subsequent changes in the CNS (Richards and McMahon, 2013).  
When a tissue injury occurs in the periphery, resident as well as recruited immune cells 
secrete a vast array of inflammatory mediators including adenosine tri-phosphate (ATP), IL-
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1β, histamine and bradykinin (Ji et al., 2014). One such immune cell is mast cells.  A primary 
role of mast cells in inflammatory conditions is to enhance the local recruitment of 
neutrophils (Galli, Borregaard and Wynn, 2011). It has been shown that mast cells, which are 
optimally positioned in close proximity to the vasculature, initiate an early phase of neutrophil 
recruitment by releasing the chemoattractants CXCL1/CXCL2 (De Filippo et al., 
2013).  Blockade of either chemokine with monoclonal antibodies, or the depletion of mast 
cells, results in a significant depletion in neutrophil recruitment (De Filippo et al., 2013). This 
early immune response has been shown to be critical in the development of pain states, for 
example, mast cell stabilisation (using sodium cromoglicate to prevent the release of 
inflammatory mediators) reduces neutrophil infiltration and consequently suppresses both 
mechanical and thermal hypersensitivity development (Perkins and Tracey, 2000).  
Additionally, the sensory nerve terminals themselves are known to release neuropeptides 
such as SP and CGRP, modulating nociceptive pathways at both peripheral and central sites 
via enhancing the immune response and directly sensitising sensory neurones (Molyva, 2010). 
Both SP and CGRP have been shown to be significantly upregulated in the synovium and 
synovial fluid in patients suffering from developmental dysplasia of the hip, a musculoskeletal 
disorder which has a strong pain component (Wang et al., 2015). In line with this, CGRP 
blockade via the use of peripherally acting antagonists can significantly reduce the mechanical 
hypersensitivity associated with joint pain in rat models of osteoarthritis (OA) (Walsh et al., 
2015a). 
Following the release of numerous inflammatory mediators in the tissue (e.g. ATP, IL-1β, 
histamine and bradykinin etc.), these substances act upon their respective receptors. The 
receptors may reside on the sensory neurone terminal (Grace et al., 2014), the axon itself 
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(Moalem et al., 2005) or on neighbouring uninjured afferents within the same vicinity (Ma et 
al., 2003).  
Examples of the receptor types involved in chronic pain states include voltage-gated and 
voltage insensitive sodium channels, ligand-gated purinoceptor channels, transient receptor 
potential (TRP) channels and G-protein-coupled receptors (GPCRs). Following receptor 
activation, a myriad of second messenger signalling pathways may be activated (Kidd and 
Urban, 2001, Gangadharan and Kuner, 2013). The resulting change in the local chemical milieu 
has the net impact of increased neuronal excitability, resulting in the induction of peripheral 
sensitisation; a phenomenon whereby non-noxious stimuli are now perceived as noxious 
(allodynia) and there is a heightened sensitivity to noxious stimuli (hyperalgesia) (Ji et al., 
2014). 
A further consideration is the presence of “silent nociceptors” located in the periphery. Unlike 
other Aδ- and C-fibres, these nociceptors do not respond within the normal range of noxious 
stimulus intensities, instead only being active at the extreme ends of this scale. These 
nociceptors are often held responsible for spontaneous neural activity, thus increasing the 
input into the spinal cord and leading to central sensitisation (Schmidt et al., 1995, Gold and 
Gebhart, 2010). 
The importance of the peripheral drive of pain is highlighted in cases where OA patients 
report a significant attenuation of their painful symptoms following removal of the diseased 
joint (Hawker et al., 1998). Furthermore, the use of biologics (therapeutics that lack a central-
acting component) to target specific mediators in the periphery, have been shown to be 
successful in a number of painful conditions, including those of a neuropathic origin (Richards 
and McMahon, 2013). Individual inflammatory mediators have been shown to have a 
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profound effect on the excitability of primary sensory neurones, as well as altering the 
secretory profile of non-neuronal cells.  
This PhD thesis will particularly focus on two peripheral inflammatory mediators; nerve 
growth factor (NGF) and tumour necrosis factor alpha (TNFα). The current evidence for their 
role in pathogenic nociceptive signalling is outlined below, along with an introduction to each 
mediator.  
1.4 NGF Signalling 
1.4.1 Biology of NGF 
NGF was discovered over 50 years ago as the signalling molecule responsible for the survival 
of sympathetic and sensory neurones during development (Levi-Montalcini and Hamburger, 
1951). NGF is a member of a group of signalling molecules known as the neurotrophins, with 
other members including brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and 
neurotrophin 4/5 (NT4/5). This growth factor is a highly conserved molecule that is 
synthesised from a pro-NGF molecule, which undergoes processing via proteases located in 
the trans-golgi network to produce mature NGF (Fahnestock et al., 2004). Although the 
majority of research has focused on the mature form of NGF, there is evidence to indicate 
that pro-NGF itself has biological activity, with possible links to neurodegenerative conditions 
such as Alzheimer’s disease (Fahnestock et al., 2001). The mature form of NGF exists as a 
dimer of a 13.2 kDa with a protomer structure consisting of three antiparallel pairs of beta 
strands (McDonald et al., 1991).   
Within the central nervous system, NGF is crucial for the survival and function of cholinergic 
neurones of the basal forebrain complex, contributing to functions such as attention, 
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motivation and memory (Dreyfus, 1989). Additionally, NGF is known to modulate the 
hypothalamus-pituitary-adrenocortical axis, thus contributing to the response to stressful 
stimuli (Scaccianoce et al., 1993, Taglialatela et al., 1991).  Within the periphery, sensory 
neurone release of neuropeptides, such as SP and CGRP, are known to be under NGF control 
(Mearowa and Kril, 1995). NGF levels within adult tissues correlate with peripheral neurone 
phenotypic features, including cell soma size, axonal sprouting and innervation density (Aloe 
et al., 2012).  Additionally, NGF is thought to exert a profound effect on the immune system, 
suggesting NGF as a key regulator of the cross-talk between the immune and nervous systems 
(Minnone et al., 2017).  
1.4.2 NGF Receptors 
NGF signals via two receptors; the high affinity TrkA receptor, a Type 1 transmembrane 
protein, and the low affinity p75 receptor (p75NTR), which belongs to the TNF receptor 
superfamily (Toni, Dua and van der Graaf, 2014). Signalling via the TrkA receptor is highly 
specific for NGF, the specificity of which has been shown to be augmented via p75NTR 
signalling (Barker and Shooter, 1994). One study has suggested that the means by which p75 
can augment trkA signalling is via a specific 29-amino acid peptide derived from the 
intracellular domain fragment of p75 (Matusica et al., 2013).  The authors show that this 
fragment interacts with, and potentiates binding of, NGF to trkA expressing cells via a 
conformational change within the extracellular domain of TrkA, resulting in enhanced neurite 
outgrowth in sympathetic neurones due to an increase in Erk1/2 and Akt signalling. 
In contrast to TrkA, the p75NTR receptor is more promiscuous, binding to all four members of 
the neurotrophin family (Longo and Massa, 2013).  In the adult nervous system, TrkA is 
expressed on approximately 40-45 % of DRG neurones (peptidergic C fibres) (Snider and 
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McMahon, 1998), sympathetic neurones (Fagan et al., 1996) and both cholinergic and non-
cholinergic neurones in areas of the brain, including the basal forebrain and neostriatum, the 
paraventricular anterior, the rostrail and intermediate subnuclei of the interpenduncular 
nucleus and the area postrema (Holtzman et al., 1995). Following wide-spread expression in 
development, the p75NTR levels decrease significantly in adulthood (Firouzi, 2012). As well as 
being co-expressed with TrkA on sensory neurones, p75NTR is also expressed on a range of 
non-neuronal cells, including oligodendrocytes (Yoon et al., 1998) and astrocytes (Hutton et 
al., 1992).  
1.4.3 Primary Signalling Pathways 
The main signalling pathways associated with these two receptors are depicted in Figure 2. 
Following binding of NGF to the TrkA receptor, the TrkA receptor monomers dimerise and the 
intracellular component of the receptor is auto-phosphorylated (Pezet and McMahon, 2006), 
leading to activation of pathways primarily associated with cell survival. These include 
activation of Ras-mitogen activated protein kinase (MAPK), phosphatidylinositol 3-kinase-Akt 
(PI3K-Akt), ERK and protein kinase C (PKC) pathways (Klesse and Parada, 1999, Reichardt, 
2006b). This promotion of cell survival is particularly important at the developmental stage. 
In line with this, mice lacking either the TrkA receptor, or the NGF molecule itself, survive 
birth but do not survive past 4 weeks of age (Klein, 1994).  
The p75NTR receptor is also critical for this signalling and its activation positively regulates TrkA 
function, with cell survival depending on the ratio of receptor activation between these two 
receptors (Horton et al., 1997). It has been shown that embryonic sensory neurones deficient 
in p75NTR require a much higher concentration of NGF to promote cell survival compared to 
wild-type neurones (Davies et al., 1993). Post-developmentally, the p75NTR receptor has been 
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primarily associated with pro-apoptotic cell signalling, however, it is now known that the 
p75NTR receptor can also mediate anti-apoptotic pathways. Two of the major signalling 
pathways associated with apoptosis are the activation of the Jun kinase signalling cascade, 
which results in apoptosis via p53 activation, and secondly, the activation of the hydrolase 
enzyme sphingomyelinase, resulting in ceramide production and activation of caspase 
cascades (Reichardt, 2006b). However, an alternative protective role of p75NTR receptor 
signalling has been described (Mamidipudi and Wooten, 2002). A study by Roux et al., 2001, 
showed that p75NTR expression increased survival of TImp75-3 cells, derived from the MG87 
fibroblast cell line, subjected to serum withdrawal, an effect thought to be due to p75NTR -
dependent phosphorylation of Akt.  
Activation of both receptors can result in activation of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB); an important transcription factor (Lee and Burckart, 
1998). This protein complex is important in the modulation of a number of cell survival 
processes and dysregulation is known to be present in a number of diseases, including cancer 
(Hoesel and Schmid, 2013) and autoimmune diseases (Aksentijevich and Zhou, 2017). It is 
known that antibodies that block binding of NGF to p75NTR prevented NF-κB activation and 
subsequently reduced the NGF survival response in developing sensory neurones (Hamanoue 




Figure 2. Primary signalling pathways associated with activation of TrkA and p75NTR following NGF activation. NGF binding 
to its high affinity receptor, TrkA, results in phosphorylation of the receptor and activation of multiple signalling pathways 
(e.g. PI3K/Akt, Ras/MAPK/ERK1/2 or PKC signalling pathways). The activation of these signalling pathways results in a range 
of biological functions, including neurite outgrowth, cell survival, neuronal differentiation and transducer channel regulation. 
The binding of NGF to its low affinity receptor, p75NTR , activates different signalling pathways depending on the cellular 
context. Activation of this receptor can result in both enhanced cell survival (through NF-κB signalling) as well as enhanced 
apoptotic signalling (via JNK/p53 signalling or caspase activation) (Wang et al., 2014).  
Abbreviations: NGF: nerve growth factor; TrkA: tropomyosin receptor kinase A; PI3K: phosphoinositide 3-kinase; MAPK: 
mitogen-activated protein kinase; ERK: extracellular signal-regulated kinases; PKC: protein kinase C; p75NTR : low affinity 
nerve growth factor receptor; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; JNK: c-Jun N-terminal 
kinase. 
 
1.5 NGF in Pain 
The role of NGF as an inflammatory mediator in acute and chronic pain states is well 
established. Interestingly, the sensitising effect of NGF seems to only occur in adult 
nociceptors, and not in embryonic nociceptors, suggesting a developmental switch, the 
nature of which is proving to be elusive (Zhu et al., 2004), in signal transduction cascades once 
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NGF has fulfilled its developmental role (Zhu et al., 2004).  Evidence for the role of NGF in pain 
signalling, originating from pre-clinical studies and human studies, is outlined below: 
1.5.1 Pre-Clinical Evidence for a Role of NGF in Pain 
In addition to the location of its cognate receptors on nociceptors, NGF is also known to be 
significantly upregulated in inflamed tissue in a number of inflammatory models, including 
Complete Freund’s Adjuvant (CFA) and carrageenan injection (McMahon, 1996). One of the 
earliest studies looking at the involvement of NGF in pain demonstrated that repeated 
application of exogenous NGF in the periphery, given to rats from birth, resulted in a profound 
mechanical and thermal hypersensitivity compared to age-matched controls (Lewin et al., 
1993). This hypersensitivity was found to coincide with the upregulation of a number of pain 
related peptides, including substance P and CGRP, an effect that could be abolished with the 
application of an anti-NGF neutralising antibody (Woolf et al., 1994). The expression of TrkA 
alone has been shown to be sufficient to mediate the noxious effects of NGF (Bergmann et 
al., 1998), and the upregulation of TrkA expression in murine DRG, following a long-lasting 
inflammatory model, is linked to the maintenance rather than the development, of the 
inflammatory state (Pezet et al., 2001).  However, it has also been observed that the induction 
of p75NTR in undamaged DRG neurones facilitates TrkA signalling (Obata et al., 2006), thus 
contributing to hyperalgesia indirectly. Furthermore, there is evidence to suggest that the 
binding of pro-NGF to P75NTR is required for CFA-induced hyperalgesia (Watanabe et al., 
2008), suggesting the involvement of NGF signalling via p75NTR should not be underestimated.  
1.5.2 Clinical Evidence for a Role of NGF in Pain 
The role of NGF in pain is clearly illustrated in those individuals who have mutations in the 
gene encoding for the NGF molecule or the TrkA receptor. One such example is individuals 
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suffering from hereditary sensory and autonomic neuropathy type IV (HSAN-IV), also known 
as Congenital Insensitivity to Pain with Anhidrosis, which is a product of a mutation in the 
TrkA gene, NTRK1 (Indo et al., 1996). Patients suffering from HSAN-IV have a severe deficit in 
sensory perception but maintain a certain degree of vibration awareness (Axelrod and Gold-
von Simson, 2007). Skin biopsies taken from HSAN-IV patients reveal a lack of C and Aδ fibres, 
thought to be caused by the absence of NGF-TrkA signalling (Nolano et al., 2000). 
Furthermore, it has been shown that the perinatal loss of sensory neurones in mice lacking 
the NGF gene, resulting in a failure to respond to noxious mechanical stimuli, cannot be 
rescued via the compensation of other neurotrophins (Crowley et al., 1994). The latter studies 
highlight the crucial role for NGF in pain signalling.  
In humans, levels of NGF in cerebral spinal fluid (CSF) have been shown to be significantly 
higher in Chronic Daily Headache (CDH) patients compared to controls, an increase which is 
positively correlated with levels of SP and CGRP (Sarchielli et al., 2001), supporting the pre-
clinical evidence. Increased levels of NGF and TrkA expression have been reported in 
pancreases of patients suffering from chronic pancreatitis (Friess et al., 1999), painful 
conditions of the urinary bladder (Lowe et al., 1997) and primary fibromyalgia syndrome 
(Sarchielli et al., 2007). The effect of administration of NGF has also been tested in healthy 
volunteers. In a double blinded, placebo-controlled study, injection of 5 μg of NGF into the 
masseter muscle resulted in significantly reduced pressure pain thresholds and tolerance 
thresholds which persisted for over 7 days (Svensson et al., 2003).   
1.5.3 Molecular Changes Associated with NGF Induced Pain 
The molecular changes associated with NGF administration are due to both local 
transcriptional-translational changes and post-translational modifications occurring at both 
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the distal axon and in the soma (Woolf and Costigan, 1999). The sub-population of 
nociceptors that are specific for TrkA also co-express the Transient Receptor Potential 
Vanilloid 1 (TRPV1) (Cavanaugh et al., 2011), an ion channel that responds to a range of 
stimuli, principally temperatures greater than 43 ˚C and capsaicin, and is associated with the 
development of hypersensitivity and allodynia (Szallasi et al., 2007). Indeed, mice lacking this 
ion channel do not develop thermal hypersensitivity following an inflammatory insult (Davis 
et al., 2000). One known mechanism for NGF sensitisation is the binding of NGF to the TrkA-
expressing nociceptors, resulting in activation of PI3 kinase, allowing for phosphorylation of 
TRPV1 at a single tyrosine residue, Y200, and increased insertion of the TRPV1 ion channel 
into the membrane (Zhang et al., 2005b) (Figure 3). In addition, NGF-mediated activation of 
PLC is thought to reduce the threshold of TRPV1 channels via phosphatidylinositol 4,5-
biphosphate (PIP2) hydrolysis (Chuang et al., 2001), thus leading to heightened thermal 
responses.  
As well as local changes occurring in the distal axons, the NGF-TrkA complex can be 
internalised (Grimes et al., 1996) and transported to the cell soma, located in the DRG, where 
it drives transcriptional changes associated with increased synthesis of peptides, such as CGRP 
and SP (Zweifel et al., 2005), as well as ion channels, such as TRPV1 (Nicol and Vasko, 2007).  
Following internalisation, it is thought that the NGF-TrkA complex undergoes endocytosis 
(Marlin and Li, 2015). The signalling endosome containing the complex and any associated 
signalling molecules are trafficked down the axon in a retrograde manner.  The latter requires 
the association of motor protein along the microtubules, as well as the prevention of 
endosome maturation in order to prolong the liganded state of the NGF-TrkA complex (Marlin 
and Li, 2015). 
48 
 
Furthermore, the increase in TRPV1 translation, and subsequent increase in heat sensitivity 
of the sensory neurone terminal, has been shown to be dependent on phospho-p38, an effect 
which can be abolished using the molecule SB203580 (a specific inhibitor of the p38-MAPK 
pathway) (Ji et al., 2002). These two distinct mechanisms explain both the rapid sensitisation 
seen with NGF application and the secondary sustained effects of NGF.  
 
Figure 3. Schematic displaying the phosphorylation pathways associated with increased opening, increased trafficking and 
increased insertion of TRPV1 into the cell membrane following NGF activation. Following NGF activation, phosphorylation 
at the S502 and S800 residues results in an increased opening of the TRPV1 channel, whereas phosphorylation of the Y200 
residue results in increased trafficking and insertion into the cell membrane. Adapted from Meents, Neeb and Reuter, 2010. 
Abbreviations: TRPV1: transient receptor potential vanilloid 1; NGF: nerve growth factor; PI3K: phosphoinositide 3-kinase; 
PKCδ: protein kinase C gamma; Src: proto-oncogene tyrosine-protein kinase. 
1.5.4 NGF Modulation of Sodium Channels 
Voltage-gated sodium channels (VGSCs), such as NaV1.7, 1.8 and 1.9 are key for translating 
external stimuli into the language of the nervous system; electrical impulses known as action 
potentials (Stuart et al., 1997). VGSCs are vital for both the initiation and propagation of 
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action potentials in neurones, a process initiated following depolarisation of the membrane 
potential to a threshold level (Stuart et al., 1997). For an action potential to be initiated it has 
been shown that a high density of VGSCs are required in a specialised region of the neurone, 
known as the axon hillock (Kole et al., 2008). Following a stimulus, a rapid opening in VGSCs 
occurs, depolarising the membrane potential via sodium influx into the cell. Following 
complete depolarisation of the membrane potential, sodium channels close at the same time 
as the opening of voltage gated potassium channels, resulting in hyperpolarisation (Kress and 
Mennerick, 2009). Subsequently, the resting membrane potential is re-established through 
potassium leak channels and the sodium-potassium pump before another action potential 
can be initiated (Vassalle, 1987, Cohen et al., 2009). Given the crucial role of VGSCs in 
neuronal activity, it is no surprise that sodium channels have been intricately implicated in 
pain states, evidence for which is presented below. 
There is abundant evidence for the involvement of sodium channels in chronic pain 
conditions. Evidence for the role of sodium channels in the detection and conduction of pain 
signals in the periphery comes from patients presenting with “gain of function” mutations in 
the SCN9A gene encoding NaV1.7. The SCN9A mutation is responsible for a number of familial 
human disorders, such as erythromelalgia and paroxysmal extreme pain disorder (Drenth and 
Waxman, 2007). The mutant gene results in channels that are either open more readily in 
response to depolarising stimuli or channels that are less affected by inactivation at resting 
membrane potentials. These properties lead to a significantly enhanced pain sensation to 
sub-threshold stimuli and a severely diminished quality of life for these patients (Levinson et 
al., 2012).  
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Sodium channels have been shown to be modulated by NGF in chronic pain models, with 
NaV1.7, 1.8 and 1.9 expressed in a variety of pain conducting pathways (Strickland et al., 2008, 
Rogers et al., 2006). NGF produces a significant increase in guinea pig DRG neuronal 
spontaneous activity following an inflammatory insult, partly due to altered sodium channel 
expression, an effect that can be prevented with NGF depletion (Djouhri et al., 2001). 
Subcutaneous administration of NGF in rats resulted in a significant upregulation of sodium 
channels in the small diameter neurones of the DRG at 23 h, reaching maximal intensity at 
one week and persisting for up to 3 months. Furthermore, pre-treatment with an anti-NGF 
antibody prevented the accompanying hyperalgesia and reduced sodium channel labelling 
(visualised via immunocytochemistry techniques) within the DRG (Gould Iii et al., 2000), 
suggesting a crucial role of sodium channels in both the development and maintenance of 
pain. In mice that had a nociceptor specific knockout of the NaV1.7 channel, NGF induced 
inflammatory responses were reduced (Nassar et al., 2004), as was the development of NGF 
induced thermal hyperalgesia in NaV1.8 null mice (Kerr et al., 2001). The acid-sensing ion 
channel 3 (ASIC3), a sodium channel specifically expressed in sensory neurones, has been 
shown to be involved in modulating moderate- to high- intensity pain sensation (Chen et al., 
2002). Furthermore, ASIC3 has increased expression in the presence of high levels of NGF 
during inflammation, an effect which correlates with neurone hyper-excitability and 
hyperalgesia (Mamet et al., 2003).   
The above section has highlighted some specific examples, out of the myriad of proteins and 
secreted factors, associated with NGF-mediated sensitisation. Based on this pre-clinical 
evidence, NGF was considered a plausible and promising pain target for use in humans with 
chronic pain disorders; osteoarthritis (OA), rheumatoid arthritis (RA) and cancer pain to name 
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a few (Chang et al., 2016). The following section examines the success of NGF blockade in the 
clinic and the obstacles that have become apparent throughout this clinical testing process. 
1.6 NGF in the Clinic 
1.6.1 Biologics as Anti-NGF Molecules 
One of the approaches used in the clinic to block NGF activity is the use of monoclonal 
antibodies (Cohen et al., 2016). Examples include tanezumab (the most advanced), 
fulranumab and fasinumab, all of which inhibit the binding of NGF to its cognate receptors, 
TrkA and p75NTR (Yeh et al., 2017). This biologic approach has been successful in a competitive 
market partly due to several advantages over the more traditional small molecule 
approaches. These include increased specificity, an improved safety profile due to a reduction 
in off-target effects and a longer duration of action leading to a higher rate of patient 
compliance (Mócsai et al., 2014). One of the difficulties in the case of NGF is the ability to 
specifically block the TrkA receptor with the small molecule approach (Su et al., 2017). This is 
in part due to the preferred target of the small molecule-the ATP binding pocket of the 
receptor kinase being identical in TrkA, TrkB and TrkC (Su et al., 2017). In line with this, despite 
reports of pain relief in animal models of cancer pain (Ghilardi et al., 2010) and bone fracture 
(Ghilardi et al., 2011) following the use of a pan-Trk inhibitor, the compound caused 
significant over-eating and consequential weight gain. The latter likely to be an effect of 
blocking BDNF/TrkB signalling (Unger et al., 2007). 
It has been shown that administration of increasing doses of tanezumab in osteoarthritic 
patients resulted in a significant reduction in knee pain scores in these patients (Mantyh et 
al., 2011). In addition, this therapy showed no signs of adverse effects on normal nociceptor 
functioning (Mantyh et al., 2011). Tanezumab has also been shown to be efficacious in 
52 
 
significantly reducing pain in patients with interstitial cystitis (Evans et al., 2011) and chronic 
low back pain (Katz et al., 2011). Likewise, fulranumab has been suggested to produce a 
significantly superior pain relief in patients with moderate to severe chronic knee pain when 
compared to controlled-release oxycodone, but not when compared to the placebo group 
(Mayorga et al., 2016). In a 36-week clinical trial, fasinumab was found to produce a significant 
improvement compared to the placebo group regarding pain scores and associated 
functionality in patients with moderate to severe OA (Maloney et al., 2017). However, 
another study showed that the administration of fasinumab showed no significant differences 
in pain scores from the placebo group in patients with acute sciatic pain (Tiseo et al., 2014).  
1.6.2 Side Effects Associated with Anti-NGF Molecules in the Clinical Setting 
Despite impressive efficacy of anti-NGF molecules seen in some pain conditions, clinical trials 
had to be halted due to safety concerns. A number of patients receiving anti-NGF therapy, 
across a number of clinical trials at different pharmaceutical companies, experienced 
worsening of their arthritic condition, resulting in joint replacement and suggesting a possible 
class effect (Garber, 2011). Retrospective analysis of these trials revealed that these cases 
were highest in the patient cohorts taking anti-NGF therapy in combination with non-steroidal 
anti-inflammatory drugs (NSAIDs) (Seidel et al., 2013). To date, as far as we are aware, the 
mechanisms underlying the rapidly progressive OA seen in patients administered both anti-
NGF and NSAIDS are yet to be elucidated.  However, it has been postulated that NSAIDs may 
contribute to the latter condition via enhancing the risk of microvascular thrombotic events 
in bone and inhibiting the repair of subchondral microfractures (Enomoto et al., 2018). 
At the time, a prevailing question was whether the higher rate of rapidly progressive arthritis 
was due to a direct action of the drug in question, or due to the analgesic property of the drug 
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resulting in overuse of the joint in patients that had a pre-existing condition (Garber, 2011). 
The lack of compelling evidence for a direct molecular mechanism linking anti-NGFs to joint 
destruction was key in reinitiating the anti-NGF molecule programme.  In addition to the 
increased cases of joint degeneration, there have also been concerns about the effect of anti-
NGF treatment on the autonomic system. Although the basis for these concerns has not been 
released in full, Pfizer have since revealed that their anti-NGF molecule, tanezumab, does not 
result in death or loss of neurones in the sympathetic nervous system. The Food and Drug 
Administration have since given approval for anti-NGF trials to continue, albeit with a number 
of changes to study protocol to address the raised safety concerns (Mullard, 2015). These 
changes include the exclusion of OA patients with pre-existing rapidly progressive OA, the 
removal of treatment groups involving the concomitant administration of NSAIDs, increased 
surveillance measures and a more thorough patient history prior to study inclusion (Holmes, 
2012).  
In conclusion, NGF is known to be a key regulator in pain states via the modulation of a 
number of signalling pathways, for example, TRPV1 phosphorylation and enhanced 
membrane insertion. Evidence has been presented for a role of NGF in several pain diseases, 
e.g. OA, and how the use of anti-NGF molecules has been an effective analgesic (albeit with 
challenges along the way). The following sections will now examine how TNFα signalling is 
implicated in pain states and how TNFα blockade may be beneficial in this instance.  
1.7 TNFα Signalling 
1.7.1 Biology of TNFα 
TNFα was discovered in 1975 as a soluble cytokine capable of causing necrosis in neoplastic 
cell lines in response to activation by the immune system (Carswell et al., 1975). It is now 
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known that TNFα is a pleiotropic cytokine, primarily secreted from immune cells, and has a 
primary role in inflammatory processes (Baugh and Bucala, 2001). TNFα is one of 19 ligands 
which make up the TNF ligand superfamily, most of which are type II transmembrane proteins 
whose extracellular domains can be cleaved to produce the soluble form (Saha and Pahan, 
2006). In the case of TNFα, the metalloprotease TNF alpha converting enzyme (TACE) induces 
proteolytic cleavage of the membrane integrated form (mTNFα) to produce the soluble form 
of TNFα (sTNFα), both of which are biologically active (Figure 4) (Saha and Pahan, 2006). This 
cleaved product exists as a homotrimer in solution, with a total molecular weight of 52-kDa 
(Saha and Pahan, 2006). Each monomer is composed of two antiparallel β-pleated sheets.  
 
 
Figure 4. Interaction between the TNFα ligands and their cognate receptors. mTNFα, which can bind to both TNFR1 and 
TNFR2 with equal affinity, is cleaved via the metalloprotease TACE to produce the soluble form of TNFα. Although sTNFα is 
capable of binding to both receptors, it displays a greater affinity for the TNFR1. Image adapted from Saha and Pahan (2006).  
Abbreviations: mTNFα: membrane tumour necrosis factor alpha, sTNFα: soluble tumour necrosis factor alpha, TNFR1: 




1.7.2 Physiological Role of TNFα 
TNFα signalling is required for normal physiological cell signalling, with a particular important 
role in host defence against pathogens (Pfeffer, 2003). For example, mice deficient in TNFR1, 
or the TNF gene itself, have a severely impaired ability to successfully manage the fungal 
infection Candida albicans (Steinshamn et al., 1996) or the bacterial infection Mycobacterium 
tuberculosis (Bean et al., 1999). In line with TNFα being a crucial cytokine for inflammatory 
processes, it has been observed that mutations in the TNFR extracellular domains are 
responsible for the family of dominantly inherited auto-inflammatory syndromes, known as 
‘TNF-receptor associated periodic syndrome’ (Aksentijevich et al., 2001). The latter results in 
patients experiencing fevers and unexplained bouts of inflammation (Hull et al., 2002). The 
possible reasons for these symptoms are wide-ranging; from aberrant folding and constitutive 
TNFR signalling to endoplasmic reticulum stress and increased levels of mitochondrial reactive 
oxygen species (Sedger and McDermott, 2014). TNFα has also been shown to be crucial in the 
recovery of muscle function following traumatic muscle injury (Warren et al., 2002) and TNFα 
signalling, via TNFR2, has been shown to be protective in neurodegeneration (Dong et al., 
2016). However, due to the delicate balance of TNFα signalling (described above) it is no 
surprise that abnormal or overactive signalling has been associated with a number of 
diseases, including Crohn’s disease, multiple sclerosis and pain (Van Deventer, 1997, Mikova 
et al., 2001, Zhang and An, 2007). 
1.7.3 TNFα Receptors 
To exert its wide range of biological functions TNFα binds to two receptors, the TNF receptor 
1 (TNFR1) and the TNF receptor 2 (TNFR2), with molecular weights of 55- kDa and 75- kDa 
respectively (MacEwan, 2002). TNFR1 and TNFR2 display a high degree of homology between 
56 
 
their murine and human counterparts, whereas the homology between the two receptors is 
much lower (28 %) and confined to the extracellular ligand-binding domains (Goodwin et al., 
1991). 
TNFR1 is thought to be constitutively expressed in the majority of cells and has assumed 
responsibility for the majority of TNFα signalling outcomes (Fischer et al., 2015). In contrast, 
TNFR2 has restricted expression to immune cells and, compared to TNFR1, has not been well 
studied (Chu, 2013). One of the reasons for the latter was the previously made assumption 
that the soluble form of TNFα was an adequate activator of TNFR2. However, it has been 
demonstrated that the transmembrane form of TNFα is far superior in this respect (Grell et 
al., 1995) suggesting that the role of TNFR2 in TNFα signalling is potentially underestimated. 
1.7.4 Primary Signalling Pathways 
1.7.4.1 Forward Signalling 
The binding of TNFα, to either receptor, results in a conformational change, recruiting adaptor 
proteins such as the Tumour Necrosis Factor Receptor Type 1-Asociated Death Domain 
(TRADD) (TNFR1-specific), Fas-Associated protein with Death Domain (FADD) and TNF 
Receptor-Associated Factor 2 (TRAF2). Subsequent intracellular cascades result in the 
activation of inflammatory or apoptotic pathways depending on the conditions. The main 




Figure 5. TNFα signalling pathways associated with binding to TNFR1 and TNFR2. TNFα activation triggers a conformational 
change in the receptors, allowing the recruitment of a number of adaptor proteins, such as TRADD, FADD and TRAF2, 
triggering signalling cascades associated with apoptosis or activation/inflammation.  
Abbreviations: TRADD: TNFR1 associated death domain, FADD: Fas-associated death domain, TRAF2: TNF receptor 
associated factor 2. 
One of the key differences between TNFR1 and TNFR2 is the presence of a death domain in 
TNFR1 (Jiang et al., 1999). In the absence of TNFα as a ligand, the death domain is kept inactive 
by the presence of a protein known as the Silencer of Death Domains (SODD). However, 
following activation, SODD disassociates and TRADD is recruited, acting as a platform for the 
recruitment of other crucial proteins (Jiang et al., 1999). Although TNFR2 does not contain a 
death domain itself, it is thought to contribute to apoptotic processes via a “ligand-passing” 
mechanism (MacEwan, 2002). Indeed, it has been shown that TNFR2 can regulate the rate of 
TNFα association with TNFR1, via increasing the local concentration of TNFα itself, thus 
enhancing death signalling indirectly (MacEwan, 2002).  
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There are several similarities between the signalling pathways activated via TNFα and NGF 
binding. These include activation of NF-κB, activation of the MAPK pathways and the 
induction of death signalling via activation of caspase cascades. Additionally, the same 
mechanism of rapid dissociation described above for TNFα has been proposed as a way that 
the p75NTR enhances NGF signalling via the TrkA receptor at the cell surface (Tartaglia et al., 
1993). 
1.7.4.2 Reverse Signalling 
The above described pathways are as a result of TNFα forward signalling. However, it is also 
possible for the membrane form of TNFα to act as a receptor itself to cell types expressing 
TNFR2 (Qu et al., 2017); enabling reverse signalling pathways. Whereas soluble TNFα is often 
associated with apoptotic responses and a heightened inflammatory profile, the reverse 
signalling associated with the membrane form is thought to take on more of a protective role. 
For example, reverse signalling through mTNFα has been shown to confer resistance to 
lipopolysaccharide (LPS)-induced TNFα, IL-6 and IL-1 release in human monocytes and 
macrophages (Eissner et al., 2000). The above highlights how the outcomes of TNFα signalling 
are a result of a delicate balance between soluble and membrane bound TNFα-mediated 
effects, in addition to the distinct mechanisms of TNFR1 and TNFR2 activation.  
1.8 TNFα in Pain 
The role of TNFα as a pro-inflammatory cytokine has been well characterized, whereas its 
function as a pain mediator has been less well described. Although TNFα signalling principally 
modulates the immune system, there are reports suggesting TNFα can act directly upon the 
sensory neurons themselves, making TNFα an intriguing pain target. Evidence supporting the 
above is outlined below.  
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1.8.1 Genetic Evidence for a Role of TNFα in Pain 
The intrigue surrounding the potential role of TNFα as a pain mediator comes in part from 
genetic studies in humans. One study looking at pain severity in lung cancer patients showed 
that patients with the TNFα-308GA single nucleotide polymorphism (SNP), resulting in 
increased TNFα production, was a strong predictor of pain (Reyes-Gibby et al., 2009). The 
above mutation has also been linked to an increased risk of developing migraines (Mazaheri 
et al., 2006, Yilmaz et al., 2010, Ates et al., 2011), in which pain is a defining feature, and the 
development of neuropathic pain following surgery (Kalliomäki et al., 2016). Furthermore, a 
polymorphism in the gene that codes for TNFR2 has recently been linked to high intensity 
pain severity in cancer patients experiencing severe cluster symptoms (two or more 
concurrent symptoms experienced by patients that are related and may or may not have a 
common cause) (Reyes-Gibby et al., 2013).  
1.8.2 Pre-Clinical Evidence for a Role of TNFα in Pain 
As with NGF, it has been shown that intraplantar injection of murine TNFα in adult male rats 
resulted in both mechanical and thermal hypersensitivity, possibly due to the subsequent 
upregulation of the pro-inflammatory cytokine IL-1β and NGF (Woolf et al., 1997). This is in 
line with studies showing that anti-TNF therapy can inhibit the production of pro-
inflammatory cytokines in a variety of conditions, including rheumatoid arthritis and psoriasis 
(Schotte et al., 2004, Gottlieb et al., 2005). However, a study by Hakim and colleagues (Hakim 
et al., 2011), showed that TNF-induced sensitisation of masseter muscle nociceptors can be 
partially reversed by the prostaglandin E2 (PGE2) inhibitor Diclofenac, whereas inhibition of 
NGF via a TrkA antibody did not alter the mechanical threshold of the nociceptors. 
Furthermore, TNFR1 and TNFR2 knockout mice were shown to have reduced thermal 
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hyperalgesia in response to injection of Complete Freund’s Adjuvant (Zhang et al., 2011), and 
following nerve injury there is an up-regulation of TNFR1 in DRG neurones as well as TNFα 
secretion from surrounding glia (Ohtori et al., 2004). TNF signalling has also been implicated 
in the development of neuropathic pain. Treatment of rats with the TNFα antagonist 
molecule, TNFRII-fc, 2 days prior to spinal nerve injury, can attenuate the mechanical 
hypersensitivity produced with administration of TNFα, an effect that has been shown to be 
dependent on activation of the MAP kinase p38 (Schäfers et al., 2003).  
1.8.3 Human Studies as Evidence for a Role of TNFα in Pain 
Patients suffering from neuropathic pain have been shown to have elevated levels of TNFα in 
both serum/plasma and cerebrospinal fluid (CSF) samples compared to healthy controls 
(Beckers et al., 2013). Furthermore, human nerve biopsies from patients with neuropathies 
showed an increase in TNFR1 in patients with centrally mediated mechanical allodynia, an 
effect which was seen alongside an up-regulation of TNFα expression in the Schwann cells 
from the same patients (Empl et al., 2001). A further study has demonstrated that patients 
suffering from chronic pain due to a lumbar disc hernia showed an increase in both mRNA 
levels and protein levels of TNFα and TNFR1 in muscle and the nucleus pulposus (the inner 
core of the vertebral disc), an effect which was positively correlated with pain severity 
(Andrade et al., 2011). A meta-analysis of 14 studies, looking at TNFα serum levels in the 
painful inflammatory condition rheumatoid arthritis, demonstrated a significant increase 
when comparing RA patients with healthy controls (Wei et al., 2015). This increase in TNFα 
levels is also seen in the synovial fluid of psoriatic arthritis patients (Partsch et al., 1997) and 
osteoarthritis (Larsson et al., 2015), an effect which is thought to be accompanied by an 
increase in self-reported pain scores (Orita et al., 2011).  
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1.8.4 Mechanisms of TNFα-Mediated Pain 
Unlike NGF, the exact mechanisms involved in TNFα-mediated pain are still to be fully 
elucidated.  Specifically, it remains unclear as to if TNFα can act directly on nociceptors or if 
its effects are due to an indirect action via non-neuronal cell types. TNFα is widely regarded 
as a “master cytokine” due to its ability to initiate the production of a range of pro-
inflammatory cytokines, including IL-6 and IL-1β, both of which have been implicated in 
pathogenic pain (Cook et al., 2018b). The culmination of this signalling cascade is the release 
of prostanoids and catecholamines from sympathetic fibres (Poole et al., 1999), resulting in a 
maintained and enhanced inflammatory state. The prostanoid system has been shown to be 
an important element in the development of long-lasting sensitisation of primary afferent 
nociceptors in mice (Villarreal et al., 2013) and the levels of noradrenaline within the ventral 
striatum shown to be correlated with pain thresholds in a murine model of neuropathic pain 
(Taylor et al., 2014). 
However, multiple lines of evidence point towards TNFα having an additional direct effect on 
the nociceptors themselves. Using electrophysiological techniques, the response of naïve, 
spinal nerve ligated (SNL)-injured or adjacent uninjured rat DRG to exogenous TNFα has 
previously been examined. It was found that in vitro perfusion of TNFα evoked short-lasting 
neuronal discharges in naïve DRG, whereas in SNL-injured and adjacent uninjured DRG, 
subthreshold concentrations of TNFα elicited high-frequency discharges of a much longer-
lasting duration (Schafers et al., 2003a). One study used a CFA-induced inflammatory 
temporomandibular joint pain in mice to show an increase in immunofluorescence staining 
for TNFα. This was observed in both non-neuronal cells of the trigeminal ganglia and the spinal 
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trigeminal nucleus caudalis (Sp5C), but also enhanced expression in the Sp5C neurones 
themselves (Bai et al., 2018). 
TNFα-mediated hyperalgesia is thought to be dependent on nociceptive TNFR1 activation 
(Hensellek et al., 2007a) triggering downstream activation of stress kinases and simultaneous 
mobilisation of calcium (Pollock et al., 2002), resulting in increased sensory neurone 
sensitivity via modulation of various channels. For example, it has been proposed that TNFα 
can enhance tetrodotoxin-resistant (TTX-R) sodium channel currents, via a phosphorylation 
mechanism that can be prevented by the use of the p38 MAPK inhibitor SB202109, in isolated 
(non-purified) mouse DRG neurones (Jin and Gereau, 2006). TTX-R sodium channel currents 
are thought to contribute to the membrane excitability of DRG sensory neurones, with 
inflammatory mediators capable of enhancing these currents and therefore contributing to 
neuronal hyperexcitability (Tan et al., 2014). Furthermore, TNFα is thought to contribute to 
thermal hypersensitivity via a similar mechanism to NGF signalling. It has been shown that 
TNFα application to both rat and mouse DRG cultures (non-purified) for 24/48 h, results in 
increased TRPV1 expression (Hensellek et al., 2007a). In TNFR1 knockout mice, but not in 
TNFR2 mice, this response was abolished, corroborating the importance of TNFR1 in the 
development and maintenance of chronic pain (Parada et al., 2003, Andrade et al., 2016, Zeng 
et al., 2014). In contrast to the apparent role of p38 in sodium channel mediated 
hypersensitivity, the increase in TRPV1 has been suggested to be dependent on activation of 
ERK (Hensellek et al., 2007a). 
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1.9 TNFα in the Clinic  
1.9.1 Biologics as Anti-TNF Molecules 
A common first-line treatment for RA patients is the use of Methotrexate, known as a disease-
modifying anti-rheumatic drug (DMARD). The mechanisms by which Methotrexate is effective 
include suppression of lymphocyte proliferation and inhibition of pro-inflammatory cytokines 
(Li et al., 2017) via inhibition of folic acid reductase. Methotrexate is known to be effective 
even after prolonged use and is a low-cost option. However, there is a relatively high rate of 
adverse effects experienced with this drug, possibly associated with concomitant treatment 
with NSAIDs and corticosteroid treatment (El-Zorkany et al., 2013).  
Once the gold standard for RA treatment, methotrexate has since been over-taken by the 
development of anti-TNF biologics. There are currently several effective biologics on the 
market; etanercept, adalimumab and infliximab to highlight a few. 
Both infliximab and adalimumab are full IgG1 monoclonal antibodies: the latter is a fully 
humanized antibody whereas infliximab is a mouse/human chimeric. They work by binding to 
and deactivating the TNFα molecule, thus preventing its activation of either TNFR1 or TNFR2. 
Infliximab is often prescribed to patients with active on-going RA. It is thought that it primarily 
exerts its effect via down-regulation of a range of pro-inflammatory cytokines, such as IL-6, 
resulting in an improvement in the patients’ symptoms. Furthermore, reduced expression of 
IL-8 and MCP-1 in the synovial tissue of patients results in reduced migration of leukocytes 
into the damaged joint (Taylor et al., 2000), a process known to be key in the pathology of RA. 
However, one study has suggested that in addition to the latter, TNFα administered 
peripherally could impact on brain responses. RA patients treated with infliximab showed 
reduced fMRI signals in brain areas associated with pain processing as early as 24 h, whereas 
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any significant anti-inflammatory effects were seen later in the treatment at day 14 (Hess et 
al., 2011). The rapid action of anti-TNF treatment seen in this study suggests that as well as 
having disease modifying effects, it may also act as an analgesic acutely.  
Etanercept exerts its therapeutic benefit by acting as a decoy TNFα receptor, therefore also 
binding to lymphotoxin. It is a fusion protein made up of recombinant human TNFR2 
monomer fused with the Fc domain of the IgG1, which can bind to TNFα and deactivate it 
(Weinblatt et al., 1999, Marotte and Cimaz, 2014). Not only has etanercept treatment alone 
been shown to be superior to methotrexate treatment in rheumatoid arthritis patients 
(Genovese et al., 2002), but combination treatment of methotrexate and etanercept results 
in significantly improved outcomes in terms of disease activity, functional disability and 
radiographic progression of the disease (Klareskog et al., 2004).  
1.9.2 Issues with Anti-TNF Molecules in the Clinic Setting 
As with anti-NGF treatment, there are a number of drawbacks associated with anti-TNF 
treatment. In line with this, one study showed that chronic treatment with either infliximab 
or adalimumab over 12 weeks resulted in an increased risk of serious infection and 
malignancies (Bongartz et al., 2006), adverse effects thought to be due to the interruption of 
the biological role of TNFα in host defence mechanisms and tumour growth regulation (Ehlers, 
2003, Balkwill, 2006). 
Furthermore, infliximab has been linked with between a two-fold to seven-fold greater risk 
for developing infections, such as tuberculosis, compared to etanercept (Wallis et al., 2004). 
One possible explanation for infliximab’s increased risk of infection, in addition to the differing 
mechanism, is that peak blood levels are several times those of etanercept (Wallis, 2008).  
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Despite their impressive efficacy in a number of indications, it is also known that not all 
patients treated with anti-TNF treatment respond sufficiently. The latter suggests that there 
are alternative mechanisms of TNFα which we are currently unaware of and scope for the 
improvement of current mainstay therapies.  
1.10 Neuroimmune Interactions 
1.10.1 Overview of Neuroimmune Interactions 
The focus on the interplay between the immune system and the nervous system has emerged 
as a crucial area of scientific research in the past decade. Previously, it had been assumed that 
immune cell types, e.g. microglia, only interacted with neurones following an inflammatory 
insult; whereas it is now evident that the communication between these two distinct cell 
types is also present in non-pathological states (Veiga-Fernandes and Pachnis, 2017, Fung et 
al., 2017, Prinz and Priller, 2017). The lines of communication between these two systems are 
bidirectional, with each capable of having a profound effect on the other (Steinman, 2004). 
Given the complexity of this bidirectional cross talk, it is no surprise that there is mounting 
evidence for the dysfunction of neuroimmune signalling in a range of disorders, including 
neurological, gastrointestinal and respiratory related diseases (Nockher and Renz, 2003, Di 
Filippo et al., 2008, Hughes et al., 2013). The following paragraphs will outline how these 
neuroimmune interactions are key in the initiation, development and maintenance of pain 
states.  
1.11 Neuroimmune Interactions in Pain 
There are several commonalities that exist between the immune and nociceptive system. 
Both cell types are widespread throughout the body, have a principal function to recognise 
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and acutely respond to a threat, and have the ability for long-term adaptation (McMahon et 
al., 2015).  Therefore, it is no surprise that these systems are intricately interlinked, important 
pathways of which are highlighted in Figure 6. In the next paragraphs, the focus will explicitly 
be on how nociceptors and immune cells are known to influence each other in the context of 
pain.  
1.11.1 Immune Modulation of the Nociceptive System 
The immune system is known to primarily exert its effect on the nervous system via the 
production of soluble products, such as cytokines (Staud, 2015). Cytokines are known to act 
upon the neurones themselves, both in the peripheral nervous system (PNS) and the CNS, 
initiating downstream signalling cascades and, depending on the cytokine in question, 
exacerbating the inflammatory response (Zhang and An, 2007). The release of a range of 
soluble factors, secreted by both resident and recruited immune cells at the tissue site injury, 
triggers a number of changes in the peripheral sensory neurone. These changes include 
increased calcium mobilisation, increased voltage- or ligand- gated channel activation and 
increased neuropeptide transcription and release, to name a few (Ji et al., 2014). The net 
result of these changes is an increase in sensory neurone excitability and reduction in 
threshold activation leading to the hallmark signs of peripheral sensitisation; hyperalgesia and 
allodynia. The importance of these soluble factors is highlighted in diseases where targeting 
pro-inflammatory mediators, such as TNFα in RA, have produced favourable clinical outcomes 
in regard to pain-related endpoints (Seymour et al., 2001). 
Recently there has been growing evidence for the role of autoantibodies (antibodies 
produced by the immune system that react with self-antigens (Elkon and Casali, 2008)) in 
pathological pain (Dawes and Vincent, 2016). It has been known in a number of disease states, 
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such as RA and systemic lupus erythematosus, that autoantibodies contribute to pain via 
enhancing inflammatory processes (Aletaha and Blüml, 2016, Dema and Charles, 2016). Pain 
can arise from an increase in neuronal excitability, or from structural damage, caused by the 
binding of the autoantibody to its complement Fc-region, causing the release of inflammatory 
mediators and the subsequent excitation of nearby nociceptors, or from the direct binding of 
autoantibodies to the nociceptor itself (Goebel, 2016). Autoantibodies have been shown to 
be involved in pain processing in a number of diseases, including complex regional pain 
syndrome (CRPS) and neuromyelitis optica (Dawes and Vincent, 2016). One study 
demonstrated that CPRS patients who received plasma exchange therapy experienced a 
significant reduction in pain compared to pain levels experienced pre-treatment (Aradillas et 
al., 2015). Furthermore, it has been shown that neuropathic pain patient-derived Contactin-
associated protein-like 2 (CASPR2) antibodies induce neuropathic pain in previously healthy 
mice via a direct action on primary afferent cell bodies (Dawes et al., 2018).  
Immune modulation of the nociceptive system occurs in the CNS as well as in the PNS. There 
has been a growing body of evidence that outline a crucial role for glia, and in particular 
microglia, in the development and maintenance of chronic pain states (Vallejo et al., 2010, Ji 
et al., 2013, Gosselin et al., 2010). Microglia constitute 5-10% of all glia within the CNS (Tsuda 
et al., 2005) and are conventionally known as the resident macrophages of the CNS. Microglia 
can be broadly classified into two forms within the CNS; resting and activated, with differing 
morphologies. The activated forms have a hypertrophied soma, retracted processes and 
increased proliferation (Inoue and Tsuda, 2009) compared to the resting phenotype which 
takes a ramified form. Following activation, they release a number of molecules, including 
pro- and anti-inflammatory cytokines, such as IL-1ß and IL-10 respectively. Although their 
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primary function is to protect against invading foreign material, they are thought to have a 
significant role in neuropathic pain (Inoue and Tsuda, 2018). Additionally, it has been shown 
in female rats, in the collagen-induced arthritis model,  that the use of microglia inhibitors can 
prevent mechanical hypersensitivity, reduce microgliosis and attenuate the microglial-
mediated release of IL-1ß in the spinal cord, highlighting the role of this cell type in painful 
conditions such as RA (Nieto et al., 2016). 
The precise triggers which activate microglia and drive their cytokine secretion, in response 
to tissue damage or injury, are not completely understood. However, there is evidence to 
suggest that pattern- and damage-associated molecular patterns, such as LPS, are key 
contributing stimuli in the activation of microglia (Qin et al., 2005a).  A number of these 
molecules have been shown to up-regulate ion channels on the cell surface membrane of 
microglia.  
One such ion channel is the P2X4 receptor. P2X4 receptors are cell surface purinoceptors 
activated by extracellular ATP, often co-expressed alongside P2X7, and reside on the plasma 
membrane as well as intracellular vesicular compartments in both central and peripheral 
neurons, endothelial cells and microglia (Suurväli et al., 2017). Experiments that have 
selectively antagonised the P2X receptor family, using the molecule TNP-ATP, are suggested 
to be effective in alleviating allodynia and hypersensitivity following a peripheral nerve injury 
(Tsuda et al., 2003). Following nerve injury, expression of P2X4R is thought to be upregulated 
in microglia and a crucial step for the development of chronic pain. This pathway has since 
been well defined by those working in this area. The P2X4 receptor is thought to drive 
microglial phospho-p38 activation, resulting in BDNF synthesis and release. BDNF in turn is 
claimed to bind to the TrkB receptor on the Lamina 1 projection neurones and down-regulates 
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neuronal potassium-chloride transporter member 5 (KCC2), which is vital for chloride 
extrusion. This results in neuronal Cl- concentrations rising, impairing the inhibitory effect on 
gamma-Aminobutyric acid (GABA) and ultimately leading to neuronal hyperexcitability (Beggs 
and Salter, 2010). Once activated, microglia can activate adjacent microglia and astrocytes by 
paracrine mechanisms allowing maintenance of the pain state (Ji and Wen, 2006). 
1.11.2 Neural Modulation of the Immune System  
Similar to immune cells, nociceptors themselves have been shown to produce and release a 
range of small proteinaceous molecules, known as neuropeptides, in response to an 
inflammatory insult (Levine et al., 1993).  These neuropeptides are key in contributing to 
“neurogenic inflammation”, a concept first introduced by Goltz in 1874 and by Bayliss in 1901 
(Bayliss, 1901). These early experiments demonstrated, via electrically stimulating dorsal 
roots, that vasodilation of the skin (and the associated inflammation) could be induced 
independently of the immune system (Chiu et al., 2012). Two key neuropeptides involved in 
neurogenic inflammation are SP and CGRP, both of which can have a direct effect on the 
surrounding vasculature, via increased capillary permeability and vasodilation respectively 
(Pinho-Ribeiro et al., 2017b). In line with this, it has been shown that using antibodies to 
neutralise the effect of SP and CGRP, the symptoms associated with neurogenic inflammation 
have been significantly reduced (Louis et al., 1989, Amann et al., 1995, Zeller et al., 2008).  
The above process is the best example of how neurones can affect the immune response, 
details of which are discussed in the below paragraphs.  
In addition to the above neuropeptides, it has been reported that upon activation, 
nociceptors can release numerous mediators; growth factors, cytokines, chemokines and 
purines to highlight a few (Pinho-Ribeiro et al., 2017a). The above signalling molecules are 
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potentially capable of not only activating neighbouring neurones but also modulating a range 
of immune cell types, including dendritic cells, neutrophils, macrophages, mast cells and T 
cells (Pinho-Ribeiro et al., 2017a).  
In addition to contributing to neurogenic inflammation, both SP and CGRP are capable of 
regulating a range of immune cell phenotypes (Chavan et al., 2017).  For example, SP causes 
mast cell accumulation, activation and degranulation following a hindlimb injury in rats (Li et 
al., 2012), enhanced lymphocyte proliferation (Lambrecht et al., 1999) and increased 
activation of NF-κB (known to regulate numerous pro-inflammatory cytokines) in murine 
macrophages and dendritic cells (Marriott et al., 2000). Likewise, CGRP can modulate 
dendritic cell phenotype, skewing T cell priming and thus affecting downstream adaptive 
immune responses (Hosoi et al., 1993). Of note, there is evidence to suggest that mediators 
of neuronal origin are capable of working in cohort with immune cells to resolve inflammation 
and restore tissue homeostasis (Pradhan et al., 2009). 
Neurones can also affect the activation state of microglia.  There are various different signals 
which neurones can use to modulate microglia activation (Biber et al., 2007).  Broadly, these 
are classified into two categories, the ‘off’ signals which keep microglia in their resting state 
and the ‘on’ signals which are inducible and include the production of purines, chemokines 
and glutamate (Biber et al., 2007).  This further highlights the bidirectional relationship 
between the immune system and the nervous system. In line with this, it has previously been 
shown that neuronal conditioned medium can modulate the levels of activated microglia 
(Polazzi and Contestabile, 2003). 
The importance of these neuromediators, and their subsequent action on immune cell types, 
are highlighted in a number of disease models. For example, the use of SP and CGRP 
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antagonists in a mouse model of psoriasis, showed a reduction in skin lesions, leukocyte 
infiltration and skin inflammation (Ostrowski et al., 2011). On the other hand, the intranasal 
administration of SP in a murine model of allergic airway inflammation resulted in an increase 
in leukocyte infiltration, as well as an increase in the number of TNF+ and IFNγ+ T cells in 
lymph nodes (Joachim et al., 2006).  In line with the involvement of neuroimmune 
involvement in the resolution phase of inflammation, the exogenous application of CGRP in a 
murine model of experimental sepsis, shows a reduction in neutrophil recruitment, decreased 
levels of pro-inflammatory cytokines (e.g. TNFα) and an increase in anti-inflammatory 
cytokines (e.g. IL-10) (Gomes et al., 2005). 
Furthermore, trigeminal nociceptors have been found to express both the toll-like receptor 4 
(TLR4) and cluster differentiation 14 (CD14) receptors, enabling a direct activation from 
bacterial substances such as LPS (Wadachi and Hargreaves, 2006), resulting in neuronal 
sensitisation and subsequent activation of a range of immune cells. Woolf and colleagues 
(Chiu et al., 2013) demonstrated that both mechanical and thermal hyperalgesia in mice is 
correlated with live bacterial load as opposed to tissue swelling or immune activation of T 
cells, B cells, neutrophils and monocytes. The authors illustrate an induction of calcium in 
nociceptor-specific neurones following bacterial infection and an inhibition of bacteria-
induced pain in neurones lacking the sodium channel Nav1.8 ((Chiu et al., 2013). Additionally, 
it has been shown that the fungal infection Candida albicans can directly activate nociceptors, 
leading to CGRP release and increased production of IL-23 from CD301b+ dermal dendritic 
cells (Kashem et al., 2015). 
In conclusion, the above sections have highlighted the intricate relationship between sensory 
neurones and immune cell types. Evidence has been presented to highlight how this 
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interaction may be relevant in inflammation and therefore contribute to pain signalling. The 




Figure 6. Neuroimmune interactions following tissue injury in the periphery. A number of immune cells release a range of 
inflammatory mediators that act upon their respective receptors on the peripheral nerve terminal. Intracellular signalling 
pathways are activated and have the net result of an increase in neuronal excitability. In turn, the sensory neurone can 
release neuropeptides, such as CGRP and SP, which contribute to neurogenic inflammation and immune cell activation.  
Abbreviations: CGRP: calcitonin gene-related peptide; SP: substance P; TRP: transient receptor potential; GPCRs: G protein-
coupled receptors; PKA: protein kinase A; PKC: protein kinase C; MAPKs: mitogen-activated protein kinases; PGE2: 




1.12 Role of Macrophages in Pain  
Although there is abundant evidence for a range of immune cell types in both the 
development and maintenance of chronic pain states, this PhD project will focus on the 
interaction between nociceptors and one immune cell type; the macrophage. Therefore, this 
introductory section will give a brief overview of the biological function of macrophages, their 
importance in the inflammatory response and how they can modulate nociceptor function.  
1.12.1 Biological Function of Macrophages 
Macrophages are bone-marrow derived leukocytes, present in all vertebrate tissues, whose 
principal role is to promote homeostasis in response to internal and external changes by 
identifying foreign bodies and destroying them via phagocytosis (Gordon and Plüddemann, 
2017). This specialised cell type is divided into subpopulations based on their anatomical 
location and functional phenotype, e.g. osteoclasts (bone), Kupffer cells (liver) and alveolar 
macrophages (lung) (Murray and Wynn, 2011).  Macrophages are critical in immune 
surveillance function and are amongst the first cell type on the scene following an injury or 
infection (Gordon, 2016, Wynn et al., 2013). To prevent mistaken identity of healthy cells, 
macrophages recognise foreign material or dead/dying cells through pattern recognition 
receptors, such as toll-like receptors and C-type lectin receptors (Takeuchi and Akira, 2010). 
Their influence over a wide-range of cell types can be demonstrated by their ability to secrete 
over 100 different substances, depending on their activation state and surrounding 
environment (Arango Duque and Descoteaux, 2014, Laskin and Pendino, 1995). For example, 
the macrophage-driven secretion of pro-inflammatory cytokines, such as IL-1β and IL-6, 
results in recruitment of neutrophils, monocytes and T cells to the site of infection or injury 
(Arango Duque and Descoteaux, 2014). These recruited monocytes can then themselves 
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differentiate into macrophages, further contributing to the inflammatory environment 
(Italiani and Boraschi, 2014). The production of macrophage-derived IL-12 and IL-23 is 
important in the differentiation and expansion of anti-microbial T cells, a process needed to 
drive inflammatory responses forward (Sica and Mantovani, 2012). Macrophages are also 
known to play a role in the resolution phase of inflammation, via the production of anti-
inflammatory cytokines, such as IL-10 (Ortega-Gómez et al., 2013). Additionally, macrophages 
have been shown to be critical for wound-healing processes; clearing apoptotic cells and 
producing factors that stimulate angiogenesis and fibroplasia (Koh and DiPietro, 2011). 
A common model used to describe macrophage activation states is that of the M1/M2 
paradigm. In this model macrophages are said to have two opposing activated states, either 
classically activated, referred to as M1 macrophages (with a pro-inflammatory phenotype), 
or alternatively activated (with an anti-inflammatory phenotype), referred to as M2 
macrophages (Mills, 2015). However, recent research has suggested that a ‘spectrum model’ 
may be more suitable to due to the multiple and diverse macrophage activation states that 
can exist (Nahrendorf and Swirski, 2016, Martinez and Gordon, 2014). For example, the 
proposed conditions associated with chronic inflammation involve TNFα, PGE2 and P3C (Xue 
et al., 2014). The above model highlights the broad range of macrophage activation states 
and by extension, the wide-reaching biological functions of macrophage signalling. 
The inflammatory responses triggered via macrophage activation are initially considered 
beneficial, with the aim of restoring and maintaining the microenvironment. However, if left 
unresolved this continued inflammatory environment can lead to considerable tissue damage 
(Nathan and Ding, 2010). In line with this, macrophage signalling has been implicated in a 
number of chronic inflammatory and autoimmune diseases, including atherosclerosis, 
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inflammatory bowel disease and fibrosis (Wynn et al., 2013). Given the focus of this PhD 
thesis, the potential role of macrophage signalling in pain mechanisms is outlined below.   
1.12.2 Evidence for a Role of Macrophage Signalling in Pain  
As described above, activated tissue-resident and recruited macrophages from the blood are 
drawn to the site of injury as a first line response. In the context of both inflammatory and 
neuropathic models of pain, it has been proposed that macrophages not only infiltrate the 
DRG but also surround the affected sensory neurone terminal (Segond von Banchet et al., 
2009, Peters et al., 2007). The infiltration of activated macrophages has been demonstrated 
in humans with symptomatic OA, with the quantity of knee-related macrophages being 
significantly associated with pain severity (Kraus et al., 2016) and the macrophage biomarker 
CD14 (Daghestani et al., 2015). Mice injected with acidic injections into the gastrocnemius 
muscle displayed an increase in the number of local muscle macrophages, whilst the 
depletion of these macrophages (via the use of clodronate liposomes prior to acid injection) 
attenuated the associated hyperalgesia produced (Gong et al., 2016). 
1.12.2.1 Macrophage Modulation of Nociceptors 
Following macrophage infiltration (in addition to a number of other cell types) into the 
affected area, a range of mediators are released into the microenvironment, including TNFα, 
NGF, prostanoids and nitric oxide (NO). The role of these macrophage-derived mediators is 
highlighted in a number of studies. A recent study used macrophage specific COX2 knock-out 
mice to show that the mechanical and thermal hypersensitivity associated with CFA-evoked 
hind paw inflammation was significantly decreased, most likely due to a reduction in 
inflammatory cell infiltration alongside PGE2, IL-1β and TNFα levels (Chen et al., 2017b). 
Another study demonstrated that enhancing the number of peritoneal macrophages (via the 
76 
 
use of thioglycolate) in mice resulted in an increased number of nociceptive writhing 
responses to zymosan and acetic acid (Ribeiro et al., 2000). Similarly, intraperitoneal injection 
of the supernatant from LPS-stimulated macrophages into mice promoted nociceptive 
behaviour, an effect which was partially prevented using antisera directed against TNFα, IL-1 
or IL-8 (Thomazzi et al., 1997). These cytokines subsequently may act directly upon the 
sensory neurone terminal itself, or indirectly via other non-neuronal cell types, to lower the 
neuronal threshold for activation and increase action potential firing (as previously discussed 
in section 1.3.2.2)(Ji et al., 2014). An additional mechanism for macrophage-mediated pain 
has been proposed by Shutov and colleagues (Shutov et al., 2016). The authors suggest a 
crucial role for the complement system; a collection of soluble and membrane-bound 
proteins that are important in both the recognition and clearance of foreign molecules. The 
authors specifically suggest that the complement component 5a induces thermal 
hyperalgesia by activating macrophage-driven signalling, initiating the mobilisation of NGF 
and subsequent sensitisation of TRPV1 in sensory neurones (Shutov et al., 2016). Finally, a 
recent study demonstrated that pain hypersensitivity in male and female mice (induced via 
angiotensin II (Ang II) injection into the hind paw) is mediated via activation of the Ang II 
receptor (AT2R) and the ion-channel TRPA1 (Shepherd et al., 2018). Crucially, the authors 
demonstrate that activation of AT2R occurs on peripheral/skin macrophages, triggering the 
production of reactive oxygen/nitrogen species, which in turn trans-activate TRPA1 on mouse 
and human DRG sensory neurones via cysteine modification of the channel (Shepherd et al., 
2018). The latter study highlights how the relationship between non-neuronal cell types and 
sensory neurones can be crucial when trying to understand the mechanisms associated with 
chronic pain.  
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1.12.2.2 Macrophage Modulation of Immune Cells 
Macrophage released mediators can also act upon other immune cells, further increasing the 
release of pro-inflammatory cytokines and contributing to the ‘inflammatory soup’ and 
sensitisation of surrounding nociceptors (Lama Tamang et al., 2012). It has been shown that 
through the glucocorticoid-induced tumour necrosis factor ligand system, the interaction 
between macrophages and T cells can mediate neuropathic pain states (Kobayashi et al., 
2015). In addition, released mediators may also act upon the macrophage itself in an 
autocrine fashion. For example, TNFα signalling in macrophages mediates the further invasion 
of macrophages to the injured area by causing the up-regulation of adhesion molecules and 
the release of proteases (Scholz and Woolf, 2007). NGF has also been shown to have this 
chemotactic effect in vitro on murine macrophages (Kobayashi and Mizisin, 2001). 
Furthermore, TNF can activate an interferon-β autocrine loop in macrophages that sustains 
the expression of inflammatory genes such as IRF7 and STAT1, thus exacerbating the 
inflammatory environment (Yarilina et al., 2008a).  
The above section has highlighted the critical role for macrophage signalling in host defence  
and the biological mechanisms by which this is achieved, e.g. cytokine production and 
immune cell recruitment. Evidence for the dysregulation of macrophage signalling in the 
context of pain has also been presented. This thesis aims to dissect further mechanisms by 
which macrophages could be contributing to pain states and their possible contribution to 























2.  Aim of PhD 
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The above introduction has outlined the crucial role of inflammatory mediators in pain states. 
Evidence has been presented for the involvement of two mediators; NGF and TNFα, and how 
they affect the excitability of nociceptors, via both direct and indirect mechanisms. However, 
in vivo, these mediators are not secreted in isolation but rather as part of a complex array of 
molecules. While the individual actions of these molecules on primary sensory neurones are 
important, the interactions between these mediators, in addition to cross-talk between 
nociceptors and non-neuronal cells, are likely to be critical in the transition to chronic pain 
states and therefore crucial to improving pain management. 
Drugs which modulate NGF and TNFα have been developed and are having some degree of 
success as analgesics, yet safety concerns still exist around their usage. Investigating the 
relationship between NGF and TNFα could unearth new pain targets that have reduced 
adverse effects compared to targeting individual mediators. 
The above is further reinforced by several in vivo studies performed in-house at AstraZeneca. 
The use of a bispecific blocker, directed against NGF and TNFα simultaneously, in rodent 
models of both inflammatory and neuropathic pain, exhibits a superior analgesic effect 
compared to the blockade of either factor in isolation. Furthermore, this apparent synergistic 
analgesia is seen at doses at which the individual components are inactive, which could 
improve the risk to benefit ratio for patients (if translatable in the clinic). Although the in vivo 
data is striking, it remains largely unknown as to the biological mechanism(s) behind these 
results. This project explores the pathogenic contribution of NGF and TNFα in the 





The primary aims of this PhD thesis are to test the hypotheses that: 
1. TNFα (and NGF) produce pain-relevant responses via direct actions on sensory 
neurones. Specifically, primary cultures of purified sensory DRG neurones and bone-
marrow derived macrophages will be stimulated with NGF or TNFα to assess their 
influence on a number of pain-relevant endpoints. These endpoints include changes 
at both the molecular and cellular level. 
2. NGF and TNFα act in a synergistic manner to drive pain-relevant responses in vitro. 
The effect of stimulating purified DRG neuronal cultures, macrophages or a co-culture 
system with a combination of NGF/TNFα (compared to either one alone), on 
molecular and cellular readouts, will be deduced.  
3. Combined individual antagonism of NGF and TNFα in vivo, (which elicits superior 
analgesic efficacy), is associated with changes in the expression of pro-nociceptive 
genes and circulating cytokines in both the CFA model of inflammatory pain and the 





















3. Investigating the Individual and 
Combined Effect of NGF and TNFα on 




The primary purpose of this chapter is to discern both the individual and combined effect of 
NGF and TNFα on sensory neurones in vitro. This chapter will present data from the neuronal 
PC12 pheochromocytoma cell line, purified adult mouse DRG neuronal cultures and mixed 
adult mouse DRG neuronal/glia cultures.  
3.1.1 NGF Effect on DRG Sensory Neurones 
The profound effect of NGF on DRG sensory neurones has been extensively examined and 
therefore a large body of literature around this topic exists (Denk et al., 2017, Delcroix et al., 
2003, McMahon et al., 1995, Winter et al., 1988, Yip and Johnson, 1984). The mechanisms by 
which NGF contributes to a chronic pain state are well understood and have been outlined in 
section 1.5 of this thesis. Therefore, the purpose of including NGF as an experimental 
treatment group within this chapter are three-fold; firstly, to confirm those effects described 
within the literature, secondly, to act as a positive control to compare the effect of TNFα 
against and thirdly, to assess if NGF can synergise with TNFα. 
3.1.2 TNFα Effect on DRG Sensory Neurones 
It is less clear whether DRG sensory neurones are a cellular target for the cytokine TNFα. Due 
to its widespread effects, via multiple cell types, and its role as a master pro-inflammatory 
cytokine, dissecting the mechanisms by which TNFα can contribute to chronic pain conditions 
is considerably harder to establish. One of the main pieces of evidence suggesting a possible 
direct activation of the nociceptive system by TNFα comes from patients suffering from 
chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. Patients 
receiving therapeutic intervention which blocked the effects of TNFα found that there was a 
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significant reduction in their pain (Walsh and McWilliams, 2012, Mobasheri, 2013). However, 
the intriguing element of the above comes from the timescale on which this effect has been 
observed. The reduction in pain following anti-TNFα infusion has been shown to be apparent 
as early as 24 h, despite markers of inflammation being unaffected at this early time point 
(Hess et al., 2011). This suggests a direct action of TNFα on the nociceptive system, rather 
than an indirect effect via resolution of the inflammatory response, a process that would take 
considerably longer. The direct effect of TNFα on neurones is made more plausible by reports 
of TNFα receptor expression on sensory neurones (Li et al., 2004), expression levels (of both 
TNFR1 and TNFR2) have been reported to further increase in a number of pain models 
(Schafers et al., 2003b, Ma et al., 2009, Dubový et al., 2006). However, which TNFα receptor 
is present, on what cell type and to what extent, is still a controversial topic. For example, 
contrary to the above studies, Inglis and colleagues have reoorted that the increase in TNFR2 
expression is exclusively present in non-neuronal cell types (Inglis et al., 2005b). Another 
study reported that within the DRG TNFR1 co-localised with nociceptive markers >99 % of the 
time whereas TNFR2 was found to be completely absent (Wheeler et al., 2014). 
A number of studies have been conducted demonstrating that TNFα can have a profound 
effect in vivo by increasing responsiveness of C-fibers to mechanical stimulation, an effect 
which can be prevented via the blockade of TNFα (Sorkin et al., 1997, Richter et al., 2010). 
There is evidence to suggest a link between TNFα and the development of heat hyperalgesia. 
Studies have shown that acute application of TNFα to rat cutaneous nociceptors in vitro 
resulted in an enhanced heat-evoked release of CGRP (Bowen et al., 2006b, Oprée and Kress, 
2000), an effect possibly explained by a reported increase in TRPV1 expression in cultured 
DRG sensory neurones following 24-48 h exposure to TNFα (Hensellek et al., 2007a).  
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However, an element which all the above studies fail to consider/address is the involvement 
of non-neuronal cell types in all the preparations used, whether in vivo or in vitro. This PhD 
thesis is unique in that, as far as we are aware, this is the first time that the direct effect of 
TNFα on nociceptive neurones has been examined in a system where the presence of non-
neuronal cell types has been removed. The advantages and disadvantages of using this 
method are briefly outlined below.  
3.1.3 Purified Neuronal Cultures from MACS Sorting 
The magnetic-activated cell sorting (MACS) technique allows for the generation of 95 % pure 
neuronal populations, the characteristics of which are unchanged when compared with 
unsorted DRG cultures (Thakur et al., 2014). This technique allows the experimenter to use a 
substantially more controlled system to address fundamental biological questions. This 
method has been utilised in this PhD project to ascertain, with a high degree of certainty, if a 
particular treatment group has a direct effect upon the neurones themselves or whether any 
effects occur through an indirect mechanism, for example, via non-neuronal cell types. 
Although the characteristics of individual neurones passed through the magnetic columns are 
unchanged, a substantial reduction in neuronal yield occurs due to the entrapment of larger 
diameter neurones in the column. This limitation will be considered when drawing 
conclusions from the data presented. Nevertheless, the enrichment of small and medium 
diameter neurones in this pain-focussed project could be beneficial (Thakur et al., 2014). 
However, this reduction in neuronal yield also poses a technical challenge, particularly in 
experiments which require large quantities of neurones to yield sufficient assay signal. 
Therefore, throughout this project there are instances where it was deemed more 
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appropriate to use a mixed DRG glial-neuronal culture (following the use of a percoll gradient 
to remove debris) to obtain sufficient cell numbers.  
3.2 Aims and Experimental Strategy  
The aims of this chapter are: 
• to determine whether TNFα can directly signal and activate DRG sensory 
neurones 
• to determine whether the direct effects of TNFα, on sensory neurones, can 
summate with or synergise with the known actions of NGF 
 Where possible, the data presented in this chapter is conducted on purified DRG sensory 
neurones in order to negate any potential indirect effects of TNFα via non-neuronal cell types 
located in the culture.  
To assay the effect on DRG sensory neurones, four primary read-outs have been selected to 
achieve a broad assessment of sensory neurone function. Specifically, modulation of neurite 
outgrowth, nociceptive gene expression, cellular signalling (e.g. phospho-p38 induction and 
cytosolic calcium) and release of the neurotransmitter CGRP. 
Throughout all following data chapters, three different culture types have been used and will 
be referred to as follows; 
1. Purified DRG neuronal cultures (MACS sorted) 
2. Mixed DRG neuronal/glia cultures (percoll gradient to remove debris) 




All animals were obtained from Charles River and housed in a designated facility and 
maintained in accordance with the United Kingdom Home Office Animals (Scientific 
Procedures) Act (1986) and Home Office regulations. Animals were kept in a 12 h light dark 
cycle and fed ad libitum. All animals were sacrificed using schedule 1.   
3.3.1 Primary Cell Culture of DRG Cultures  
Adult C57BL/6 mice aged approximately 7-10 weeks were used to obtain primary sensory 
neurones. DRGs were collected from all levels of the spinal column. To access the DRGs, spinal 
columns were dissected out from the surrounding tissue and any extraneous muscle, fat and 
excess tissue removed. Using a scalpel, a longitudinal cut along the midline of the dorsal 
aspect of the spinal column was made to produce two equal halves. The spinal cord was then 
carefully removed in a rostral to caudal direction to reveal the DRGs. To remove the DRGs, 
the meninges were peeled back and the DRG was cut at its root prior to carefully being pulled 
out and transferred to ice-cold 1X Hank’s Balanced Salt Solution (HBSS) (Life Technologies, 
14175-053) in a 60 mm low bind petri dish (Corning, CLS3261). DRGs were incubated for 1 h 
at 37 ᵒC in an enzymatic mix made up of 3 mg/mL dispase (Life Technologies, 17105 041) and 
0.1 % collagenase (Type 1) (Life Technologies, 17100 017).  Following incubation, DRGs were 
carefully triturated in the enzyme mix up to 40 times before filtering through a 100 µM cell 
strainer (Corning, 352360) and basal F12 medium (Life Technologies, 21765-069), with fetal 
bovine serum (FBS) (Life Technologies 10500-064), added to inactivate the enzyme mix. Cells 
were centrifuged at 111 g for 5 min (ALC Centrifuge PK110) before being re-suspended in 1mL 
basal F12 and layered on top of a percoll gradient to remove any myelin and nerve debris 
from the resulting culture. The percoll gradient consisted of a 12.5 % mix layered on top of a 
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28 % mix to form a gradient interface. Mixes were made by diluting percoll (GE Healthcare, 
17-0891-01) in basal F12. Cells were spun for a further 10 min at 1300 g with the deceleration 
set to 6 (Hettich Zentrifugen). The debris and percoll gradient were removed prior to the cell 
pellet being re-suspended in the desired medium.   
3.3.1.1 Mixed DRG Neuronal/Glia Cultures 
For the mixed DRG neuronal/glia cultures, neurones were re-suspended in BS medium (basal 
F12, 1X N2 supplement (ThermoFisher Scientific, 17502048), FBS and Penicillin-Streptomycin 
(Pen/Strep) (Sigma Aldrich, P4333)) and plated at the desired density.  
3.3.1.2 Purified DRG Neuronal Cultures 
For purified DRG neuronal cultures, dissociated DRGs, following debris removal, proceeded 
to be purified using the MACS sorting technology and the Miltenyi Neuron Isolation Kit 
(Miltenyi, 130-098-752). Following removal of the percoll gradient the cell pellet was re-
suspended in 160 µL ice-cold MACS buffer (Miltenyi autoMACS HBSS-based washing solution 
with 0.5 % bovine serum albumin (Sigma Aldrich, A9418)), followed by the addition of 40 µL 
of non-neuronal antibody cocktail (including antibodies against astrocytes, oligodendrocytes, 
microglia, endothelial cells and fibroblasts) and a 5 min incubation at 4 ᵒC. Subsequently, 440 
µL of MACS buffer and 160 µL anti-biotin microbeads were added. The cell solution was 
incubated for 10 min at 4 ᵒC using an over-end mixer to ensure thorough mixing. The cell 
solution was passed through pre-washed LD exclusion columns (Miltenyi Biotech, 130 042 
901). This process retains ~95 % of non-neuronal biotin bound cells within the column, and 
only allows antibody free cells to pass through, resulting in a purified neuronal elute. The 
columns were rinsed through with MACS buffer and spun down at 400 g for 5 min (ALC 
Centrifuge PK110). The cell pellet was re-suspended in B27 media (Ham’s F12 with L-
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Glutamine, 2 % B27 (Life Technologies, 17504 044), 1 % 100X Pen/Strep) and the cells plated 
at the desired density. The specific densities were dependent on the experimental design, 
details of which are given below. If cultures were kept for a prolonged period of time, cultures 
were fed with the above media every 2-3 days.  
3.3.2 Culture of the Rat PC12 Neuronal Cell Line 
For experiments requiring the use of the rat PC12 pheochromocytoma neuronal cell line, a 
sub clone of the PC12 culture, Neuroscreen-1 cells were purchased from ThermoScientific. 
PC12 cells were plated in 100 µL fresh Roswell Park Memorial Institute medium (RPMI) 
(ThermoFisher Scientific, 11875093) supplement with 15 % FBS, 1 % 100X Pen/Strep and L-
glutamine) at 75K cells/well on Poly-D-Lysine-coated 96-well plates (Greiner). 
3.3.3 Neurite Outgrowth Experiments  
Following the culture and purification of adult mouse DRG neurones, purified neuronal 
cultures were plated on Poly-L-lysine (Sigma Aldrich, P4707) coated 13 mm coverslips 
(Academy, 400-04-17) placed in a 4-well plate (Thermo Scientific, 176740) incubated with 
growth-factor reduced matrigel (BD Bioscience, 356230) diluted 1:10 in pre-cooled F12 at 
room temperature (RT) for at least 1 h. Neurones were plated at a density of between 2-3K 
cells/well. Neurones were allowed to settle for 1 h, prior to being stimulated with NGF 
(Cambridge Bioscience, GFM11-1000), TNFα (Peprotech, 315-01A) or a combination of the 
two, see Table 2 for specific concentrations. Following a 24 h stimulation period, neurones 
were fixed in pre-warmed 2 % (w/v) paraformaldehyde (PFA) for 20 min at 37 ᵒC. Prior 
warming of the PFA in these sets of experiments prevented the breakdown of the matrigel 
and therefore the loss of cells. Following fixation, neurones were blocked in normal goat 
serum (ThermoFisher Scientific, 31873) made up in 0.2 % PBS Triton-X (Sigma Aldrich, T8787-
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50ML) for 30 min at RT to prevent non-specific binding. Following the removal of the blocking 
solution, the cells were incubated in the primary antibody solution mouse anti- III tubulin 
(Promega, G712A), at a concentration of 1:1000 in 0.2 % PBS Triton X for 30 min at RT. Cells 
were then washed three times in 1X Dulbecco’s Phosphate-Buffered Saline (DPBS) before 
being incubated with the secondary antibody Alexa Fluor 488 donkey anti-mouse IgG (H+L) 
(Life Technologies, A21202), at a concentration of 1:1000 in 0.2 % PBS Triton X for 30 min at 
RT.  The cells were then washed for a final three times before the coverslips were mounted 
onto slides using Prolong Gold Anti-fade Mountant with DAPI (LifeTechnologies, P-36931). 
Fluorescence was visualised using Carl Zeiss Axioplan2 microscope and Axiovision software.  
3.3.3.1 Data Analysis for Neurite Outgrowth Experiments 
Neurite outgrowth was analysed using ImageJ. The following measures were analysed: the 
average neurite length per cell and the percentage of cells with neurite outgrowth. Neurones 










Table 2. List of stimulations and concentrations of NGF and TNFα used throughout the neurite outgrowth experiments. 
NGF TNFα Combinations 
NGF 1 ng/mL TNFα 1 ng/mL 
NGF 1 ng/mL + TNFα 
1 ng/mL 
NGF 10 ng/mL TNFα 10 ng/mL 
NGF 10 ng/mL + TNFα 
1 ng/mL 
 TNFα 50 ng/mL 
NGF 1 ng/mL + TNFα 
10 ng/mL 
 TNFα 100 ng/mL 
NGF 10 ng/mL + TNFα 
10 ng/mL 
 
3.3.4 Gene Expression Analysis of Adult Mouse DRG Neurones 
For gene expression analysis of both purified DRG neuronal cultures and mixed DRG 
neuronal/glia cultures, neurones were plated at 8-10K cells/well in pre-coated poly-D-lysine 
coated Greiner 96-well plates (Greiner Bio-One, 655946) incubated with laminin (Sigma 
Aldrich, L2020) diluted 1:50 in basal F12 for 2 h at 37 °C. Both types of neuronal cultures were 
left overnight to settle prior to stimulation with varying concentrations of NGF, TNFα or a 





Table 3. List of stimulations and concentrations of NGF and TNFα used throughout the gene expression experiments. 
Condition NGF TNFα Combinations 
1 NGF 10 ng/mL TNFα 10 ng/mL 
NGF 10 ng/mL + TNFα 
10 ng/mL 
2 NGF 100 ng/mL TNFα 100 ng/mL 
NGF 100 ng/mL + TNFα 
100 ng/mL 
 
3.3.4.1 RNA Extraction and cDNA Synthesis 
RNA was isolated using the RNeasy plus micro kit (Qiagen, 74034) according to the 
manufacturer’s instructions: following stimulation, the supernatant was removed, and the 
remaining cells lysed via the addition of 75 µL RLT (RNeasy lysis buffer) Plus (Qiagen, 
1053393). RLT Plus buffer was supplemented with β-mercaptoethanol (Sigma Aldrich, 
M6250), at a ratio of 1:100 (10 µL to every 1 mL of buffer). The homogenised lysate was 
transferred to a gDNA Eliminator Spin Column and centrifuged for 30 secs at 8000 g 
(Eppendorf centrifuge 5424). The column was discarded and the flow through saved. An equal 
volume of 70 % ethanol was added to the saved flow through and mixed thoroughly prior to 
being transferred to a RNeasy MinElute Spin Column and centrifuged for 15 secs at 8000 g 
(Eppendorf centrifuge 5424).  At each of the following steps the flow through was discarded. 
The column was washed with 700 µL RW1 (RNeasy wash buffer), centrifuged for 15 secs at 
8000 g, (Eppendorf centrifuge 5424) followed by 500 µL RPE (RNeasy wash buffer) and 
centrifuged once more (same settings). Subsequently, 500 µL 80 % ethanol was added to the 
column and centrifuged for 2 min at 8000 g (Eppendorf centrifuge 5424) to further wash the 
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membrane. At this point the column was transferred to a new collection tube and centrifuged 
at full speed for 5 min (Eppendorf centrifuge 5424) with the lid open in order to fully air dry 
the membrane. Finally, the column was placed in a new 1.5 mL collection tube and 14 µL 
RNase-free water added directly to the centre of the membrane. To elute the RNA, the 
column was spun for a final time at full speed for 1 min (Eppendorf centrifuge 5424).  
Resulting RNA was quantified using the Agilent 2100 Bioanalyzer instrument. Samples were 
run using the Agilent RNA 6000 Pico Kit (Agilent, 5067-1513). This assay is based on traditional 
gel electrophoresis that have been transferred to a chip format, allowing for accurate 
quantification and integrity evaluation. Only samples with a RNA integrity number (RIN) < 
than 7 were taken forward for further analysis. Based on this quantification 15 ng of RNA was 
reverse transcribed using the Life Tech Vilo mastermix (Life Technologies, 11755050) 
following sample dilution with RNase free water. Total RT reaction consisted of 24 µL sample 
and 6 µL Vilo mastermix. The following RT cycling conditions were utilised; 25 ᵒC for 10 min, 
42 ᵒC for 60 min and 85 ᵒC for 5 min. Samples were diluted 3.5-fold in order to have enough 
sample for subsequent analysis and kept at 4 ᵒC until ready for use.  
3.3.4.2 RT-qPCR 
To obtain the relative quantification of the desired transcripts, samples were run in duplicate 
(unless otherwise stated) on the QuantStudio 12-FLEX Real-Time PCR system (Applied 
Biosystems) using TaqMan® Gene Expression Assays (Applied Biosystems). The use of TaqMan 
probes exploits the 5’-3’ nuclease activity of the Taq polymerase to detect and quantify 
specific PCR products. The target-specific TaqMan probe is conjugated with a reporter and 
quencher fluorochrome. Only in the presence of the target sequence is the probe degraded 
by the Taq polymerase, resulting in separation of the reporter and quencher dye. 
93 
 
Consequently, the fluorescence signal originating from the reporter dye is detected and 
increases during following PCR signals (van der Velden et al., 2001). 
Reaction mixtures were prepared on ice and contained: 5 µL TaqMan® Fast Universal PCR 
Master Mix 2X (Applied Biosystems, 4366073), 0.5 µL Eukaryotic 18S rRNA Endogenous 
Control, VIC®/MGB Probe (Life Technologies, 4319413E), 0.5 µL primer/probe (see Table 4 for 
complete list of mouse gene transcripts examined), 2.5 µL of sample and 1.5 µL of ddH2O, 
giving a final reaction volume of 10 µL.  A blank sample of water was used as a negative control 
in all experiments. The following cycling conditions were utilised; 25 ᵒC for 10 min, 42 ᵒC for 
60 min and 85 ᵒC for 5 min. 
3.3.4.3 Data Analysis for Gene Expression Experiments 
mRNA transcripts were normalised to the expression of the housekeeping gene 18S using the 
∆∆Ct method (Schmittgen and Livak, 2008) and data expressed as ∆∆Ct changes from the 















Tyrosine Kinase 1 
Mm01219406_m1 
Ngfr 





































Tumour Necrosis Factor 
Receptor 1 
Mm00441875_m1 
3.3.5 CGRP Release Enzyme Immunometric Assay 
Levels of CGRP in culture supernatants from mixed DRG neuronal/glia cultures were examined 
using SPI Bio’s Rat CGRP EIA kit (SPI Bio/Bertin Pharma, A05482). All reagents were made up 
according to the manufacturer’s instructions. The principle of the assay is based on a double-
antibody sandwich technique (Frobert et al., 1999). The CGRP antibody coated on the bottom 
of the plate binds to any CGRP from the sample, while the addition of an AChE 
(acetylcholinesterase)-Fab’ conjugate also binds selectively to a different epitope on the CGRP 
96 
 
molecule, creating an immobilised sandwich. The concentration of CGRP is measured using 
Ellman’s Reagent to detect the enzymatic activity of the AChE (Grassi and Pradelles, 1991). 
The intensity of the yellow colour formed is proportional to the amount of CGRP present in 
that sample (Mitchell, 2006).  
The above cultures were prepared as previously described in section 3.3.1.1. At the point of 
stimulation, performed in either duplicate or triplicate, 50 µL of culture supernatant was 
removed (leaving 100 µL of supernatant) and the desired concentration of stimulators (NGF 
0.1 ng/mL, 1 ng/mL, 10 ng/mL or 100 ng/mL, TNFα 10 ng/mL) added at a 6X stock in a volume 
of 20 µL BS medium. Cultures were allowed to respond to the above stimulations for 48 h. 
Following stimulations, CGRP release was evoked by challenging cultures with 100 µL 25 mM 
potassium (K+) solution, followed by a 30 min incubation at 37 ᵒC. Control wells were 
stimulated with ‘normal’ extracellular solution as a negative control for CGRP release. Normal 
extracellular control solution consisted of the following: 1L dH2O, NaCl (140 mM), KCl (2 mM), 
CaCl2 (2 mM), MgCl2 (1 mM) and HEPES (10 mM). The 40 mM stock of high K+ buffer solution 
consisted of the following: 1L dH2O, NaCl (102 mM), KCl (40 mM), MgCl2 (1 mM), CaCl2 (2 mM) 
and HEPES (10 mM). Both solutions were made to a pH of 7.4 and an osmolarity of 293 mOsm. 
To make the working solution of 25 mM K+ solution, 25 mL of the 40 mM high K+ buffer 
solution was added to 15 mL of normal extracellular solution. The resulting supernatant was 
diluted in an equal volume of EIA buffer and diluted further as necessary. 100 µL of either 
sample or standard was added to the provided pre-washed CGRP pre-coated 96-well strip 
plate. Non-specific binding wells (100 µL EIA buffer) and blank wells were also incorporated 
in the plate layout. The anti-CGRP AChE tracer was made up in EIA buffer and 100 µL added 
to each well (except blank wells). The plate was sealed with a plastic film and incubated for 
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72 h at 4 ᵒC. Following the incubation period, the plate was washed six times with 180 µL 
wash buffer for 2 min on the orbital shaker before the addition of 200 µL/well of Ellman’s 
Reagent. The plate was incubated in the dark for 45 min at RT using an orbital shaker for 
optimal development.  
3.3.5.1 Data Analysis for CGRP Release Experiments 
The absorbance was read at 405 nm on an EnVision Multimode Plate Reader (Perkin Elmer). 
The absorbance values of the standards were used to plot a standard curve, from which 
absorbance values of experimental samples were interpolated to determine their 
concentrations.  
3.3.6 Calcium Imaging 
For all calcium imaging experiments in this chapter, purified DRG neuronal cultures were 
utilised. Following the culture and purification of DRG sensory neurones, purified neurones 
were plated on Poly-L-lysine coated 13 mm coverslips placed in a 4 well plate incubated with 
growth-factor reduced matrigel as previously described in section 3.3.1.2. Neurones were 
plated at a density of approximately 1.5K cells/well in B27 medium and imaged 24 h later. 
Calcium imaging experiments were performed using a physiological extracellular solution 
(ECS); NaCl (8.176 g), KCl (0.373 g), glucose (1.801 g), HEPES (2.383 g), CaCl2.6H2O (0.294 g) 
and MgCl2.6H2O (0.203 g) was added to 1 litre of distilled H20 and the pH adjusted to 7.4 via 
the addition of hydrochloric acid or sodium hydroxide solutions.  Neurones were loaded with 
Fura-2 AM, a ratiometric calcium indicator dye which has its emission peak at 505 nM and 
changes its excitation peak from 340 nm to 380 nm in response to calcium binding (Barreto-
Chang and Dolmetsch, 2009). A stock concentration of 2.5 µM Fura-2 AM (Invitrogen, 
1881420), with 0.01 % Pluronic Acid (Invitrogen, 1899021), was diluted to 1:1000 in the above 
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ECS and 1 mM Probenecid (Sigma Aldrich, P8761) added to prevent the extrusion of the dye 
from the cell via its action as an anion transporter inhibitor, and kept protected from the light 
for the duration of the experiment. To load the neurone-plated coverslips, the culture media 
was gently removed and 500 µL of the above Fura-2 AM solution added. Cover slips were 
incubated at 37 °C for an hour prior to imaging commencing.  
For all experiments conducted, a perfusion system was utilised whereby the neurones were 
exposed to either a continuous flow of the above ECS or the physiological solution containing 
a desired concentration of the experimental stimulus. Each coverslip received a minimum of 
3 min perfusion with the ECS to establish a robust baseline. KCl was always applied at the end 
of the experimental procedure to identify neurones and confirm their viability. Imaging was 
conducted using the NIKON ECLIPSE TE200 microscope, the ORCA Flash 4.0 camera and the 
Easy Ratio Pro Software. 
3.3.6.1 Direct Activation on Purified DRG Neuronal Cultures with TNFα 
To determine if TNFα could trigger calcium transients directly a simple protocol was used 
(Figure 7).  Both TNFα and KCl solutions were made up in the above ECS and were perfused 







Figure 7. Schematic of timeline for calcium imaging experiments involving direct application of TNFα. 
 
3.3.6.2 Determining Purified DRG Neuron Response to Capsaicin 
To determine an appropriate dose of capsaicin to use, to produce a robust, sub-maximal 
response, a series of capsaicin concentrations were applied to purified DRG neurones as in 
the protocol summarised below (Figure 8). Both capsaicin and KCl solutions were made up in 
the above ECS. Capsaicin was perfused over the coverslip for 3 min and KCl for 1.5 min.  
 
 
Figure 8. Schematic of timeline for calcium imaging experiments determining appropriate capsaicin dose. 
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3.3.6.3 TNFα as a Sensitisation Agent on Purified DRG Neuronal Cultures 
To determine if TNFα could act as a sensitising agent and therefore increase the response of 
the neurones to capsaicin, coverslips were cultured for 24 h prior to calcium imaging in either 
B27 medium or TNFα 10 ng/mL (in B27 medium). A simple protocol was used to determine 
the response of purified neurones to a capsaicin concentration of 50 nM (Figure 9). Both 
capsaicin and KCl solutions were made up in the above ECS. Capsaicin was perfused over the 
coverslip 3 min and KCl for 1.5 min.  
 
 
Figure 9. Schematic showing the experimental set-up and timeline for calcium imaging experiments regarding TNFα 
sensitisation capability. 
3.3.6.4 Data Analysis for Calcium Imaging Experiments  
Images were extracted from the Easy Ratio Pro software as Tiff files and further image 
processing was undertaken using ImageJ Version 1.8. Subsequent data evaluation, graphing 
and statistical analysis was achieved using Microsoft Excel and GraphPad software (version 
7.04). Statistical analysis included either two-tailed t-tests or One-Way ANOVA followed by 
multiple comparison post-hoc tests. A P value <0.05 was considered significant.  
In order to generate traces of calcium signals from time lapse images, cell bodies of neurons 
were circled using the oval selection tool in ImageJ. Cell bodies were circled with minimal 
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overlap where possible. To generate normalised data (as neurons show differences in their 
baseline fluorescence), the baseline period (at least 3 min) of fluorescence for each cell and 







Where Ft is the fluorescence at time t and F0 is the fluorescence average over a baseline 
period. 
3.3.7 Homogenous Time Resolved Fluorescence Assay  
As both TNFα and NGF signalling initiate the activation of a variety of MAP kinases, a phospho-
p38 homogenous time resolved fluorescence (HTRF) assay (Jia et al., 2006) was employed to 
determine if any synergistic actions could be identified in this pathway. In order for p38 to be 
in an active form it must be phosphorylated on Thr180 and Tyr182 amino acid residues 
(Wilson et al., 1996). Following lysis of the cells, these phosphorylated forms can be detected 
using the following two monoclonal antibodies: the anti-phospho-p38 antibody conjugated 
to the donor molecule Eu3+-cryptate and the anti-p38 antibody conjugated to the acceptor 
molecule d2. Only when p38 has been phosphorylated, and therefore the acceptor and donor 
molecules are in close proximity, will there be a transfer of energy resulting in a fluorescent 
signal (on excitation of the Eu3+). The fluorescence produced is proportional to the amount of 
phospho-p38 present.  
Cisbio’s phospho-p38 kit (Cisbio, 64P38PEG) was used according to the manufacturers’ 
instructions. This assay was performed on the PC12 neuronal cell line and purified DRG 
neuronal cultures. Both cell types were stimulated with NGF, TNFα, a combination of the two 
or 100 µM anisomycin (Sigma Aldrich, A5862-0.5M), which acted as a positive control for p38 
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activation, for 5 or 20 min, for further details see Table 5. At the end of the specified time 
course the media was removed and 50 μL of lysis buffer from the Cisbio p38 kit was added. 
Subsequently, cells were placed on a shaker at 400 rpm at RT for 20 min. Following lysis, 16 
μL of each lysate was transferred to a parallel HTRF white 384-well plate (Cisbio, 66PL384025) 
for the Cisbio HTRF reaction. A 4 μL mix of diluted d2-labelled anti-phospho IgG and Europium 
labelled anti-p38 IgG was added to each lysate sample. A number of controls were used; 
control lysate (as a positive control), blank control (used to check the cryptate signal at 620 
nm) and a negative control (to check the non-specific signal). The plate was incubated with 
the antibody mix for 3 h at RT before being read on an EnVision Multilabel Plate reader 
equipped with a Xenon lamp. Upon the excitation of the donor (337 nm), the energy is 
transferred from the donor (620 nm emission) to the acceptor molecule (665 nm emission) if 
the two are in close proximity. This fluorescence resonance energy transfer (FRET) signal is 
proportional to the amount of phospho-p38 present in the samples.  
Table 5. Information regarding details of cell type, concentrations and stimulation times for the HTRF assay. 
Cell Type Density 






















3.3.8 Immunocytochemistry-Phospho-p38 Staining of Purified DRG Neuronal Cultures 
Levels of phospho-p38 were also measured using immunocytochemistry (ICC) techniques. 
Timings and stimulations were the same as previously described for the set-up of HTRF 
experiments (section 3.3.7) conducted with purified DRG neuronal cultures. Cultures were 
plated in pre-coated poly-D-lysine Greiner 96 well plates. DRG neurones were plated at 5K 
cells/well in 100 µL BS medium.  
Following the stimulation of neuronal cultures for 5 or 20 min, the supernatant was removed, 
and the cells fixed in 300 µL 4 % formaldehyde/PBS methanol-free (w/v) (Pierce™, 28906) for 
10 min at RT. Following aspiration of the fixative agent, cells were washed 3X with 1X PBS 
prior to being blocked in serum (1X PBS/ 5 % normal serum/ 0.3 % Triton™ X-100) for 1 h at 
RT. During this incubation period the primary antibody was prepared. Neuronal cultures were 
stained with a phospho-p38 MAPK 9Thr180/Tyr182 (D3F9) XP® Rabbit monoclonal antibody 
(Cell Signalling, 4511) diluted at a concentration of 1:1600 in the antibody dilution buffer (1X 
PBS/ 1 % BSA/ 0.3 % Triton™ X-100). The blocking solution was removed and 300 µL/well of 
primary antibody solution added overnight at 4 ᵒC. The following day the cells were washed 
3X in 1X PBS for 5 min each wash before being incubated with the secondary antibody Alexa 
Fluor 488 donkey anti-rabbit IgG (H+L) (Life Technologies, A21202), at a concentration of 
1:1000 in 0.2 % PBS Triton X for 2 h at RT. After the addition of secondary antibody, cells were 
protected from the light. The cells were again washed 3X in 1X PBS as before, after which cells 
were exposed to a Hoechst® (ThermoFisher Scientific, H1399) staining solution, diluted 
1:2000 in 1X PBS, in order to counterstain the nuclei. Cells were incubated in this solution for 
10 min, after which a final 3X wash with 1X PBS was performed. Neuronal cultures were 
visualised on the Olympus IX81 fluorescence microscope.   
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3.3.8.1 Data Analysis for Immunocytochemistry Experiments 
CellSens Dimension 1.11 (Olympus) imaging software was used for fluorescent image analysis 
of phospho-p38 staining intensity. Within cellSens, the ‘Count and Measure’ toolbar was 
activated and a suitable threshold for detecting FITC positive regions in the image was 
evaluated and set at 8,500 RFU counts. The images were then segmented and regions of the 
image which showed FITC fluorescence above this threshold were detected and areas 
calculated using cellSens. Mean intensity values for each detected object were also 
determined. Excel exports of these collated values were created and graphed in GraphPad. 
3.3.9 Statistical Analysis 
All statistical analysis was performed using GraphPad software (version 7.04). Prior to any 
statistical analysis taking place, the data were tested for normality using the Shapiro-Wilk 
normality test. Within this chapter, all experimental conditions were compared to the control 
untreated group and analysed using the following statistical tests; unpaired two-tailed t-test, 
One-Way ANOVA or Two-Way ANOVA followed by post-hoc correction tests for multiple 
comparisons. In all instances, data are displayed as Mean ± SEM and n numbers and specific 
post-hoc correction tests used reported within the figure legend. A P value <0.05 was 






3.4.1 Effect of Purifying Neuronal Cultures Using a Percoll Gradient In Vitro 
In standard DRG cell culture protocols that do not include a percoll gradient (or similar 
method), debris can remain (Figure 10G). The presence of debris could obscure cells of 
interest or alter the properties of the neurones themselves. Therefore, throughout this PhD 
thesis all neuronal cultures underwent a debris removal step via the use of a percoll gradient. 
The addition of the percoll gradient successfully removed debris and resulted in clearer 
visualisation of cells (Figure 10G and H). Within the DRG there are multiple cell types present 
in addition to the sensory neurones. A MACS sorting technique has been employed to remove 
non-neuronal cells and obtain purified DRG neuronal cultures. One of the limitations of the 
purification method is the reduction in neuronal yield (Thakur et al., 2014) (Figure 10C, F and 
I), therefore assays which required higher number of neurones (to improve reliability of said 












Figure 10. The effects of percoll gradient on the composition of plated cells in mixed and pure DRG neuronal cultures from 
adult mouse DRG. A-C) Images of neurones in a mixed DRG neuronal/glia culture minus a percoll gradient, mixed DRG 
neuronal/glia culture plus a percoll gradient and a purified DRG neuronal culture plus a percoll gradient. Cultures were 
stained with the neuronal marker βIII-tubulin. D-F) Images of the presence of non-neuronal cell types (highlighted with 
arrows) within the same cultures. Cultures were stained with the satellite glial cell marker glutamine synthetase. G-I) Images 
displaying the level of debris between the three different types of culture. Scale bar represents 20 μM.  





3.4.2 TNFα has No Significant Effect on Neurite Outgrowth 
A neurite outgrowth assay was used as a measure of the general sensitivity of the neurons to 
a range of TNFα concentrations. Purified DRG neuronal cultures were used to remove any 
involvement from non-neuronal cell types. Following a 24 h stimulation period, cultures were 
fixed, stained and visualised on the microscope. Two read-outs were performed; the average 
neurite outgrowth per cell and the % of cells with neurite outgrowth.  
It was found, as shown previously (Wong et al., 2015), that treating purified neuronal cultures 
with NGF (10 ng/mL) resulted in a significant increase in average neurite outgrowth per cell 
(Figure 11A), with treated cells (average neurite outgrowth of 571.3 ± 76.99 µm, n=5 
biological replicates, One-Way ANOVA; F(5,24)=22.31, P<0.0001) showing approximately 16 
times more neurite outgrowth, compared to untreated cells (average neurite length of 34.88 
± 12.05 µm, n=5 biological replicates) (Figure 11D). The presence of NGF (10 ng/mL) did not 
affect the average % of cells with neurite outgrowth (Figure 11B).  
Following the confirmation of NGF as a relevant positive control, a range of TNFα 
concentrations (ng/mL) were examined: 1, 10, 50 and 100. Neither average neurite outgrowth 
per cell nor % of cells with neurite outgrowth displayed any significant changes with TNFα at 
any concentration (Figure 12). 
Since no effect of TNFα alone was observed, two concentrations of TNFα were chosen, 1 
ng/mL and 10 ng/mL, and their effect on neurite outgrowth evaluated in combination with 
that of NGF (10 ng/mL) (Figure 12). Regarding average neurite outgrowth per cell, both 
combination groups (TNFα 1 ng/mL or 10 ng/mL in combination with NGF 10 ng/mL) produced 
a significant increase compared to both the untreated group and the individual TNFα 
treatment group (Figure 13A and B). The combination treatments showed no significant 
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difference to the NGF alone treatment group (Figure 13A and B). No significant changes were 
detected in relation to the % of cells with neurite outgrowth (Figure 13C and D).  
To ensure that the use of NGF at 10 ng/mL was not a saturating concentration, and therefore 
able to mask any synergistic effect with TNFα in the combination treatment groups, the 
concentration of NGF was lowered to 1 ng/mL. Compared to the untreated group, NGF at 1 
ng/mL induced a significant increase in the average neurite outgrowth per cell (211.9 ± 48.01 
µm to 1032 ± 434 µm, n=3 biological replicates, One-Way ANOVA; F(7,16)=3.38, P=0.0206). 
No significant changes were seen in neurite outgrowth between the untreated group and the 
range of individual TNFα groups or the combination groups (Figure 14A). No significant 











Figure 11. Neurite outgrowth of purified DRG neuronal cultures in response to NGF (10 ng/mL). A) The mean neurite 
outgrowth or B) the % of neurones with neurite outgrowth following 24 h treatment with NGF (10 ng/mL). C-D) 
Representative fluorescent micrographs following immunostaining for the neuronal marker βIII-tubulin, and the nuclear stain 
DAPI, in purified DRG neuronal cultures which were untreated or treated with NGF (10 ng/mL, 24 h). Data displayed as Mean 
± SEM, n=5 biological replicates (displayed as individual data points). Data were analysed using One-Way ANOVA followed 
by Tukey’s multiple comparisons test. *** P<0.001.  Scale bar represents 50 μM.  




Figure 12. Neurite outgrowth of purified DRG neuronal cultures in response to a range of TNFα concentrations. A) The 
mean neurite outgrowth or B) the % of neurones with neurite outgrowth following 24 h treatment with TNFα (1, 10, 50 or 
100 ng/mL). C-F) Representative fluorescent micrographs following immunostaining for the neuronal marker βIII-tubulin, 
and the nuclear stain DAPI, in purified DRG neuronal cultures which were untreated or treated with TNFα. Data displayed as 
Mean ± SEM, n=5 biological replicates (displayed as individual data points). Data were analysed using One-Way ANOVA 
followed by Tukey’s multiple comparisons test. *** P<0.001.  Scale bar represents 50 μM.  







Figure 13. Neurite outgrowth of purified DRG neuronal cultures in response to the combination treatment of NGF and 
TNFα. A-B) The mean neurite outgrowth or C-D) the % of neurones with neurite outgrowth following 24 h treatment with 
NGF 10 ng/mL + TNFα 1 ng/mL or NGF 10 ng/mL + TNFα 10 ng/mL. E-F) Representative fluorescent micrographs following 
immunostaining for the neuronal marker βIII-tubulin, and the nuclear stain DAPI, in purified DRG neuronal cultures treated 
with the combination treatments. Data displayed as Mean ± SEM, n=5 biological replicates (displayed as individual data 
points). Data were analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test. * P<0.05, ** P<0.01, *** 
P<0.001, **** P<0.0001.  Scale bar represents 50 μM.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; DAPI: 4’,6-diamidino-2-phenylindole; DRG: 





Figure 14. Neurite outgrowth of purified DRG neuronal cultures in response to low dose NGF (1 ng/mL). A) The mean 
neurite outgrowth or B) the % of neurones with neurite outgrowth following 24 h treatment with NGF 1 ng/mL, TNFα 1, 10, 
50 or 100 ng/mL. Data displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data were 
analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test. * P<0.05.  










3.4.3 TNFα Showed no Regulation of Pain-Relevant Genes Within Purified DRG Neuronal 
Cultures 
The ability of the NGF-TrkA complex to be internalised and retrogradely transported to the 
cell body, where it can drive extensive transcriptional changes relating to increased pain 
sensitivity, have been well documented (Costigan and Woolf, 2000) and discussed previously 
in this thesis (section 1.5.3). Therefore, the possible effect of TNFα at the transcriptional level, 
on both a mixed and purified culture, on a panel of pain-related genes were investigated. In 
support of this line of research, it has previously been shown, in a neuropathic model of pain 
in mice, that the upregulation of a number of gene transcripts (Atf3, Npy and Il-6) in the L5 
DRG could be significantly suppressed following lentiviral-mediated silencing of TNFα in the 
DRG (Ogawa et al., 2014). 
In the first instance, the basal level of receptor expression for both NGF and TNFα was 
determined. Ntrk1, Ngfr and Tnfrsf1a were all detectable in both purified DRG neuronal 
cultures and mixed DRG neuronal/glia cultures (Figure 15). Levels of Ntrk1 and Ngfr were 
found to be similar in purified DRG neuronal cultures, with an average Ct value of 29.97 ± 0.46 
(Ct) and 28.58 ± 0.25 (Ct) respectively (n=3 biological replicates). However, the Ct value of 
Tnfrsf1a was found to be slightly higher with an average Ct value of 31.71 ± 0.55 (Ct) (n=3 
biological replicates) (Figure 15). In mixed DRG neuronal/glia cultures, the average Ct values 
were found to be lower across all three receptors, with Ct values of 27.61 ± 0.48 (Ct), 25.89 ± 
0.45 (Ct) and 30.4 ± 0.56 (Ct) (n=3 biological replicates) for Ntrk1, Ngfr and Tnfrsf1a 
respectively (Figure 15). 
Following confirmation of all mRNA receptor transcripts in both culture types, the 
transcriptional effect of a 72 h stimulation with either NGF, TNFα or a combination of the two, 
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on a number of pain-related genes was examined. Experiments were performed at 
concentrations of both 10 ng/mL and 100 ng/mL.  
In purified DRG neuronal cultures, the effect of NGF, TNFα and a combination of the two on 
gene expression was tested using a Two-Way ANOVA; a significant treatment effect was 
observed (F(3,108)=17.79, P<0.0001).  It was found that NGF (10 ng/mL) produced a 
significant increase in Trpv1 expression (2.49 ± 0.91 ΔΔCt, n=4 biological replicates) compared 
to the baseline untreated group and a trend for an increase in the expression of all other 
genes (Figure 16A). No significant changes in the expression of Ntrk1, Ngfr, Scn10a, Scn11a, 
Trpv1, Calca, Ptgs2, F2rl1 or Tac1 were detected when cultures were stimulated with TNFα 
alone or with TNFα in combination with NGF (Figure 16A).  
Interestingly, in mixed DRG neuronal/glia cultures, treated in the exact same manner, the NGF 
effect was much less prominent, with no genes being significantly upregulated (Figure 16B). 
In mixed DRG neuronal/glia cultures, the effect of NGF, TNFα and a combination of the two 
on gene expression was tested using a Two-Way ANOVA; a significant treatment effect was 
observed (F(3,108)=12.6, P<0.0001). In these mixed DRG neuronal/glia cultures, the effect of 
TNFα was still minimal in the majority of genes examined but a prominent and significant 
increase was detected in both the expression of Ptgs2 (prostaglandin-endoperoxidase 
synthase 2) and F2rl1 (protease activated receptor 2) (an increase of 1.09 ± 0.39 ΔΔCt and 
1.10 ± 0.58 ΔΔCt respectively, n=4 biological replicates) (Figure 16B). These genes also 
changed significantly in the combination group (Figure 15B) with increases of 1.06 ± 0.39 ΔΔCt 
and 1.70 ± 0.34 ΔΔCt (n=4 biological replicates) observed from the baseline untreated group 
regarding Ptgs2 and F2rl1 expression (Figure 16B).  
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On increasing the concentration of NGF to 100 ng/mL, a much more prominent effect, in both 
purified DRG neuronal cultures and mixed DRG neuronal/glia cultures on the expression of 
the pain-relevant genes (Ntrk1, Ngfr, Scn10a, Scn11a, Trpv1, Calca, Ptgs2, F2rl1, Tac1, 
Tnfrsf1a, Scn9a) was detected (Figure 17A and B). In the purified DRG neuronal cultures, the 
effect of NGF, TNFα and a combination of the two on gene expression was tested using a Two-
Way ANOVA; a significant treatment effect was observed (F(3,77)=23.68, P<0.0001). NGF (100 
ng/mL) produced significant increases in the expression of Ntrk1, Ngfr, Scn10a, Scn11a, Trpv1 
and Calca (Figure 17A) (increases of 1.74 ± 0.79 ΔΔCt, 2.05 ± 0.43 ΔΔCt, 1.93 ± 0.84 ΔΔCt, 1.65 
± 0.88 ΔΔCt, 2.44 ± 0.01 ΔΔCt and 1.65 ± 0.94 ΔΔCt respectively, n=3 biological replicates) 
from the baseline untreated group. In the mixed DRG neuronal/glia cultures, a significant 
treatment effect was also observed (F(3,88)=17.37, P<0.0001). NGF produced significant 
increases in the expression of similar genes (Ngfr, Scn10a, Scn11a, Trpv1, Calca as well as 
Tac1) (increases of 1.15 ± 0.32 ΔΔCt, 1.04 ± 0.48 ΔΔCt, 1.03 ± 0.42 ΔΔCt, 1.18 ± 0.19 ΔΔCt, 
1.04 ± 0.56 ΔΔCt and 1.59 ± 0.32 ΔΔCt respectively, n=3 biological replicates). Interestingly, 
NGF-mediated enhancement of Tac1 gene expression (encodes for substance P) was 
significantly dampened by the addition of TNFα (Figure 17B). The only detectable TNFα-driven 
change detected in this series of experiments were an increase in the mRNA expression levels 
of Ptgs2 and F2rl1 (Figure 16B and 17B). The TNFα-driven increases in Ptgs2 and F2rl1 
(increases of 1.67 ± 0.23 ΔΔCt and 2.45 ± 0.53 ΔΔCt respectively, n=3 biological replicates), 
were only present in mixed DRG neuronal/glia cultures and not purified DRG neuronal 
cultures (Figure 16 and 17). The magnitude of the TNFα induced changes in mRNA for Ptgs2 






Figure 15. Expression levels of NGF and TNFα receptor mRNA in purified DRG neuronal cultures or mixed DRG 
neuronal/glia cultures. The graphs shown display the basal Ct values of Ntrk1, Ngfr and Tnfrsf1a as well as the housekeeping 
gene 18S. Data displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points).  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; Ntrk1: neurotrophic receptor tyrosine kinase; 





Figure 16. Comparison of transcriptional changes at the mRNA level in pain-relevant genes in either purified DRG neuronal 
cultures or mixed DRG neuronal/glia cultures (10 ng/mL). ΔΔCt values in A) purified DRG neuronal cultures or B) mixed DRG 
neuronal/glia cultures following treatment with NGF 10 ng/mL, TNFα 10 ng/mL or a combination of the two for 72 h. Data 
displayed as Mean ± SEM, n=4 biological replicates. Data were analysed using Two-Way ANOVA followed by Tukey’s multiple 
comparisons test. * P<0.05, *** P<0.001, **** P<0.0001, significance displayed represents changes from the normalised 
baseline ‘untreated’ group.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; Ntrk1: neurotrophic receptor tyrosine kinase; 
Ngfr: nerve growth factor receptor; Scn10a: sodium voltage-gated channel alpha subunit 10; Scn11a; sodium voltage-gated 
channel alpha subunit 11; Trpv1: transient receptor potential vanilloid 1; Calca: calcitonin related polypeptide alpha; Ptgs2: 







Figure 17. Comparison of transcriptional changes at the mRNA level in pain-relevant genes in either purified DRG neuronal 
cultures or mixed DRG neuronal/glia cultures (100 ng/mL). ΔΔCt values in A) purified DRG neuronal cultures or B) mixed 
DRG neuronal/glia cultures following treatment with NGF 100 ng/mL, TNFα 100 ng/mL or a combination of the two for 72 h. 
Data displayed as Mean ± SEM, n=3 biological replicates. Data were analysed using Two-Way ANOVA followed by Tukey’s 
multiple comparisons test. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001, significance displayed represents changes from 
the normalised baseline ‘untreated’ group.  # P< 0.01, significance displayed represents changes from the NGF alone group 
compared to the combination group.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; Ntrk1: neurotrophic receptor tyrosine kinase; 
Ngfr: nerve growth factor receptor; Scn10a: sodium voltage-gated channel alpha subunit 10; Scn11a; sodium voltage-gated 
channel alpha subunit 11; Trpv1: transient receptor potential vanilloid 1; Calca: calcitonin related polypeptide alpha; Ptgs2: 
prostaglandin-endoperoxide synthase; F2rl1: proteinase-activated receptor 2; Tac1: tachykinin precursor 1; Tnfrsf1a: tumour 





3.4.4 K+ Evoked CGRP Release is Sensitised by NGF, but not TNFα Treatment in Mixed DRG 
Neuronal/Glia Cultures 
The release of CGRP, following K+ stimulation, was used as a pain-relevant read-out to assess 
whether TNFα could modulate sensory neuronal activity. NGF increased K+ induced CGRP 
release in a concentration-dependent manner (Figure 18A), with the top concentration of 
NGF (100 ng/mL) inducing CGRP release to a level of 3233 ± 349.7 pg/mL (n=at least 4 
biological replicates) compared to the untreated treatment group (720.1 ± 72.81 pg/mL, n=at 
least 4 biological replicates) (Figure 18A). To avoid saturation, the effect of a 10 ng/mL dose 
of NGF was compared to the same dose of TNFα. Despite the lower dose, NGF (10 ng/mL) 
induced a significant increase in K+ induced CGRP release (an increase ~176 %) when 
compared to the untreated control cultures (720.1 ± 72.81 pg/mL to 1988 ± 218.3 pg/mL, 
One-Way ANOVA; (F(2,39)=37.35, P<0.0001) n= at least 4 biological replicates) (Figure 18B). 
However, TNFα treatment showed no difference compared to the untreated control cultures 
(720.1 ± 72.81 pg/mL and 732.7 ± 65.63 pg/mL respectively, n=at least 4 biological replicates) 








Figure 18. CGRP release following K+ stimulation in a mixed DRG neuronal/glia culture. A) 25 mM K+-evoked CGRP release 
in mixed DRG neuronal/glia cultures pre-treated (48 h) with varying NGF concentrations; 0.1 ng/mL (black triangle), 1 ng/mL 
(black upside-down triangles), 10 ng/mL (black diamonds) and 100 ng/mL (hollow hexagon). B) 25 mM K+-evoked CGRP 
release in mixed DRG neuronal/cultures pre-treated with TNFα (10 ng/mL, 48 h, hollow squares) or NGF (10 ng/mL, 48 h, 
black diamonds). Data displayed as Mean ± SEM, data points represent data collected from at least 4 biological replicates.  
Data were analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test. **** P<0.0001.  
Abbreviations: CGRP: calcitonin gene-related peptide; DRG: dorsal root ganglia; NGF: nerve growth factor; TNFα: tumour 




3.4.5 Direct Application of TNFα Does Not Sensitise Calcium Responses in Purified DRG 
Neuronal Cultures  
To further examine the possible action of TNFα using a functional read-out, calcium imaging 
was utilised to assess any modulation of neuronal activity. Both the ability of TNFα to directly 
activate neurones, or to sensitise them, was assessed.  
In the first instance, the possible direct effect of TNFα was examined via the perfusion of a 
TNFα (10 ng/mL) solution directly over purified DRG neuronal cultures. Purified neurones 
showed no detectable response to TNFα stimulation (Figure 19A). However, strong and 
consistent responses to a positive control (KCl 25 mM) were seen, with 93.81 ± 2.3 % (n=848 
neurones across 3 mice) of neurones responding (Figure 19B), suggesting that the lack of 
response seen in the TNFα condition is not due to the death/poor health of the neurones.  
Next, the level of sensitisation of purified neurones cultured in TNFα (10 ng/mL in BS medium) 
was examined via the application of capsaicin.  
To determine an appropriate dose of capsaicin to use in subsequent experiments, a pilot 
experiment was performed. Four concentrations of capsaicin were tested; 10 nM, 50 nM, 100 
nM and 500 nM. Three read-outs were examined: the % of cells responding to capsaicin, the 
difference between the maximum capsaicin response and the baseline, to establish the 
magnitude of the response, and the % of cells responding to KCl (25 mM).  It was found that 
very few neurones responded directly to 10 nM capsaicin (0.67 ± 0.07 % responding neurones, 
n=607 neurones across 2 mice), whilst more responded to 50 nM capsaicin (12.66 ± 1.69 % 
responding neurones, n=406 neurones across 2 mice). However, once the capsaicin 
concentration reached 100 nM, resulting in 18.7 ± 1.71 % recruitment of neurones (n=446 
across 2 mice), a further increase to 500 nM did not increase the percentage of responding 
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neurones (18.13 ± 0.62 % responding neurones, n=361 neurones across 2 mice) (Figure 20A). 
Different concentrations of capsaicin did not significantly alter the magnitude of the 
responses to capsaicin (as measured by the difference between the maximum capsaicin 
response and the baseline) or the % of cells responding to KCl (Figure 20B and C). Based on 
the above data, a dose of 50 nM capsaicin was deemed a suitable concentration to deliver a 
robust, but not saturated, response during the imaging sessions. This would allow for the 
detection of changes in either the number or magnitude of responses to capsaicin in a 
putative sensitised state.  
Following 24 h incubation of purified DRG neuronal cultures with either untreated or TNFα 
containing media, the response of the neurones to capsaicin (50 nM) was determined. It was 
found that there were no significant differences between the two groups in the % of cells 
responding to capsaicin. In the untreated group, 14.61 ± 1.81 % (n=1343 neurones across 3 
mice) neurones responded to capsaicin compared to 14.26 ± 2.7 % (n=1177 neurones across 
3 mice) neurones responding in the TNFα 10 ng/mL treatment group (Figure 21A-C). Likewise, 
there was no difference between the groups in the magnitude of the response to capsaicin 
(50 nM) (0.5 ± 0.09 ΔF/F in the untreated group (n=1343 neurones across 3 mice) compared 
to 0.49 ± 0.06 ΔF/F in the TNFα (10 ng/mL) treatment group (n=1177 neurones across 3 mice)) 
(Figure 21E) or KCl (25 mM) (0.54 ± 0.06 ΔF/F in the untreated group (n=1343 neurones across 
3 mice) compared to 0.54 ± 0.06 ΔF/F  in the TNFα (10 ng/mL) treatment group (n=1177 
neurones across 3 mice)) (Figure 21F). The majority of neurones were responsive to KCl, 95.42 
± 1.79 % in the untreated group (n=1343 neurones across 3 mice) and 94.61 ± 1.44 % in the 
TNFα 10 ng/mL treatment group (n=1177 neurones across 3 mice) (Figure 21A, B and D), 





Figure 19. Calcium transients in purified DRG neuronal cultures following direct application of either TNFα (10 ng/mL) or 
KCl (25 mM). A) Representative trace from a coverslip displaying ΔF/F versus time. TNFα (10 ng/mL) was applied for 2 min 
followed by a wash-out period and a final KCl (25 mM) stimulus to ensure cell viability. B) Quantification of % of responding 
cells to both TNFα (10 ng/mL) or KCl (25 mM). Data displayed as Mean ± SEM, n=848 neurones across 3 mice. Data points on 
graphs represent individual cover slips.  






Figure 20. Calcium transients in purified DRG neuronal cultures following direct application of a range of capsaicin 
concentrations (10 nM, 50 nM, 100 nM or 500 nM) or KCl (25 mM). A) % of cells responding to each concentration of 
capsaicin. B) The maximum response after exposure to different capsaicin concentrations (calculated by taking the difference 
between the maximum capsaicin response recorded and the average intensity of ten frames pre-capsaicin stimulus.) C) % of 
cells responding to KCl (25 mM). D) Representative neuronal calcium displaying ΔF/F versus time. Capsaicin stimulus 
represents 50 nM capsaicin. Data displayed as Mean ± SEM, n=1820 neurones across cultures from 2 independent mice (1 
coverslip/condition for each mouse). Capsaicin 10 nM (607 neurones), 50 nM (406 neurones), 100 nM (446 neurones), 500 
nM (361 neurones).  






Figure 21. Calcium transients in purified DRG neuronal cultures following 24 h in untreated medium or medium treated 
with TNFα (10 ng/mL). A-B) Representative neuronal calcium transients displaying ΔF/F versus time. Capsaicin (50 nM) was 
applied for 3 min followed by a wash-out period and a final KCl (25 mM) stimulus to ensure cell viability. C-D) Quantification 
of % of responding cells to both capsaicin (50 nM) or KCl (25 mM). E-F) The maximum response seen after capsaicin (50 nM) 
or KCl (25 mM) application (calculated by taking the difference between the maximum capsaicin/KCl response recorded and 
the average intensity of ten frames pre-capsaicin/KCl stimulus.) Data displayed as Mean ± SEM, n=2520 neurones across 
cultures from 3 independent mice. Untreated (1343 neurones), TNFα 10 ng/mL (1177 neurones). Data were analysed using 
unpaired two-tailed t-test. Data points on graphs represent individual cover slips.  
Abbreviations: DRG: dorsal root ganglia; TNFα: tumour necrosis factor alpha; KCl: potassium chloride. 
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3.4.6 TNFα does not Stimulate the Activation of the p-38 Pathway in Purified DRG 
Neuronal Cultures  
It is well documented that both NGF and TNFα can activate MAP kinase signalling pathways 
in different cell types (Sabio and Davis, 2014, Reichardt, 2006a). Therefore, the induction of 
phospho-p38 was assessed, initially in the PC12 neuronal cell line and then subsequently in 
purified DRG neuronal cultures, in response to NGF, TNFα or a combination of the two. In 
contrast to the previous experiments outlined in this chapter, the time of stimulations (5 min 
and 20 min) was substantially shorter due to the more acute effects of MAP kinases (Pearson 
et al., 2001). In the following experiments anisomycin was used as a positive control as it is a 
known activator of stress-activated protein kinases, including phospho-p38 (Torocsik and 
Szeberenyi, 2000). 
In the PC12 cell line, both NGF (100 ng/mL) and TNFα (25 ng/mL) could induce p-38 activation 
by 1.39 ± 0.14-fold over basal (n=3 biological replicates) and 1.32 ± 0.04-fold over basal (n=3 
biological replicates) respectively. (Figure 22A). When the cell line was stimulated with a 
combination of the two, an additive response of the two individual inflammatory mediators 
was observed at 20 min (1.92 ± 0.19-fold over basal, n=3 biological replicates), a response 
similar to that of the positive control, anisomycin (2.14 ± 0.24-fold over basal, n=3 biological 
replicates) (Figure 22A). Although the PC12 cell line has been extensively used in neuronal 
differentiation studies (Greene, 1978b, Satoh et al., 1988, Greene, 1978a, Morooka and 
Nishida, 1998), it is a neuronal-like cell type and therefore has a number of limitations (as 
summarised in the discussion). Therefore, the same experiment was repeated in the primary 
cell purified DRG neuronal cultures.  
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In contrast to the PC12 cell line, the purified DRG neuronal cultures showed no differences 
from the untreated group when examining phospho-p38 induction in response to NGF, TNFα 
or a combination of the two (10 ng/mL). This was also true when examining the response to 
the positive control anisomycin, where only a difference in fold-over basal from 1 (untreated 
group) to 1.1 was observed (Figure 22B).  
Levels of phospho-p38 in both the cell line and the primary cells were determined using HTRF 
technology. Due to the lack of a detectable response in the purified DRG neuronal cultures 
(when assayed using the phospho-p38 HTRF assay, Figure 22B) an alternative method of 
measuring phospho-p38 was explored, namely immunocytochemical detection. Therefore, 
immunocytochemistry techniques were employed. Figure 23A and B display the 
immunostaining for phospho-p38 following stimulation with NGF, TNFα or a combination of 
the two (10 ng/mL) for either 5 min or 20 min. These representative images show no clear 







Figure 22. Induction of phospho-p38 in the PC12 neuronal cell line and purified DRG neuronal cultures. A) Levels of 
phospho-p38 induction in the PC12 neuronal cell line following treatment with NGF (100 ng/mL, 20 min), TNFα (25 ng/mL, 
20 min), a combination of the two (20 min) or with the positive control anisomycin (100 µM, 20 min) as assessed by HTRF 
assay. B) Levels of phospho-p38 induction in purified DRG neuronal cultures following treatment with NGF (10 ng/mL, 20 
min), TNFα (10 ng/mL, 20 min), a combination of the two (20 min) or with the positive control anisomycin (100 µM, 20 min) 
as assessed by HTRF assay. Data displayed as Mean ± SEM, n=3 biological replicates (A) and n=2 biological replicates (B) 
(displayed as individual data points).  
Abbreviations: PC12: pheochromocytoma; NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; HTRF: 






Figure 23. Visual representation of 
phospho-p38 induction in the PC12 
neuronal cell line and purified DRG 
neuronal cultures. A-B) 
Representative fluorescent 
micrographs following 
immunostaining for phospho-p38 
following treatments at (A) 5 min 
(B) 20 min with NGF (10ng/mL) or 
TNFα (10 ng/mL) and (C) the 
secondary stain only condition.  
Abbreviations: PC12: 
pheochromocytoma; NGF: nerve 
growth factor; TNFα: tumour 







There is growing evidence within the literature to suggest that TNFα may contribute to both 
the generation and maintenance of pain states via multiple mechanisms, such as direct 
activation of primary nociceptors (as reviewed by (Pinho-Ribeiro et al., 2017a)) or via an 
indirect orchestration of inflammatory responses (as reviewed by (Kress, 2010)). Within this 
chapter we utilised a MACS sorting technique, enabling the isolation of purified DRG neurones 
from adult mice. This technique circumvents the limitations of previous studies (Sorkin et al., 
1997, Richter et al., 2010, Bowen et al., 2006b, Hensellek et al., 2007a), conclusions from 
which may have been inadvertently affected by the presence of non-neuronal cell types.  
One of the assays used to assess any changes in neuronal function in response to TNFα was 
the degree to which it could stimulate neurite outgrowth. Neurite outgrowth in vitro is a 
valuable tool commonly utilised as a proxy for the development and health of neurones in 
response to a range of compounds (Radio and Mundy, 2008). Therefore, any significant 
effects seen in this assay would be a good indicator of neuronal responsiveness to TNFα. 
Furthermore, previous work has indicated that TNFα can drive neurite outgrowth, albeit in 
hypothermic conditions (Schmitt et al., 2010). 
Although a trend was apparent for an increase in neurite outgrowth at the lower 
concentration of NGF (1 ng/mL), this change was not significant. Instead, NGF (10 ng/mL) 
drove significant neurite outgrowth in purified DRG neuronal cultures when compared to the 
untreated cultures. This finding is consistent with studies within the literature (Liu et al., 
2007). Indeed, it has been well established that NGF can stimulate neurite outgrowth in both 
sensory and sympathetic neurons (Levi-Montalcini and Angeletti, 1968), a property that is 
considered to be crucial for its role in stimulating neuronal connections in early development. 
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From work conducted in the PC12 cell line, it is thought that NGF induces neurite outgrowth 
via the assembly of microtubule proteins such as tau and MAP1 (Drubin et al., 1985). 
Additionally, research conducted in cultured adult DRG neurones showed that Src and FAK 
are key early signalling intermediates required for NGF-driven neurite outgrowth (Tucker et 
al., 2008).  
When examining the effect of TNFα in this assay it was found that over a range of 
concentrations there was no significant increase or decrease in neurite outgrowth. Although 
no significant differences were found in our hands, one previous study showed that TNFα can 
inhibit neurite outgrowth and branching via a Rho-dependent mechanism (Neumann et al., 
2002). However, this study was conducted in a mixed cell population and therefore the 
changes observed could be driven via a non-neuronal mechanism. In agreement with the 
above study, it has been demonstrated that rats which have undergone a peripheral nerve 
injury and subsequent treatment with an anti-TNFα drug, have an enhanced rate of axonal 
regeneration (Kato et al., 2010), suggesting a role for TNFα in the inhibition of neurite 
outgrowth. Again, the role of neuronal vs non-neuronal cells was not considered.  
When examining the effect of the combination of NGF and TNFα on neurite outgrowth, only 
a significant increase from the untreated group was found. However, contrary to our findings, 
there is evidence in the literature to suggest that TNFα may be able to inhibit the effects of 
NGF. A study by Wheeler and colleagues (Wheeler et al., 2014) showed that TrkA-positive 
peptidergic nociceptors require TNFα-TNFR1 forward signalling to suppress NGF-induced 
outgrowth during development.  
In addition to looking at anatomical markers of neuronal activation, transcriptional changes 
in a range of pain-relevant genes were examined. Although the gene expression studies 
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conducted within this chapter suggest that all three receptor types are present (Ntrk1, Ngfr 
and Tnfrsf1a) in both purified and mixed cultures, it is important to note that this does not 
necessarily translate into the expression of the receptor protein, or indeed the cell surface 
expression of the receptor protein.   
The genes studied were selected due to evidence suggesting a strong link to either the 
generation or maintenance of pain states (Levinson et al., 2012, Iyengar et al., 2017, Levine 
and Alessandri-Haber, 2007, Tillu et al., 2015, Lee et al., 2004, Zhang and An, 2007). The effect 
of the treatment groups (NGF, TNFα, or a combination of the two) was examined in both 
purified DRG neuronal and mixed DRG neuronal/glia cultures. By studying expression changes 
in both a purified and a mixed culture, it was possible to evaluate direct vs indirect effects of 
these cytokines on sensory neurones.  
Interestingly, one of the main things that became apparent from this dataset was that purified 
DRG neuronal cultures seemed to have an enhanced response to NGF, at both concentrations 
of 10 ng/mL and 100 ng/mL, in comparison to the mixed DRG neuronal/glia preparations. The 
effect was particularly noticeable at the lower concentration of NGF (10 ng/mL). One 
explanation for this observation could be non-neuronal cells provide a source of NGF, 
therefore increasing the basal level of NGF signalling in these cultures (Hanani, 2005). Indeed, 
it has been shown that enteric glia release a number of neurotrophic factors, including NGF, 
which enhances neurite outgrowth in DRG neurones (Hansebout et al., 2012). This would 
mean that any exogenously applied NGF will have a smaller window to exert an effect.  
In the majority of pain-relevant genes examined it was found that NGF induced an increase in 
expression whereas TNFα exerted no effect. The combination treatment in most cases 
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seemed to produce a response similar to that of NGF alone, with the exception of a significant 
reduction in Tac1 expression compared to the NGF alone treatment group.   
Although TNFα was found not to influence Trpv1 expression in either purified DRG neuronal 
or mixed DRG neuronal/glia cultures in our hands, there are conflicting reports within the 
literature regarding this finding. A recent study suggests that TNFα, induced by the application 
of vincristine, upregulates the expression of TRPV1 in DRG nociceptive neurones and 
consequently contributes to both mechanical and thermal hyperalgesia in this pain model 
(Wang et al., 2018). Furthermore, another study showed that cultured DRG neurones treated 
with TNFα for a prolonged period of time (24-48 h) significantly enhanced the proportion of 
neurones expressing TRPV1 via the TNFR1 receptor (Hensellek et al., 2007b). This latter 
finding could explain enhanced heat-evoked release of CGRP from sensory nerve terminals in 
rat skin following TNFα application (Opree and Kress, 2000).  
Within this chapter, and a subsequent chapter, the levels of CGRP release have been used as 
a pain-relevant read-out. CGRP is a 37 amino acid neuropeptide which has diverse biological 
functions in both the peripheral and central nervous systems (as reviewed by (Russell et al., 
2014)). The role of CGRP in migraine pain has been well established, with possible 
mechanisms including dilation of cerebral and dural blood vessels, release of inflammatory 
mediators from mast cells and transmission of nociceptive information from intracranial 
blood vessels to the nervous system (Durham, 2006). A recent clinical trial has shown the 
potential of CGRP as a therapeutic target. Here, an anti-CGRP migraine drug resulted in a 
significantly greater percentage of patients achieving pain relief together with a reduction in 
unpleasant migraine-associated symptoms (PharmaTimes online, 2018). Interestingly, TNFα 
has been implicated in the above pathophysiology, with studies showing that in rat trigeminal 
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ganglion neurones, TNFα stimulation can result in an increase in CGRP expression and 
secretion (Bowen et al., 2006a).  
CGRP is not only implicated in migraine but rather a wide range of painful conditions. Indeed, 
CGRP is widely distributed throughout nociceptive pathways and can contribute significantly 
to both inflammatory and neuropathic pain conditions (Iyengar et al., 2017). For example, 
one study has demonstrated that CGRP is upregulated in arthritic joints, leading to peripheral 
sensitisation and activation of cell types that are crucial in the inflammation process (Walsh 
et al., 2015b). Likewise, it has been shown that CGRP can promote MAP kinase mediated glial 
activation, resulting in CCL5 production and an increase in behavioural hypersensitivity 
following a spinal nerve transection (Malon and Cao, 2014). This suggests that CGRP release 
is an important factor in multiple pain conditions and may provide a useful proxy for the 
effects of NGF and TNFα in pain pathways. However, when we examined the effect of TNFα 
on CGRP release (following depolarising of the cells), we found no change in CGRP levels 
compared to the control group.  
Similarly, there are numerous reports in the literature of TNFα mediated modulation of 
sodium channels. Jin and Gereau (2006) suggest that TNFα application, in mouse DRG 
neurones (non-purified), results in a p38-dependent modulation of TTX-resistant Na+ 
channels, leading to acute peripheral sensitisation. However, in the data presented above, we 
found no modulation in the expression of Scn9a, Scn10a or Scn11a, the latter two of which 
have been shown to be TTX-resistant (Lee and Ruben, 2008).  
The major difference between the above studies and the data presented within this chapter 
is our utilisation of purified DRG neuronal cultures. The combination of our findings with those 
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in the literature, strongly support the hypothesis that the effect of TNFα on sensory neurons 
is most likely via a non-neuronal cell type.   
One of the most striking differences in the gene expression patterns between purified DRG 
neuronal cultures and mixed DRG neuronal/glia cultures was that of TNFα-induced 
modulation of Pgst2 and F2rl1. In the mixed DRG neuronal/glia cultures, TNFα strongly 
upregulated Pgst2 and F2rl1 mRNA levels, an effect which was absent in purified DRG 
neuronal cultures, despite reports that TNFα stimulates the expression of Pgst2 in DRG 
sensory neurone cultures (Fehrenbacher et al., 2005). Taken together, this suggests that the 
TNFα effects seen in the mixed cultures are most likely mediated via non-neuronal cell types. 
In line with this, Zhang et al., 2010 showed that mast cells incubated with TNFα exhibited a 
2.4-fold increase in expression of PAR2. Likewise, TNFα induced COX2 expression in spinal 
endothelial cells (Kanda et al., 2017) and enhanced COX2 expression in synovial fibroblasts 
from patients suffering from joint pain (Ke et al., 2007).  
As expected, the use of NGF 100 ng/mL exerted a stronger response at the transcriptional 
level (compared to NGF 10 ng/mL). However, in further experiments lower concentrations of 
NGF were used to avoid ceiling effects. Indeed, to detect synergistic properties of NGF and 
TNFα, the relative concentrations of each factor should be significantly less than their 
respective EC100 (the maximal effective concentration), enabling an increased effect to be 
detected when the two factors are co-administered in the culture system (Foucquier and 
Guedj, 2015).  
The use of calcium imaging is particularly useful in the field of neuroscience as calcium 
transients in a cell are indicative of neuronal activation. This method therefore allows for 
visualisation of neuronal activity and how this may be affected by the application of a variety 
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of different stimuli (Grienberger and Konnerth, 2012). Furthermore, increased calcium 
transients in sensory neurones have been shown to be indicative of neuronal sensitisation in 
a surgical mouse model of osteoarthritis (Miller et al., 2018). Studies from the literature have 
demonstrated that NGF can act as a sensitising agent and therefore increases the neuronal 
response to other pain-related agents, such as capsaicin (Bonnington and McNaughton, 2003, 
Zhang et al., 2005c, Zhu and Oxford, 2007). 
The primary aims of the calcium imaging experiments within this chapter were to ascertain 1) 
if TNFα was capable of directly producing calcium transients in purified neurons and 2) if TNFα 
could act as a sensitising agent in a similar manner to NGF.  
It was found that the application of TNFα, directly to purified DRG neuronal cultures in a 
perfusion set-up, did not produce a response. However, in contrast to NGF, it was also found 
that culturing purified neurones in TNFα for 24 h prior to calcium imaging did not alter the 
response of the neurones to capsaicin. This would suggest that the previous findings showing 
TNFα-induced upregulation in Trpv1 expression (Kochukov et al., 2009, Wang et al., 2018, 
Rozas et al., 2016) did not occur because of direct activation of neurones in culture.  
Although no response was seen to TNFα, either as direct activation or as sensitisation, almost 
all neurones responded to an application of KCl. This suggests that the application of TNFα 
did not alter the response of the neurones to a known activator and that TNFα application is 
not detrimentally toxic to these purified DRG neuronal cultures, either acutely or in a more 
chronic stimulation situation. 
Both NGF and TNFα activate a range of secondary messenger signalling pathways that 
culminate in a myriad of cellular effects, ranging from pro-survival processes to apoptotic 
ones depending on the cellular environment. A crucial signalling pathway is that of the MAP 
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kinases, as previously described (Wu et al., 2016, Taves et al., 2016, Santulli et al., 2015, 
Edelmayer et al., 2014).  
Due to the strong links between phospho-p38 and pain (as described above), the ability of 
NGF and TNFα to induce phospho-p38 was examined. Specifically, we wanted to address if 
TNFα can activate this pathway in neurones. Experiments were conducted in the PC12 
neuronal cell line using HTRF technology in the first instance. In these experiments it was 
found that both NGF and TNFα were capable of activating p38, with TNFα producing a much 
more sustained activation compared to NGF (data not shown). When the combination 
treatment of both NGF and TNFα was used in this assay, an additive effect was observed. 
Following this intriguing result, the same experiment was performed in primary purified DRG 
neuronal cultures. However, we were unable to detect an effect of NGF, TNFα, a combination 
of the two or the positive control on phospho-p38 levels. This may have been due to a high 
basal level of phospho-p38 in the untreated group, making further modulation of p38 
activation following stimulation difficult to detect or due to the low n number, 
consequently,the above experiment should be repeated. Additionally, it should be noted that 
PC12 cells were plated at 75K/well, whereas due to cell yield issues during the purification 
process (as discussed in the introduction of this chapter) it was only possible to plate 10K/well 
of purified neurones. Therefore, the density of neurones plated may not have been sufficient 
to detect changes with this assay. Finally, when using purified neurones, the concentration of 
cytokines was reduced to 10 ng/mL to enable a larger effect size window, which may have 
affected the results. However, the lack of response seen in the positive control condition, 




It is possible that the difference observed between PC12 cells and purified neuronal cultures 
were a function of the cells themselves. Although the use of cell lines has many advantages 
(including high cell yield and ease of use), there are also numerous disadvantages, including 
the fact that PC12 cells are not themselves neurones. As a result, numerous studies have 
described profound differences between PC12 cells and neurones. For example, one study 
showed that PC12 cells lacked functional NMDA receptors (Edwards et al., 2007). Therefore, 
there is no guarantee that the effects seen in this cell line can be reproduced in primary 
neuronal cultures.  
3.6 Summary of Chapter  
In summary, the data presented in this chapter have focussed on the individual and combined 
effects of NGF and TNFα on mouse adult DRG neurones. Within the suite of assays utilised to 
understand cellular responsiveness, we have demonstrated that the sensory neurone itself 
displays a distinct lack of TNFα sensitivity whether alone or in combination with NGF. In 
contrast, we provide further evidence of the profound effect of NGF on sensory neurones, 
including effects on neurite outgrowth, modulation at the transcriptional level, CGRP release. 
Furthermore, we demonstrate that at the level of the sensory neurone, the lack of synergistic 
effects (of NGF and TNFα) would argue against the sensory neurone as being the only sight of 
action for these two mediators in delivering the superior analgesic efficacy observed with the 
















4. Investigating the Individual and 
Combined Effect of NGF and TNFα on 





In the previous chapter, we assayed functional responses of adult mouse sensory DRG 
neurones to NGF, TNFα or a combination of the two. However, it has been well established 
that the generation and maintenance of pain states is not solely due to changes in sensory 
neurones (Ji et al., 2016a). As outlined in the main introduction of this thesis (section 1.11), 
the role of non-neuronal cell types in chronic pain states is both crucial and extensive. The 
following chapter will present data relating to the role of BMDM in this process. 
4.1.1 The Effect of TNFα on Macrophage Signalling 
Macrophages and monocytes are major sources of TNFα synthesis and release in vivo (Idriss 
and Naismith, 2000). Additionally, TNFα is known to act on macrophages themselves, 
affecting their physiology (Parameswaran and Patial, 2010). The pro-inflammatory actions of 
TNFα signalling in macrophages is thought to be primarily through the TNFR1 receptor, rather 
than through the potential regenerative actions of signalling via the TNFR2 receptor (Tseng et 
al., 2018). Exogenous application of TNFα stimulates well-established inflammatory pathways 
in macrophages in vitro (Parameswaran and Patial, 2010), including NGF signalling. Indeed, 
one study demonstrated that TNFα can upregulate NGF expression in both synovial 
fibroblasts and macrophages in osteoarthritic mice (Takano and Uchida, 2016). A further 
study confirmed that depleting levels of macrophages in an animal model of osteoarthritis, 
resulted in a significant reduction of TNFα, as well as NGF and IL-1β (Takano and Uchida, 
2017), confirming that macrophages are a possible source of TNFα in this model. The same 
study also demonstrated that treatment of human synovial macrophages from osteoarthritic 
knee joints with either IL-1β or TNFα induced an increase in the levels of NGF mRNA and 
subsequent protein levels (Takano and Uchida, 2017) (Takano et al., 2016). It seems however, 
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that macrophage-produced TNFα does not only influence expression of cytokines in 
macrophages themselves but instead can induce expression of inflammatory cytokines in 
other cell types. This was suggested by Bondeson and colleagues (Bondeson et al., 2006) via 
the use of a model of osteoarthritis synovitis. In this model the removal of synovial 
macrophages not only depleted levels of TNFα but also resulted in a significant reduction in 
several other cytokines, including IL-6 and IL-8, which are predominantly produced by synovial 
fibroblasts in this model. The above highlights the crucial role of TNFα in the production of 
downstream pro-inflammatory cytokines, which can be released both by macrophages 
themselves as well as other cell types.  
4.1.2 The Effect of NGF on Macrophage Signalling 
Macrophages have been shown to express both the NGF receptors, TrkA and p75NTR (Ricci et 
al., 2004, Garaci et al., 1999, Williams et al., 2015). Various effects of NGF have been observed 
with respect to macrophage function. NGF treatment in mouse macrophages markedly 
increases the production of TNFα via MAP kinases as well as the secretion of nitric oxide, 
suggesting an important role in inflammatory responses (Barouch et al., 2001). It has been 
shown that NGF could act as an activator of macrophages in vivo, with increasing 
concentrations of NGF enhancing murine macrophage phagocytic ability of microspheres and 
leading to a significant increase in IL-1β release (Susaki et al., 1996). Human 
immunodeficiency virus (HIV) resistance in macrophages may be partly due to autocrine 
production and secretion of NGF (Balestra et al., 2001). Furthermore, treatment of 
macrophages with an anti-TrkA antibody prevents NGF-induced chemotaxis (Kobayashi and 




In summary, the literature would suggest that NGF and TNFα are both capable of signalling 
via BMDM. The interaction between the two mediators, at the level of the macrophage, may 
facilitate a heightened pain state.   
4.2 Aims and Experimental Strategy 
The aims of this chapter were to test the following hypotheses: 
• TNFα signalling in macrophages drives pain-relevant responses 
• NGF can directly signal and activate pain-relevant signalling pathways in BMDM 
• The direct effects of TNFα can summate with, or synergize with that of NGF, to 
produce a heightened pain state 
 The data within this chapter aims to clarify the basal expression of NGF and TNFα receptors 
in macrophages. Subsequently, any changes occurring at either the transcriptional or cellular 












All animals were obtained from Charles River and housed in a designated facility and 
maintained in accordance with the United Kingdom Home Office Animals (Scientific 
Procedures) Act (1986) and Home Office regulations. Animals were kept in a 12 h light dark 
cycle and fed ad libitum. All animals were sacrificed using schedule 1.  Experiments which 
involved intraperitoneal injections to the abdomen of mice where performed under the 
appropriate Home Office Licence. 
4.3.1 Primary Cell Culture of Different Macrophage Types 
Macrophage cultures were generated from adult C57BL/6 mice aged 7-10 weeks. 
4.3.1.1 Bone-Marrow Derived Macrophages 
To obtain BMDM, a protocol adapted from Trouplin et al., 2013 was used. The bone cavities 
of the tibia and femur from each hind limb were flushed through with pre-cooled 1X DPBS, 
until the cavity appeared white. The eluent was then centrifuged for 7 min at 850 g (Hettich 
Zentrifugen). The resulting cell pellet was re-suspended in 3 mL of pre-warmed Dulbecco’s 
Modified Eagle Medium + Glutamax™ (Gibco®, 32430027) supplemented with 10 % FBS, 1 % 
Pen/Strep and 25 ng/mL recombinant macrophage colony stimulating factor (MCSF) and 
filtered through a 40 µM cell strainer (Corning, 352340). MCSF induces the proliferation and 
differentiation of myeloid progenitors into cells of the macrophage/monocyte lineage 
(Weischenfeldt and Porse, 2008a). In a number of experiments, NGF 10 ng/mL was also added 
into the above differentiation process. The cell suspension was made up to the desired 
volume with the supplemented medium, 25 mL cell suspension was plated per petri dish 
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(VWR International, 391-1502) and the progenitor cells allowed to differentiate for 7 days at 
37 ᵒC, 5 % CO2. No media change was required during this incubation period.  
Following the incubation period, culture supernatants were discarded. The remaining 
adherent cells were washed with 10 mL pre-warmed 1X DPBS, followed by 15 mL pre-warmed 
non-enzymatic cell dissociation solution (Millipore, S-014-B). Afterward, cells were incubated 
for 10 min at 37 ᵒC, 5 % CO2. To aid cell detachment a cell scraper was used to lift the adherent 
cells from each petri dish. Cells were pooled into a 50 mL conical tube, washed with pre-
cooled 1X DPBS and centrifuged for 7 min at 478 g (Hettich Zentrifugen) at 4 ᵒC. Cells were 
re-suspended in an appropriate volume of Dulbecco’s Modified Eagle’s Medium (DMEM) 
(+MCSF supplement) and plated at the desired density for 24 h prior to any experimental 
stimulations taking place.  
4.3.1.2 Resident Peritoneal Macrophages 
To obtain resident peritoneal macrophages, the culled mouse torso was sterilised with 70 % 
ethanol, the abdominal skin retracted, and the peritoneal wall exposed.  10 mL of sterile 1X 
HBSS was injected into the peritoneal cavity using a 23 g needle (BD Microlance, 300800), 
taking care not to puncture any internal organs. The peritoneal cavity was gently massaged 
to dislodge any cells of interest from linings within the cavity. Using a syringe and a 23 g 
needle, the peritoneal fluid was retrieved and spun at 212 g for 10 min at RT (Hettich 
Zentrifugen) to obtain a cell pellet. The pellet was re-suspended in 1 mL pre-warmed DMEM 
+ 10 % FBS + 1 % Pen/Strep and plated at the desired density. Approximately 2 h post-plating, 
the cells were washed with 1X HBSS and the medium replaced to remove any unspecific cells. 
The cells were ready to use 24 h post-plating.  
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4.3.1.3 Activated Peritoneal Macrophages 
To allow time for an appropriate inflammatory response, 4 days prior to the collection and 
culture of peritoneal macrophages (see section 4.3.1.2), 1 mL of Bio-Gel P-100 2 % 
polyacrylamide beads (Bio-Rad, 1504174) was delivered via intraperitoneal injection to the 
mice, being careful to avoid the bladder upon injection. The Bio-Gel beads (2 g) were washed 
twice in 20 mL DPBS and subsequently centrifuged at 400 g for 5 min prior to being 
resuspended in 100 mL PBS to give a 2 % solution ready for administration into the peritoneal 
cavity.  A 26-gage needle was used to administer the injection (at an angle of 45 ° to the skin) 
into the lower right quadrant of the abdomen to avoid any vital organs.  Following the 
incubation period of 4 days, the procedure followed the same process outlined above (see 
section 4.3.1.2) for the culture of resident peritoneal macrophages.  
4.3.2 Viability Assessment of BMDM  
To confirm that cultured macrophages were viable after stimulation with either NGF, TNFα or 
a combination of the two, both an alamarBlue™ assay and FACS analysis were employed.  
4.3.2.1 AlamarBlue™ Assay 
AlamarBlue™ contains a permeable, non-fluorescent molecule which is converted to a highly 
fluorescent compound in healthy cells. The change in supernatant colour acts as an indicator 
of cell health and subsequent viability.  
BMDM were plated in a 96-well plate format and allowed to adhere prior to being treated 
with NGF 10 ng/mL, TNFα 10 ng/mL, a combination of the two or LPS 1 mg/mL as a positive 
control (Enzo, ALX-581-008-L002) for 24 h. Following the treatment period, 1/10th volume of 
alamarBlue™ reagent (Invitrogen, DAL1025) was added directly to the cells in culture medium 
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and incubated for 5 h at 37 °C, 5 % CO2. The absorbance was read at 570 nm, using 600 nm as 
a reference/normalisation wavelength. 
4.3.2.2 Flow cytometry  
Following 24 h stimulation with the same treatments as described above (section 4.3.2.1), 
BMDMs were washed with cold 1X PBS and gently dislodged following a 10 min incubation 
period with non-enzymatic dissociation buffer. Cells were centrifuged for 7 min, 688 g at 4 °C 
(Hettich Zentrifugen), and subsequently re-suspended in 200 µL FACS buffer and transferred 
to FACS tubes for staining. Macrophages were stained with Amcyan-conjugated viability dye 
for 30 min on ice in the dark. The latter is a cell membrane impermeable amine-reactive dye. 
The dye can enter dead cells that have compromised membrane integrity and subsequently 
bind to intracellular proteins. On live cells, the dye can interact with cell surface proteins but 
the resulting staining is significantly lower to dead cells (Biotium, 2018). Cells were then 
washed with complete FACS buffer and fixed in 3.8 % PFA for 5 min. Fixed samples were 
washed and resuspended in FACS buffer until ready to analyse.  
4.3.2.3 Flow Cytometry Data Analysis 
Flow cytometry was performed on a BD FACS Fortessa (BD Pharmingen) and data analysed 
using FlowJo software (Treestar). Cell discrimination was achieved by applying the following 
gating strategy: 1) BMDMs were identified based on forward scatter (FSC) and side scatter 
properties 2) live cells were gated as negative for live/dead staining and 3) cells negative for 
the viability dye were used to quantify percentage of positive cells.  
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4.3.3 HTRF (Homogenous Time Resolved Fluorescence) Assay 
Cisbio’s phospho-p38 kit (Cisbio, 64P38PEG) was used according to the manufacturers’ 
instructions as previously described in section 3.3.7. In this instance, the assay was performed 
on BMDM plated at 50K/well. BMDM were stimulated with NGF, TNFα, a combination of the 
two or anisomycin (Sigma, A5862), for 5 or 20 min.  
4.3.4 MSD® U-PLEX Platform as a Cytokine Secretion Measure 
In U-PLEX immunoassays, the biotinylated capture antibody is coupled to U-PLEX linkers, 
which self-assemble onto unique spots on the assay plate. Following sample addition, 
analytes bind to the capture antibody. To complete the immunoassay, a detection antibody 
conjugated with an electro-chemiluminescent label (SULFO-TAG) binds to the analytes. 
Applying a voltage to the plate causes the captured label to emit light; the intensity of the 
emitted light is proportional to the amount of analyte present in the sample.  
A custom-made kit (MSD, K15069L-1) was utilised to measure the levels of the GM-CSF, IL-10, 
IL-6, TNFα, IL-1β, KC/GRO, MCP1, MIP1α, MIP-3α or NGF in the supernatant of BMDM, 
stimulated with NGF 10 ng/mL, TNFα 10 ng/mL or a combination of the two, for 24 h. For 
TNFα secretion, BMDM were stimulated with LPS 100 ng/mL for 24 h as a positive control. 
For NGF secretion, the cynom-K1 keratinocyte cell line was used as a positive control.  Cynom-
K1 cells were obtained from the European Collection of Authenticated Cell Cultures. Cynom-
K1 cells were seeded at 15K/well on 96 well PDL plates supplemented with DMEM 10 % FCS 
and 1 % pen/strep and collected following the 24 h stimulation period.  
The assay was performed according to manufacturer’s instructions. All reagents were bought 
to RT prior to use. For each biotinylated antibody, one per cytokine (provided in the kit), 200 
µL was added to 300 µL of the assigned linker and vortexed prior to being incubated at RT for 
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30 min. Following the addition of 200 µL of Stop Solution, the mix was vortexed and incubated 
for a further 30 min at RT. To prepare the multiplex coating solution, 600 µL of each U-PLEX-
coupled antibody solution was combined into a single tube and vortexed. The solution was 
made up to 6 mL with Stop Solution to result in a final 1X concentration and vortexed a further 
time. To coat the U-PLEX plate, 50 µL of the multiplex coating solution was added to each 
well. The plate was sealed with an adhesive plate seal and incubated with shaking at 4 ˚C 
overnight. The following morning the plate was washed 3X with 150 µL/well of 1X DPBS + 0.05 
% Tween-20.  
Following plate preparation, 25 µL of Diluent 41 (diluent containing protein, blockers and 
preservatives) was added to each well followed by 25 µL of calibrator (prepared in Diluent 41) 
or sample, the plate was sealed with an adhesive plate seal and incubated at RT with shaking 
for 1 h. Following this incubation period, the plate was washed 3X with 150 µL/well of 1X 
DPBS + 0.05 % Tween-20 and subsequently 50 µL of 1X detecting antibody solution was added 
to each well. The plate was once more sealed and incubated at RT with shaking for 1 h. The 
plate was washed 3X with 150 µL/well of 1X DPBS + 0.05 % Tween-20 and finally 150 µL of 2X 
Read Buffer T was added to each well. The plate was read on a SECTOR Imager 6000 (MSD). 
4.3.5 Gene Expression Analysis of BMDM Using Custom TaqMan Array Microfluidic Cards 
or SYBR Green Technology  
For the TaqMan Array cards, BMDM were collected as previously described (section 4.3.1.1) 
and plated at 1x106 cells/well in a 6-well plate (Thermo Scientific, 140675) with DMEM + 10 
% FBS + 1 % Pen/Strep + 25 ng/mL M-CSF (2 mL/well). 24 h later, the medium was removed, 
and the cells were washed in 1 mL 1X DPBS. Following this wash step, the cells were exposed 
to various stimulations (2 mL/well) made up in DMEM + 10 % + 1 % Pen/Strep for 24 h. The 
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treatment groups were as follows: Untreated, NGF 10 ng/mL, TNFα 10 ng/mL, NGF 10 ng/mL 
+ TNFα 10 ng/mL or LPS 100 ng/mL (Enzo, ALX-581-008-L002) as a positive control. No M-CSF 
was added to the medium at this stage.   
To assess the expression levels of NGF/TNFα receptors (Tnfrsf1a, Ntrk1 and Ngfr), SYBR green 
technology was used. Following isolation, BMDM, peritoneal and induced peritoneal 
macrophages were collected as previously described (section 4.3.1) and plated at 1x106 
cells/well in a 6-well plate with DMEM + 10 % FBS + 1 % Pen/Strep + 25 ng/mL M-CSF (2 
mL/well). Cells were allowed to settle for 24 h before the medium was removed and the cells 
were washed in 1 mL 1X DPBS. Following this wash step, the cells were exposed to either fresh 
DMEM + 10 % + 1 % Pen/Strep or LPS 100 ng/mL (2 mL/well) for 24 h. No M-CSF was added 
to the medium at this stage.   
4.3.5.1 RNA Extraction and cDNA Synthesis 
Following the stimulation period, RNA was extracted as previously described (section 3.3.4.1) 
using the RNeasy Micro Kit (Qiagen, 74004) with the following exceptions; cell lysates were 
collected in 1 mL RLT buffer + β-mercaptoethanol and genomic DNA was removed via a 15 
min incubation at RT with 80 µL DNase I and RDD buffer solution using an RNase-Free DNase 
Set (Qiagen, 79254).  
Resulting RNA was immediately quantified and tested for purity on the NanoDrop ND-100 
Spectrophotometer (Thermo Fisher Scientific) prior to cDNA synthesis. Based on this 
quantification, 200 ng of RNA was reverse transcribed using the SuperScript® III First-Strand 
Synthesis Supermix kit (Invitrogen, 11752-050). For cDNA synthesis, samples were diluted as 
required using RNase-free water to make a solution of 12 µL in qPCR tubes (STARLAB, A1402-
3800). To this solution, 1 µL of dNTPs (1:10 dilution from 100 mM stock (Promega, U1240) in 
150 
 
RNase-free water and 1 µL of random primers (100 µg/mL) (Promega, C1181) were added. 
Samples were run on the PCR machine at 65 ᵒC for 4 min, followed by 1 min on wet ice. To 
make up the final volume to 20 µL, 6 µL of a second mix was added. Per reaction, this 
mastermix consisted of: 4 µL 5X first strand buffer, 1 µL DTT (0.1 M) and 1 µL Superscript® III 
Reverse Transcriptase. The following RT cycling conditions were used: 25 ᵒC for 5 min, 50 ᵒC 
for 60 min, 70 ᵒC for 15 min, samples were held at 4 ᵒC until collection and kept at -20 ᵒC until 
ready for use.  
4.3.5.2 RT-qPCR for TaqMan Array Microfluidic Cards 
Custom made TaqMan 384-well PCR array microfluidic cards (Applied Biosystems) were used 
to analyse the effects of NGF, TNFα or a combination of the two on 48 gene transcripts 
simultaneously, including three housekeeping genes; 18S ribosomal RNA (18s), β2-
Microglobulin (β2m) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh). See Table 6 
for full list of gene transcripts quantified.  Sample cDNA was diluted to 2 ng/mL in 50 µL 
molecular grade water before a TaqMan universal PCR master mix (Applied Biosystems, 
4304437) was added at a 1:1 ratio to give a final volume of 100 µL. Each custom card held 
eight cDNA samples and was allowed to acclimatise to RT prior to loading. Once thoroughly 
mixed, 95 µL of the sample mix was loaded into the corresponding channel and centrifuged 
at 158 g for 1 min (Sorvall ST 40 Centrifuge), twice. The card was sealed, and entry wells 
removed prior to the card being run on the ABI 7900HT Real Time PCR instrument (Applied 
Biosystems, serial number: 201276). The following cycling conditions were used: 25 ᵒC for 10 
min, 42 ᵒC for 60 min and 85 ᵒC for 5 min.  
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4.3.5.3 RT-qPCR for SYBR Green Technology 
To obtain the relative quantification of the desired transcripts, real time qPCR was performed 
in triplicate on a LightCycler 480 (Roche) using SYBR Green Real-Time PCR Master Mix (Roche, 
04 887 352 001). cDNA samples were diluted to 5 ng/µL in RNase-free water. Reaction 
mixtures were prepared on ice and contained the following per reaction; 5 µL 2X SYBR green 
master mix, 0.5 µL primer pair mix at 10 µM, 3.5 µL ddH2O and 1 µL of cDNA sample, giving a 
final reaction volume of 10 µL.  See Table 7 for transcripts quantified and primer pair details. 
A blank sample of water was used as a negative control in all experiments. The completed 
384-well PCR plate (Roche, 04 729 749 001) was centrifuged for 20 secs to ensure collection 
of sample mix at the bottom of the well before being run on the machine. The following 
cycling conditions were utilised; 25 ᵒC for 10 min, 42 ᵒC for 60 min and 85 ᵒC for 5 min.   
4.3.5.4 Data Analysis 
mRNA transcripts were normalised to the expression of the housekeeping genes (TaqMan 
Array Microfluidic Cards: average of 18s, β2m and Gapdh expression; SYBR green method: 









Table 6. List of gene transcripts included on the PCR TaqMan card (housekeeping genes are identified in bold font) 
Gene Transcripts 
Aif1 Ccl5 Fcgr1 Ifnƴr1 Jak2 P2x4r Stat6 
Atf3 Ccr2 Fcgr2b Ifnƴr2 Ngf P2y12r Tlr4 
Bdnf Ccr5 Fcgr3 Il10ra Ngfr Ptgs2 Tnf 
C3 Cd63 Gfap Il-18 Ntrk1 Slfn2 18s 
C4b Csf1r Gm2002 Il-1β Ntrk2 Slfn5 β2m 
Ccl12 Cst7 Gpr84 Il-6 Ntrk3 Stat1 Gapdh 
Ccl2 Ctss Ifnb1 Il6ra Oprm1 Stat3  
 
Table 7. List of gene transcripts and the corresponding primer pairs 
Gene Transcript Primer Pairs (oligo sequence 5’-3’) 
Ntrk1 


















4.3.6 Statistical Analysis 
All statistical analysis was performed using GraphPad software (version 7.04). Prior to any 
statistical analysis taking place, the data were tested for normality using the Shapiro-Wilk 
normality test. Within this chapter, all data were analysed using the following statistical tests; 
One-Way ANOVA, Two-Way ANOVA or Linear Models for Microarray (LIMMA) (for the 
TaqMan card data) followed by post-hoc correction tests for multiple comparisons. In all 
instances, data are displayed as Mean ± SEM, n numbers and specific post-hoc correction tests 














4.4.1 Diverse Macrophage Cultures Express Similar Levels of NGF and TNFα Receptors 
Three types of macrophages are commonly used in vitro; BMDM, peritoneal macrophages 
and activated peritoneal macrophages. One of the first things we explored was if the 
expression of the receptors for NGF and TNFα (Ntrk1, Ngfr and Tnfrsf1a) differed between 
macrophage types.  
Across all three macrophage cell types similar results were found. Tnfrsf1a was expressed 
highly in all three, with a Ct value of 24.9 ± 0.61 in BMDM (n=3 biological replicates), 23.91 ± 
0.54 in peritoneal macrophages (n=3 biological replicates) and 25.66 ± 1.65 in induced 
peritoneal macrophages (n=3 biological replicates) (Figure 24A-C), corroborating the 
extensive literature surrounding the significant role of TNFα signalling in immune cell types 
(Horiuchi et al., 2010, Ji et al., 2016b, Bradley, 2008). 
NGF receptor levels were also similar between all three macrophage cell types, with Ntrk1 
displaying a Ct value of 38.83 ± 1.17 in BMDM (n=3 biological replicates), 38.67 ± 1.33 in 
peritoneal macrophages (n=3 biological replicates) and 35.95 ± 2.03 in activated peritoneal 
macrophages (n=3 biological replicates) (Figure 24A-C). Ngfr displayed a Ct value of 37.22 ± 
1.39 in BMDM (n=3 biological replicates), with slightly higher levels of expression in the 
peritoneal and activated peritoneal macrophage types, with Ct values of 31.62 ± 0.32 (n=3 
biological replicates) and 31.83 ± 0.46 (n=3 biological replicates) respectively (Figure 24A-C). 
Relative to Tnfrsf1a expression, Ntrk1 expression displayed a fold change of 0.00025 (-13.93 
± 1.75 ΔΔCt, n=3 biological replicates), 0.00008 (-14.76 ± 1.35 ΔΔCt, n=3 biological replicates) 
and 0.02520 (-10.29 ± 3.36 ΔΔCt, n=3 biological replicates) in unstimulated BMDM, 
unstimulated peritoneal macrophages and unstimulated activated peritoneal macrophages 
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respectively (Figure 24G). Ngfr expression displayed a fold change of 0.00048 (-12.32 ± 1.61 
ΔΔCt, n=3 biological replicates), 0.00677 (-7.71 ± 0.86 ΔΔCt, n=3 biological replicates) and 
0.03065 (-6.16 ± 1.27 ΔΔCt, n=3 biological replicates) in unstimulated BMDM, unstimulated 
peritoneal macrophages and unstimulated peritoneal macrophages respectively (Figure 24G). 
No significant differences were observed.  
To establish if introducing a pre-stimulus would alter the responsiveness of these cell types 
to NGF or TNFα, all three types were stimulated with LPS 100 ng/mL and the expression levels 
of the receptors re-examined. Following stimulation with LPS 100 ng/mL it was found that the 
expression levels were unchanged in all three cell types compared to their unstimulated state 
(Figure 24D-F). Relative to Tnfrsf1a expression, Ntrk1 expression displayed a fold change of 
0.00005 (-14.65 ± 0.81 ΔΔCt, n=3 biological replicates), 0.00005 (-15.16 ± 1.16 ΔΔCt, n=3 
biological replicates) and 0.00254 (-10.66 ± 1.78 ΔΔCt, n=3 biological replicates) in LPS-
stimulated BMDM, LPS-stimulated peritoneal macrophages and LPS-stimulated activated 
peritoneal macrophages respectively (Figure 24H). Ngfr expression displayed a fold change of 
0.00015 (-13.3 ± 1.11 ΔΔCt, n=3 biological replicates), 0.00038 (-11.66 ± 0.71 ΔΔCt, n=3 
biological replicates) and 0.00186 (-9.83 ± 1.07 ΔΔCt, n=3 biological replicates) in LPS-
stimulated BMDM, LPS-stimulated peritoneal macrophages and LPS-stimulated peritoneal 
macrophages respectively (Figure 24H). No significant differences were observed.  
In our subsequent studies evaluating NGF and TNFα effects on macrophages, it was decided 
that BMDM would be utilised. One major advantage of utilising BMDM (over peritoneal 
macrophages) is that they exist in a quiescent form and therefore represent a suitable system 
to detect even subtle changes in their behaviour following stimulation (Weischenfeldt and 
Porse, 2008b). The use of peritoneal and activated peritoneal macrophages could instead 
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introduce significant variation into the culture system due fluctuating levels of pre-activation 










Figure 24. Expression levels of TNFα and NGF receptors (Tnfrsf1a, Ntrk1, Ngfr) in different activation states of 
macrophages. A-C) Graphs displaying the Ct values of Tnfrsf1a (black triangles, white bars), Ntrk1 (black circles, white bars), 
Ngfr (hollow squares, white bars) and the housekeeping gene β2m (black upside-down triangles, white bars) in unstimulated 
BMDM, peritoneal macrophages and activated peritoneal macrophages. D-F) Graphs displaying the Ct values of Tnfrsf1a 
(black triangles, shaded bars), Ntrk1 (black circles, shaded bars), Ngfr (hollow squares, shaded bars) and the housekeeping 
gene β2m (black upside-down triangles, shaded bars) in LPS-(100 ng/mL) stimulated BMDM, peritoneal macrophages and 
activated peritoneal macrophages. G-H) Expression levels of Ntrk1 (black circles) and Ngfr (hollow squares) relative to 
Tnfrsf1a expression (normalised to β2m expression) in (G) unstimulated BMDM, peritoneal or activated peritoneal 
macrophages or (H) LPS-stimulated (100 ng/mL) BMDM, peritoneal or activated peritoneal macrophages. Data displayed as 
Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data were analysed using Two-Way ANOVA 
followed by Tukey’s multiple comparisons test.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 
Ntrk1: neurotrophic receptor tyrosine kinase; Ngfr: nerve growth factor receptor; Tnfrsf1a: tumour necrosis factor receptor 




4.4.2 Addition of NGF in the Differentiation Process does not Alter NGF or TNFα Receptor 
Expression in BMDM 
The culture of BMDM includes a 7-day period in which they are cultured in the presence of 
MCSF, a growth factor which is essential to stimulate the bone-marrow derived progenitors 
to differentiate into a macrophage lineage cell. Previous work has highlighted a role for NGF 
in regulating human macrophage phenotype (Williams et al., 2015). To address whether NGF-
driven modulation of macrophage differentiation was indeed possible, and regulated via 
receptors such as Ntrk1 and Ngfr, we assessed the effect on receptor expression, following 
addition of NGF into the differentiation period. It was found that adding NGF 10 ng/mL into 
the culture system for the full 7-day period of bone marrow differentiation (in addition to the 
presence of MCSF) had no significant effect on the expression levels of all three receptor types 








Figure 25. Expression levels of TNFα and NGF receptors in BMDM following NGF treatment in the differentiation process. 
A-C) Graphs displaying the Ct values of Tnfrsf1a, Ntrk1, Ngfr and the housekeeping gene β2m in BMDM grown in either MCSF 
alone or MCSF with NGF (10 ng/mL) throughout the 7-day differentiation process. Data displayed as Mean ± SEM, n=3 
biological replicates (displayed as individual data points). Data analysed using Two-Way ANOVA followed by Tukey’s multiple 
comparisons test. 
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 
Ntrk1: neurotrophic receptor tyrosine kinase; Ngfr: nerve growth factor receptor; Tnfrsf1a: tumour necrosis factor receptor 













4.4.3 BMDM Viability was Unaffected by NGF or TNFα Treatment 
To assess BMDM viability following stimulation, both an alamarBlue™ assay and flow 
cytometry analysis was employed. BMDM viability (as assessed by both assays) was 
unaffected by treatment with NGF (10 ng/mL, 24 h), TNFα (10 ng/mL, 24 h) or a combination 
of the two factors (10 ng/mL, 24 h) (Figure 26). Indeed, no significant changes (in response to 
either factor) were detectable from the untreated group in the alamarBlue™ assay (Figure 
26A). Furthermore, flow cytometry analysis revealed that the % of live BMDM did not 
decrease, relative to the untreated group level, in any of the stimulation groups (Figure 26B). 
The untreated group displayed 80.25 ± 0.05 % (n=2 biological replicates) of live BMDM, 
compared to 81.35 ± 1.75 % (n=2 biological replicates) of live BMDM in the NGF (10 ng/mL) 
group, 87.95 ± 0.95 % (n=2 biological replicates) of live BMDM in the TNFα (10 ng/mL) and 
84.55 ± 0.35 % (n=2 biological replicates) of live BMDM in the combination group. Due to the 






Figure 26. Confirming BMDM viability following treatment with NGF, TNFα or a combination of the two for 24 h. A) % of 
BMDM viability (normalised to the untreated group) determined using the alamarBlue® assay and B) % of live BMDM 
determined via flow cytometry analysis across the different conditions; untreated (black circles), NGF (10 ng/mL, 24 h, black 
squares), TNFα (10 ng/mL, 24 h, black triangles), NGF + TNFα (both at 10 ng/mL, 24 h, black upside-down triangles) or LPS as 
a positive control (1 mg/mL, 24 h, hollow diamonds). Data displayed as Mean ± SEM, for A) n=3 biological replicates (displayed 
as individual data points). Data were analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test. For B) 
n=2 biological replicates (displayed as individual data points), therefore statistics were not performed.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 




4.4.4 TNFα (not NGF) Activates p38 Signalling in BMDM 
To further characterise the response of BMDM to both NGF and TNFα, induction of phospho-
p38 was investigated, using both methods described in sections 3.3.7 and 3.3.8 (HTRF and 
immunocytochemistry).  
Representative images of the ICC from each group (Figure 27A and B) and the corresponding 
quantification (Figure 28A and B) show a clear effect of TNFα (10 ng/mL) on phospho-p38 
induction, with an overall fluorescence increase of 2461 ± 192.5 % (n=2 biological replicates) 
at 5 min (Figure 28A) and 3710 ± 1674 % (n=2 biological replicates) at 20 min (Figure 28B), 
from the untreated group. No effect of NGF (10 ng/mL) was observed from the untreated 
group and the combination group (NGF + TNFα) saw the same effect as TNFα alone (Figure 27 
and 28). At both time points, levels of phospho-p38 induction in response to TNFα alone and 
the combination treatment (NGF/TNFα) reached the levels of induction seen with the positive 
control, anisomycin (Figure 28A and B). Statistical analysis was not performed on this data set 
due to a low n number of 2 biological replicates. 
BMDM induction of phospho-p38 following stimulation with NGF, TNFα or a combination of 
the two was also determined using the HTRF approach. Using this technique, the above 
findings (as measured using ICC) were replicated. NGF treatment of BMDM was found to have 
no significant effect, whereas both the TNFα alone and combination group displayed a 3-fold 
significant increase over basal levels (One-Way ANOVA; F(4,10)=689.3, P<0.0001) (Figure 
29A). Anisomycin treatment of BMDM was found to induce an approximately 8-fold increase 
over basal phospho-p38 levels (One-Way ANOVA; F(4,10)=689.3, P<0.0001)  (Figure 29A), a 
stronger response than what we previously saw from the immunocytochemistry data. This 
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Untreated NGF 10 ng/mL TNFα 10 ng/mL NGF + TNFα 10 ng/mL 
5 min stimulation 
20 min stimulation 
Untreated NGF 10 ng/mL TNFα 10 ng/mL NGF + TNFα 10 ng/mL 
Figure 27. Visual representation of phospho-p38 induction in BMDM following treatment with NGF, TNFα or a combination of the two (10 ng/mL as measured by 
ICC. A) Representative ICC images of phospho-p38 staining following treatments for 5 min or B) 20 min.  






Figure 28. Quantification of levels of phospho-p38 in BMDM following treatment with NGF, TNFα or a combination of the 
two (10 ng/mL) as measured by ICC. A-B) Quantification of overall fluorescence following immunocytochemistry with a 
phospho-p38 antibody following a 5 min stimulation period C) or a 20 min stimulation period D) Data displayed as Mean ± 
SEM, n=2 biological replicates (displayed as individual data points). 









Figure 29. Levels of phospho-p38 in BMDM in response to NGF, TNFα or a combination of the two (10 ng/mL) as measured 
by HTRF assay. A-B) Levels of BMDM phospho-p38 in response to NGF (10 ng/mL, 20 min, black squares), TNFα (10 ng/mL 
20 min, black triangles), NGF + TNFα (10 ng/mL, 20 min, black upside-down triangles) or Anisomycin (100 µM, 20 min, black 
diamonds) displayed as fold-over basal (A) or displayed as % of anisomycin-induced (B) following a 20-minute stimulation 
period. Data displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data were analysed 
using One-Way ANOVA followed by Tukey’s multiple comparisons test. **** P<0.0001. 
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 






4.4.5 NGF and TNFα do not Stimulate the Release of Each Other from BMDM In Vitro 
One theory that we wanted to explore was the presence of a possible feedback mechanism 
whereby NGF or TNFα may drive the release of each other, leading to a heightened pain state 
(Figure 30). However, it was found that BMDM cultures stimulated with NGF (10 ng/mL) did 
not secrete any detectable TNFα (Figure 31A) and likewise, BMDM cultures stimulated with 
TNFα (10 ng/mL) did not secrete any detectable NGF (Figure 31B). Significant increases in 
secreted NGF or TNFα were however detectable in the following positive controls (used in the 
ELISA/MSD assay) (Figure 31A and B). For TNFα secretion, LPS 100 ng/mL was used as a 
positive control (One-Way ANOVA; F(2, 6)=197.6, P<0.0001) (van der Bruggen et al., 1999). 
For NGF secretion, the cynom-K1 cell line was used as a positive control (One-Way ANOVA; 








Figure 30. Schematic showing possible signalling pathways initiated by NGF/TNFα in BMDM leading to heightened pain 
states. A) TNFα causes a possible increase in Ngf expression and NGF secretion in BMDM (Takano and Uchida, 2017), the 
release of which may then act directly on the sensory neurone resulting in increased neuronal activity and contributing to 
pain states. B) NGF may cause a possible increase in Tnf expression and TNFα secretion in BMDM (Rina et al., 2001), the 
release of which may act on a variety of immune cell types causing the release of a range of inflammatory mediators which 
may act directly on the sensory neurone resulting in increased neuronal activity and contributing to pain states (Ji et al., 
2014).  








Figure 31. Levels of NGF or TNFα Secretion in cell culture supernatants of BMDM. A) Levels of TNFα secretion from BMDM 
in response to NGF (10 ng/mL, 24 h) and B) levels of NGF secretion from BMDM in response to TNFα (10 ng/mL, 24 h). Data 
displayed as Mean ± SEM, n=3-4 biological replicates (displayed as individual data points). Data were analysed using One-
Way ANOVA followed by Tukey’s multiple comparisons test. **** P<0.0001. Significance represents a change from the 
‘untreated’ group. 
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 













4.4.6 TNFα (not NGF) Enhances Cytokine Secretion from BMDM in vitro 
Diverse inflammatory mediators (other than NGF and TNFα) have been implicated in pain 
states, including IL-1β (as reviewed by (Ren and Torres, 2009)), KC/GRO (also known as CXCL1) 
(as reviewed by (Silva et al., 2017)) and IL-10 (as reviewed by (Ouyang et al., 2011)). Thus, we 
also determined whether macrophage release of these factors in response to NGF and TNFα 
treatment (24 h) could be observed. Due to the low n number, statistics were not performed 
in this instance, but there was a clear trend for TNFα to induce the secretion of IL-10, IL-1β 
and KC/GRO compared to the untreated group (increases of 6.03 pg/mL (fold change of 2.8), 
8.26 pg/mL (fold change of 4.2) and 22.6 pg/mL (fold change of 4.1) respectively) (Figure 32A-
C). This trend was also observed in the combination group. Consistent with the previous data 
presented, NGF at 10 ng/mL was found to have no detectable effect (Figure 32A-C). Levels of 
GM-CSF, TNFα, IL-6, MCP-1, MIP-1α and MIP-3α were also examined but were below 






Figure 32. Modulation of BMDM cytokine release in response to NGF and TNFα. Levels of A) IL-10 secretion, B) IL-1β 
secretion and c) KC/GRO secretion from BMDM in response to NGF (10 ng/mL, 24 h, hollow squares) TNFα (10 ng/mL, 24 h, 
black triangles) or a combination of the two (10 ng/mL, 24 h, black upside-down triangles). Data displayed as Mean ± SEM, 
n=3 biological replicates for untreated group and n=2 biological replicates for all other treatment groups (displayed as 
individual data points). Lower limits of quantification (LLOQ) for these assays were 3.8 pg/mL (IL-10), 3.1 pg/mL (IL-1β) and 
0.43 pg/mL (KC/GRO).  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 












4.4.7 TNFα Drives the Expression of a Number of Pain-Relevant Genes in BMDM 
Since we observed only modest differences in a small panel of cytokines, we decided to study 
the effects of NGF, TNFα or a combination of the two (10 ng/mL) on a wide range of genes 
and examine BMDM modulation at the transcriptional level. To enable a broad analysis, a 
TaqMan array card with 45 known inflammatory genes (and 3 control housekeeping genes; 
18s, β2m and Gapdh) was employed. Figure 33 displays a heat map showing the relative 
overall expression levels of each gene in response to treatments. TNFα alone, or in 
combination with NGF, drove the upregulation of a number of genes, whereas NGF alone 
showed no effect on the expression of genes in this panel (Figure 33). The gene expression 
upregulation with TNFα was similar to that of TNFα in combination with NGF (Figure 33).  
Statistical analysis revealed a number of genes which were significantly upregulated following 
TNFα alone (or in combination with NGF) (Figure 34A); Aif1, C3, Ccl12, Gpr84, Il-1β, Slfn2 and 
Tnf itself. The highest regulated gene was C3 with an increase in ΔΔCt value of 8.88 ± 2.25 
(n=4 biological replicates) from the baseline untreated group (Figure 34B), followed by GPR84 
with an increase in ΔΔCt value of 7.19 ± 0.61 (n=4 biological replicates) (Figure 34B), equating 









Figure 33. Heat map demonstrating the differential expression of mRNA transcripts in BMDM following 24 h treatment 
with NGF (10 ng/mL), TNFα (10 ng/mL) or NGF (10 ng/mL) + TNFα (10 ng/mL). Each row represents a different gene and 
each column represents a different treatment group. Data represents the average ∆∆Ct value of 4 biological replicates. Red 
represents an upregulation in gene expression whereas green represents a downregulation in gene expression.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 





Figure 34. Genes significantly regulated by TNFα treatment. A) Heat map demonstrating the differential expression of mRNA 
transcripts in BMDM in genes that reached statistical significance. Each row represents a different gene and each column 
represents a different treatment group. B) Quantification of data in the above heat map.  Data represents the average ∆∆Ct 
value of 4 biological replicates displayed as Mean ± SEM. Data were analysed using LIMMA and adjusted for multiple 
comparisons.  ****P<0.0001, **P<0.01, *P<0.05. Asterisks signify significance from the untreated group. 
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived macrophages; 
Aif1: allograft inflammatory factor 1; C3: complement component 3; Ccl12: chemokine (C-C motif) ligand 12; Gpr84: G-
protein coupled receptor 84; IL-1β: interleukin-1β; Slfn2: schlafen 2; Stat1: signal transducer and activator of transcription 1; 





Evidence in the literature (outlined in the introduction of this chapter) suggested that 
macrophages are a potential target for both NGF and TNFα and could be important in chronic 
pain states. Although we saw a convincing effect of TNFα on a number of pain-relevant read-
outs in macrophages, this was not the case following macrophage stimulation with NGF. 
Furthermore, we saw no evidence that NGF could augment TNFα-driven responses of the 
macrophages.  
In a range of culture models of adult murine macrophages (BMDM, peritoneal or activated 
peritoneal) the expression of Ntrk1 was undetectable, and the presence of Ngfr only 
detectable at very low levels. Furthermore, despite reports demonstrating that the use of a 
pre-stimulus, such as LPS, could increase human macrophage NTRK1 expression (Caroleo et 
al., 2001, Rina et al., 2001), we found that this was not the case in our hands.  However, gene 
transcription is not directly correlated to the level of receptor protein expression, and 
therefore no firm conclusions may be drawn regarding the protein receptor expression level.  
In line with this absence of receptor expression, no macrophage response to NGF was 
detected at either the transcriptional or protein level. This finding contrasted with the 
reported modulatory effect of NGF and TNFα on one another in this cell type (summarised in 
section 4.1). The viability assays performed also suggest that the lack of response seen from 
NGF treatment was not due to the deterioration of the health of the BMDMs. A recent study 
showed that although an increase in NGF expression was detected in injured intervertebral 
discs from C57Bl/6J mice, this was not reduced following macrophage depletion (Miyagi et 
al., 2018). This suggests that the changes observed in NGF expression were not mediated by 
macrophages in this instance.  
176 
 
One possible explanation for a lack of NGF effect seen could be that the in vitro model we 
have been utilising is too simplified. In vivo, macrophages will receive signals coming from 
multiple different cell types, which could modify their behaviour and modulate their receptor 
expression levels (Sica and Mantovani, 2012). Our in vitro model may be lacking a component 
which is critical for such a response.  
Despite the lack of NGF effect observed, TNFα stimulation resulted in a range of pain-relevant 
changes, which the combination treatment mimicked closely. It was found that BMDMs 
stimulated with TNFα showed an increase in the release of KC/GRO, IL-1β and IL-10, an effect 
which is in line with the literature (Zhang and An, 2007).   
KC/GRO is known to be involved in neutrophil chemotaxis (De Filippo et al., 2013) and has 
numerous links to pain (Zhang et al., 2013). It has been shown that both spinal nerve ligation 
and inflammation in the periphery induced a significant upregulation of KC/GRO in the DRG 
itself (Li et al., 2007, Xie et al., 2006). Furthermore, KC/GRO has been shown to directly 
modulate sensory neurone activity via increasing sodium current activity (Wang et al., 2008), 
inducing an increase in TRPV1 activity measured via patch clamp methods (Dong et al., 2012) 
and increasing NMDA receptor activity along with COX2 expression in spinal cord neurones 
via activation of CXCR2 (Cao et al., 2014). However, despite the above studies demonstrating 
a pro-nociceptive effect of KC/GRO, one study has demonstrated a potential anti-nociceptive 
role for this chemokine. It was found that a spinal nerve ligation induced a significant increase 
in KC/GRO only in CD40 knock-out mice, and injection of KC/GRO in wild-type mice 
significantly reduced the mechanical hypersensitivity usually seen in this model of 
neuropathic pain (Malon and Cao, 2016). The above demonstrates that regulation of KC/GRO 
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through TNFα may be a crucial component in the pathway that allows intricate 
communication between non-neuronal cell types and neurones in pain states.  
The pro-inflammatory actions of IL-1β have been extensively described in a number of 
therapeutic areas (Dinarello, 2011). TNFα is known to stimulate the production of IL-1β, as 
confirmed in this dataset (at mRNA and protein level), and together they recruit and activate 
a number of non-neuronal cell types, including macrophages (Nadeau et al., 2011), further 
potentiating the inflammatory cascade. Injection of IL-1β itself results in both thermal and 
mechanical hyperalgesia (Fukuoka et al., 1994) and models of inflammatory pain, such as the 
use of CFA, are associated with a significant increase of IL-1β (Safieh-Garabedian et al., 1995). 
Interestingly, the latter study demonstrated a crucial role for IL-1β in the upregulation of NGF 
and associated hypersensitivity in these inflammatory states, an effect which could be 
prevented via the use of an IL-1 receptor antagonist. This suggests an alternative way in which 
TNFα may be able to modulate NGF signalling. Disrupting IL-1β signalling has been shown to 
be an effective method in the clinic to improve a number of inflammatory conditions 
(Dinarello et al., 2012). Currently, a number of methods are employed; an IL-1 receptor 
antagonist (anakinra) (Arend, 2002), a soluble decoy receptor (rilonacept) (Hoffman et al., 
2008) and a neutralising monoclonal antibody directed again IL-1β (canakinumab) (Dhimolea, 
2010). It has been shown that patients with rheumatoid arthritis have a reduced intimal layer 
macrophage accumulation following treatment with anakinra, an effect associated with the 
halt of progressive joint damage (Cunnane et al., 2001). Furthermore, these patients report a 
significant improvement in their pain scores (visual analogue scale), disease activity and 
number of swollen/tender joints (Bresnihan et al., 1998). Patients suffering from Schnitzler 
syndrome, a systemic inflammatory disease, benefit greatly from treatment with both 
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anakinra and canakiumab (Szturz et al., 2011). Additionally, the blockade of IL-1β signalling in 
auto-inflammatory diseases has shown a significant improvement in patients reported pain, 
in conjunction with a marked reduction in levels of pro-inflammatory markers (Jesus and 
Goldbach-Mansky, 2014). 
In contrast to IL-1β and KC/GRO, IL-10 is traditionally considered an anti-inflammatory 
cytokine that is produced in response to inflammatory insults to try and bring the system back 
into balance where possible. It has previously been shown that IL-10 application, to a 
macrophage cell line as well as peritoneal macrophages, results in a reduction in both 
secretion and expression of TNFα (Fiorentino et al., 1991). Additionally, IL-10 has been shown 
to be significantly upregulated following chronic constriction injury (Okamoto et al., 2001) as 
well as in the CFA model of inflammatory pain (Chen et al., 2010). Our data supports the 
upregulation of IL-10 following an insult (in our case TNFα stimulation).  
At the transcriptional level, TNFα significantly upregulated several pain-relevant genes, the 
involvement in pain states are briefly described below: 
Aif1 is also known as ionised calcium-binding adapter molecule 1 (Iba1) and encodes for a 
protein that is specifically expressed in macrophage and microglia. Aif1 is upregulated 
following activation in pain models, such as peripheral nerve injury (PNI) and chronic 
constriction injury (CCI) (Romero-Sandoval et al., 2008, Li et al., 2013, Patro et al., 2010). 
These studies highlight the importance of TNFα in this activation pathway and in the 
subsequent production of a pro-inflammatory feedback loop which could be crucial in 
maintaining a painful state.  
C3 is a gene that encodes for the complement component 3 protein. This plays a crucial role 
in the activation of the complement system which is vital in contributing to innate immunity 
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(Ricklin et al., 2010). It has previously been described that abnormal activation of this protein, 
in the spinal dorsal horn of the spinal cord in rats which had undergone PNI, leads to a cascade 
reaction of other complements that are involved in the development of hyperalgesia (Nie et 
al., 2013). Additionally, mice lacking C3 demonstrated a 2-fold increase in sensory axon 
regeneration within the spinal cord, following a peripheral conditioning lesion, compared to 
wildtype mice (Peterson et al., 2017). The administration of C3a into the cerebral ventricles 
of mice resulted in the inhibition of morphine induced analgesia (Jinsmaa et al., 2000). It has 
been shown that mice infected with Ross River Virus (RRV), leading to severe inflammation of 
bones, joints and skeletal muscle tissue, develop considerably less severe symptoms when 
deficient in C3 (Morrison et al., 2007). Furthermore, it has previously been shown that both 
C3a and C5a (an additional complement component protein) upregulates expression of NGF 
mRNA in rat astrocytes (Jauneau et al., 2006), once more highlighting the important role of 
non-neuronal cell types.  
Although in our work the expression levels of C5a were not examined, recent work outlines a 
possible mechanism for C5a induced thermal hyperalgesia (Shutov and Warwick, 2016). The 
authors suggest that C5a can produce thermal hyperalgesia via macrophage-dependent NGF 
mobilisation which then allows the subsequent NGF-dependent sensitisation of TRPV1. Based 
on the above study, the secretion of C5a protein was examined via ELISA following TNFα 
treatment of BMDM (data not shown), however no presence of C5a was detectable.  
The Ccl12 gene encodes for a cytokine that belongs to the chemokine family within mice and 
has many similarities with the human chemokine MCP-1.  In agreement with our data, it has 
been shown to be significantly upregulated at the mRNA level in activated macrophages 
where it may act as a potent chemoattractant for peripheral blood monocytes (Sarafi et al., 
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1997). The expression of Ccl12 has previously been identified as being significantly 
upregulated in rat cartilage of the knee joint in the monosodium iodoacetate (MIA) chronic 
pain model (Dawes et al., 2013). Its human analogue, MCP1, has been implicated in the 
pathophysiology of fibromyalgia (Ang et al., 2011) and in the maintenance of chronic pain 
states in a murine urinary tract infection model (Rosen et al., 2018). 
The Gpr84 gene encodes an orphan receptor, known to be upregulated in inflammatory 
conditions (Suzuki et al., 2013, Bouchard et al., 2007, Oh and Lagakos, 2011). The exact 
physiological function of GPR84 has remained elusive but its role in pain mechanisms has 
recently been dissected. It has been found that GPR84 knock-out mice exhibited normal pain 
behaviours in response to acute stimuli, but were unable to develop either mechanical or 
thermal hypersensitivity in response to partial sciatic nerve ligation (PNL) (Nicol et al., 2015). 
The authors concluded that the GPR84 receptor contributes to nociceptive signalling via the 
modulation of macrophages, with GPR84 knockout mice resulting in an impaired pro-
inflammatory response from macrophages. In line with the above, a recent study has 
demonstrated that activation of the GRP84 receptor in murine macrophages results in 
enhanced levels of several inflammatory mediators, including TNFα, IL-6, IL-12B, CCL2, CCL5 
and CXCL1 (Recio et al., 2018). TNFα stimulated macrophages could therefore be contributing 
to a pain state via the GPR84 driven pro-inflammatory response. 
The SLFN2 protein has been implicated in a number of functions, including cell growth, 
differentiation and contributing to the immune response (Mavrommatis et al., 2013). A recent 
study has demonstrated a crucial role for SLFN2 in modulation of T cell quiescence via 
regulation of cholesterol levels and endoplasmic reticulum stress (Williams et al., 2015). In 
line with above, mice with Slfn2 mutations have fewer naïve T cells, reduced responsiveness 
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to IL-7 (a crucial regulator of T cells (Bradley et al., 2005)) and increased apoptotic signals 
(Sprent and Surh, 2011). These results are corroborated by data suggesting that mice with a 
mutation encoding SLFN2 are more susceptible to both viral and bacterial infections (Berger 
et al., 2010). SLFN2 protein has also recently been demonstrated to be involved in the control 
of IFN-stimulated genes and the subsequent regulation of IFN-mediated biological responses 
via modulation of the NFκB pathway (Fischietti et al., 2018). It has been shown that ablating 
IFNγ receptors significantly impairs nerve injury induced microglia activation and the 
associated tactile allodynia (Tsuda et al., 2009), suggesting a potential link between Slfn2 and 
pain behaviours.  
Stat1 is a gene that encodes a transcription factor which plays an important role in both IFNα 
and IFNγ signalling (Schindler et al., 2007). Macrophages lacking STAT1, display an attenuation 
of the TLR-induced production of inflammatory cytokines, such as TNFα (Kim et al., 2015). 
TNFα itself can activate an IRF1-dependent autocrine loop leading to a sustained expression 
of chemokines and STAT1-dependent type 1 interferon response genes (Yarilina et al., 2008b) 
Furthermore, levels of both STAT1 mRNA and protein have been shown to be upregulated in 
isolated microglia following spinal nerve injury in mice (Denk et al., 2016). The above studies 
therefore suggest a potential crucial role of STAT1 in the generation and maintenance of pain 
states. 
It is well known that TNFα can result in an increased expression of itself (Parameswaran and 
Patial, 2010), an effect that we also see in our data set. However, the increase in TNFα 
production may also be due to the upregulation of a number of other pro-inflammatory 
cytokines, as described above, leading to a sustained inflammatory environment.  
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Although the effect of NGF treatment was below the detection threshold in our macrophage 
cultures, the reported effects of TNFα in this chapter strongly suggest a crucial role for both 
TNFα and macrophages in pain signalling. Furthermore, given the lack of an effect of TNFα 
seen in neurones within the first data chapter, the data presented above suggest a more 
plausible hypothesis of an indirect effect of TNFα on sensory neurones, via a non-neuronal 
cell type which could potentially drive chronic pain states.  
It is noted that the primary read out of gene expression in this chapter, may not be taken as 
a direct indicator of protein expression. Future work could investigate the levels of protein 
expression in addition to the regulation of gene expression which is reported within this 
chapter.   
4.6 Summary of Chapter 
In summary, the data presented in this chapter suggest that TNFα is capable of modulating 
macrophage responses, while NGF does not show a direct effect in this particular cell type. In 
BMDM, we have demonstrated that TNFα can produce a strong and reproducible effect in a 
number of pain-relevant read-outs, including phospho-p38 activation, enhanced cytokine 
secretion and an increase in the expression of a number of pain-relevant genes. In contrast, 
NGF failed to produce any notable effects on the same readouts. The latter findings are in line 
with the receptor expression work we have reported. Once more, the lack of any additive or 
synergistic effects of the two inflammatory mediators on macrophages, suggest that this cell 
type is unlikely to be the sole site of action of the NGF/TNFα dual blockers which we have 
















5. Investigating the Individual and 
Combined Effect of NGF and TNFα in 
a Co-Culture System of Sensory 




Our previous data demonstrates that BMDM express high levels of Tnfrsf1a, whereas their 
expression of NGF receptors (Ntrk1 and Ngfr) is low or absent. However, the situation in 
sensory neurones is much the converse, with only low levels of Tnfrsf1a expression and high 
levels of Ntrk1 and Ngfr expression (Figure 35A). Therefore, any potential interaction between 
NGF and TNFα is unlikely to be occurring at the level of an individual cell type.  
This chapter will focus on the optimisation of a co-culture system between sensory neurones 
and macrophages, two cell types which we have seen can respond to NGF and TNFα, 
respectively. We believe a co-culture of these two cell types, both of which are known to have 
critical roles in chronic pain signalling (Cheng and Ji, 2008, Ristoiu, 2013, Pinho-Ribeiro et al., 
2017a), can provide a proxy of the DRG in vivo in such disease states. Furthermore, given the 
apparent selectivity of the sensory neurone to NGF, and the macrophage to TNFα, a co-
culture can provide a useful system in which to assay any additive or synergistic pain-relevant 








Figure 35. Rationale for and development of a co-culture of sensory neurones and macrophages. A) Schematic representing 
the rationale behind a co-culture set-up, focussing particularly on the levels of NGF and TNFα receptors in each cell type 
(adult DRG sensory neurone or BMDM). B-C) Representative fluorescent micrographs following immunostaining with the 
neuronal marker β-III tubulin (green), macrophage associated marker IBA1 (red) and the nuclear stain DAPI (blue) with 
BMDM plated at 80K cells/well. Scale bar represents 50 μM.  
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; DRG: dorsal root ganglia; BMDM: bone 











5.2 Aims and Experimental Strategy 
The aims of this chapter are to test the hypothesis that: 
• Additive or synergistic pain-relevant effects of NGF and TNFα can be detected in a 
system where sensory neurones and macrophages can communicate with one 
another 
Specifically, we aim to: 
• to develop a direct co-culture system between sensory DRG neurones and BMDM 
• to utilise the above co-culture system to further elucidate the interaction between 
NGF and TNFα in vitro on pain-relevant readouts 
• to determine the effect of BMDM-derived conditioned medium (CM) on DRG 
neurones in vitro on pain-relevant readouts  
The results presented below originate from the use of the following key assays to assess the 
effect of NGF/TNFα in this system: levels of stimulus-evoked sensory neuronal CGRP release, 
levels of stimulus-evoked IL-1β release, quantification of mRNA transcripts (for a panel of 
inflammatory and pain-related genes) and determination of sensory neuronal calcium levels. 
In addition to using direct co-culture methods (where cells exist in direct cell-cell contact), 
data is also presented from the effect of BMDM-derived CM on purified DRG neuronal 
cultures. This allows us to identify if any changes in pain-relevant readouts occur in sensory 
neurones as a result of secreted factor(s) from macrophages. Additionally, this method 
removes the complication of a secondary cell type being physically present in the neuronal 




All animals were obtained from Charles River and housed in a designated facility and 
maintained in accordance with the United Kingdom Home Office Animals (Scientific 
Procedures) Act (1986) and Home Office regulations. Animals were kept in a 12 h light dark 
cycle and fed ad libitum. All animals were sacrificed using schedule 1.   
5.3.1 Mixed DRG Neuronal/Glia and BMDM Co-Cultures 
All direct co-culture experiments were undertaken using mixed DRG neuronal/glia cultures to 
enable a high enough cell yield for subsequent assays described. Both cell type cultures 
(mixed DRG neuronal/glia cultures and BMDM cultures) were carried out as previously 
described (sections 3.3.1.1 and 4.3.1.1). Neurones were plated at 8K/well in 100 µL BS 
medium on pre-coated poly-D-lysine coated Greiner 96 well plates incubated with laminin 
diluted 1:50 in basal F12 for at least 2 h. Mixed DRG neuronal/glia cultures were left to settle 
overnight prior to the addition of BMDM the following day. BMDM were added to the culture 
at a density of either 20K cells/well, 40K cells/well or 80K cells/well in 50 µL BS medium. These 
cell densities were based on reports in the literature that had utilised macrophage co-cultures 
in vitro (Dobbertin et al., 1997, Kwon et al., 2015, Massier et al., 2015). Additionally, it has 
been shown that the number of macrophages infiltrating the DRG, following transection of 
the sciatic nerve in vivo, increases 3-fold in the initial days following injury and up to 10-fold 
compared with control DRGs at day 7 post-injury (Kwon et al., 2013). The two cell types were 
acclimatised to one another overnight prior to any experimental protocols taking place. 
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5.3.2 LDH Viability Assay  
To determine that the mixed DRG neuronal/glia + BMDM co-cultures were healthy and 
remained viable, we quantified viability using the Pierce LDH Cytotoxicity Assay Kit 
(ThermoFisher Scientific, 88953 88954). This assay is a colorimetric method used to quantify 
the level of lactate dehydrogenase (LDH) in the supernatant of samples, an indicator of 
cellular toxicity (Weyermann et al., 2005). Briefly, direct co-cultures (7-8K neurones/well + 
80K BMDM) were treated with TNFα 10 ng/mL, staurosporine (as positive control for cell 
death), or with the kit supplied lysis solution (an additional positive control) for 48 h. 50 µL of 
culture supernatant was transferred to a new flat-bottomed, clear 96-well plate and an equal 
volume of reaction mixture added (0.6 mL of Assay Buffer with 11.4 mL of Substrate Mix). The 
above reaction was incubated at RT for 30 min before 50 µL of stop solution was added, taking 
care to avoid bubbles. Absorbance was measured at both 490 nm and 680 nm on FLUOstar 
Omega plate reader (BMG Labtech). LDH activity was determined via the subtraction of the 
680 nm absorbance value from the 490 nm absorbance to remove background signal from 
the instrument.  
5.3.3 Enzyme Immuno Assay to Quantify CGRP Release 
Levels of CGRP in culture supernatants from mixed DRG neuronal/glia cultures, the co-culture 
system and BMDM alone were examined using SPI Bio’s Rat CGRP EIA kit (SPI Bio/Bertin 
Pharma, A05482) as previously described in section 3.3.5, with the following changes: 
At the point of stimulation, performed in either duplicate or triplicate, 50 µL of culture 
supernatant was removed (leaving 100 µL of culture supernatant) and a 6X stock of the 
desired concentration of stimulators (NGF, TNFα, or a combination of the two) added in a 
volume of 20 µL BS medium. Cultures were stimulated for 48 h (see Table 8 for details). On 
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the day of the CGRP release assay, culture supernatants were removed and cultures were 
challenged with either 100 µL 25 mM K+ solution (made as previously described in section 
3.3.5), 100 nM capsaicin (Sigma Aldrich, 50 mg stock, M2028-50MG) or 31.25 μM veratridine 
(Sigma Aldrich, 10 mg stock, V5754-10MG) made up in 1X HBSS, followed by a 30 min 
incubation at 37 ᵒC for both high K+ and capsaicin and a 10 min incubation at 37 ᵒC for 
veratridine.  
Table 8. Table of concentrations of NGF and TNFα used throughout the CGRP release experiments. 
NGF Concentration TNFα Concentration 
0 ng/mL 10 ng/mL 
0 ng/mL ✓ ✓ 
0.1 ng/mL ✓ ✓ 
1 ng/mL ✓ ✓ 
10 ng/mL ✓ ✓ 
 
5.3.4 Gene Expression Analysis of Purified DRG Neurones after Treatment with BMDM-
Derived Conditioned Medium  
To further examine the possible relationship between DRG sensory neurones and BMDM, a 
series of CM experiments were performed. Throughout these experiments purified DRG 
neuronal cultures were utilised.  
5.3.4.1 Purified DRG Neuronal Cultures 
Following the culture and purification of adult mouse DRG neurones (as previously described 
in section 3.3.1.2), purified DRG neuronal cultures were plated on Poly-L-lysine coated 13 mm 
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coverslips placed in a 4 well plate incubated with growth-factor reduced matrigel as 
previously described. Initially, purified DRG neurones were plated at a density of 
approximately 5000 cells/well in a small volume (80 µL) of B27 medium. Following a time 
period of 1 h to allow for the attachment of the purified DRG neurones, 500 µL BMDM-derived 
CM was added and cells allowed to incubate at 37 °C for 24 h prior to RNA collection.  
5.3.4.2 BMDM-Derived Conditioned Medium Collection and Transfer to Purified DRG Neuronal 
Cultures 
CM was collected from BMDM which had been cultured as previously described (section 
4.3.1.1). Following the 7-day differentiation period, BMDM were re-plated in a 24-well plate 
at a density of either 40K cells/well or 80K cells/well. BMDM then received media only 
(control) or TNFα (10 ng/mL) for 24 h. Following this time period, the CM was removed from 
the BMDM and centrifuged at 212 g for 5 min (Hettich Zentrifugen) to remove any cellular 
debris. Purified DRG neuronal cultures could then be treated with one of the following 
conditions for 24 h: 
1. Untreated, no BMDM control (media only) 
2. TNFα (10 ng/mL), no BMDM control (media with TNFα) 
3. CM from untreated BMDM plated at 40K cells/well  
4. CM from TNFα (10 ng/mL) treated BMDM plated at 40K cells/well  
5. CM from untreated BMDM plated at 80K cells/well  
6. CM from TNFα (10 ng/mL) treated BMDM plated at 80K cells/well  
Following the addition of CM to the purified DRG neuronal cultures, one set of wells received 
no further treatment whereas the second set of wells received an additional stimulation with 
NGF (10 ng/mL). This enabled us to test whether the neuronal action of NGF could summate 
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with the TNFα effect on BMDM and therefore further contribute to pain signalling pathways. 
Wells which did not receive NGF, had the Trk-Inhibitor (Sigma Aldrich, PZ0254) added at a 
concentration of 200 μM to prevent any basal NGF signalling occurring.  
5.3.4.3 RNA Collection, Amplification and Qubit Quantification 
Following the 24 h neuronal treatment period, RNA was collected using the Qiagen RNAeasy 
Micro Kit and samples checked for quantity and quality on the Agilent 2100 Bioanalyzer 
instrument as previously described (section 3.3.4.1). Only samples with a RIN < than 7 were 
taken forward for further analysis. 
Due to the relatively low number of purified DRG neurones plated, it was necessary to amplify 
the sample material to be able to run the samples on custom made TaqMan 384-well PCR 
array microfluidic cards (Applied Biosystems). 
Amplification of cDNA samples was performed using the REPLI-g® WTA Single Cell Kit (Qiagen, 
150065). Briefly, 3 µL of NA Denaturation Buffer was added to 8 µL of purified RNA in a 
microcentrifuge tube. The resulting product was mixed by vortexing and incubated at 95 °C 
for 3 min. Subsequently, 2 µL of gDNA Wipeout Buffer WTA was added and incubated for a 
further 10 min at 42 °C. During this latter incubation, the Quantiscript RT mix was prepared 
fresh as outlined in Table 9, before 7 µL were added to the lysed cell sample. After being 






Table 9. Table displaying the components and associated volumes for the Quantiscript RT mix. 
Component Volume/reaction 
RT/Polymerase Buffer 4 µL 
Random Primer 1 µL 
Oligo dT Primer 1 µL 
Quantiscript RT Enzyme Mix 1 µL 
Total volume 7 µL 
 
To stop the reaction, samples were incubated at 95 °C for 3 min before being cooled on ice. 
At this stage, 10 µL ligation mix was added and the resulting mix was vortexed and incubated 
for 24 °C for 30 min. The ligation mix was prepared as shown in Table 10: 
Table 10. Table displaying the components and associated volumes for the ligation mix.  
Component Volume/reaction 
Ligase Buffer 8 µL 
Ligase Mix 2 µL 
Total volume 10 µL 
 
To stop the reaction, samples were incubated at 95 °C for 5 min. Following this step, the REPLI-
g SensiPhi amplification mix was prepared (as shown in Table 11), 30 µL added to the solution 
from above and the resulting mix vortexed and incubated at 30 °C for 2 h. 
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Table 11. Table displaying the components and associated volume for the REPLI-g SensiPhi amplification mix. 
Component Volume/reaction 
REPLI-g sc Reaction Buffer 29 µL 
REPLI-g SensiPhi DNA Polymerase 1 µL 
Total volume 30 µL 
 
The above reaction was stopped by incubating at 65 °C for 5 min. Amplified cDNA was stored 
at -20 °C until ready for cDNA quantification and downstream use.  
cDNA was quantified using the Qubit dsDNA Broad Range Assay Kit (ThermoFisher Scientific, 
Q32853) and read on the Qubit Fluorometer (ThermoFisher, Scientific) as illustrated below 
(Figure 36).  
 




Custom made TaqMan 384-well PCR array microfluidic cards (Applied Biosystems) were used 
to analyse the effect of CM on purified DRG neurones. These were composed of 48 pain-
related gene transcripts simultaneously, including three housekeeping genes; 18s, Ywhaz and 
Gapdh. See Table 12 for full list of gene transcripts quantified.  Sample cDNA was diluted to 6 
ng/mL in 50 µL molecular grade water before a TaqMan universal PCR master mix (Applied 
Biosystems, 4304437) was added at a 1:1 ratio to give a final volume of 100 µL. Each custom 
card held eight cDNA samples and was allowed to acclimatise to RT prior to loading. Once 
thoroughly mixed, 95 µL of the sample mix was loaded into the corresponding channel and 
centrifuged at 158 g for 1 min (Sorvall ST 40 Centrifuge) twice. The card was sealed, and the 
entry wells removed prior to the card being run on the ABI 7900HT Real Time PCR instrument 
(Applied Biosystems, serial number: 201276). The following cycling conditions were used: 25 
ᵒC for 10 min, 42 ᵒC for 60 min and 85 ᵒC for 5 min.  
5.3.4.5 Data Analysis 
mRNA transcripts were normalised to the expression of the housekeeping genes (18s, YWhaz 








Table 12. List of gene transcripts included on the PCR TaqMan card (DRG pain-related). Housekeeping genes are 
highlighted in bold font. 
Gene Transcripts 
Adcyap1 Ccl20 Cxcl12 Il-1β Npy Scn10a Trpa1 
Areg Ccl3 Ereg Il-6 Ntrk1 Scn11a Trpv1 
Atf3 Ccl4 Gal Il-6ra Ntrk2 Scn9a Vgf 
Bdnf Ccl5 Gch1 Il-6st Ntrk3 Stat3 18s 
Cacna2d1 Csf1 Il-11 Ngf Oprm1 Tac1 Ywhaz 
Calca Csf2ra Il-17a Ngfr P2xr3 Tlr4 Gapdh 
Ccl2 Csf3 Il-18 Nos1 P2xr4 Tnf  
 
5.3.5 Gene Expression Analysis of Direct Co-Cultures of Mixed DRG Neuronal/Glia Cultures 
with BMDM  
Direct co-cultures between mixed DRG neuronal cultures and BMDM were set-up as 
previously described (section 5.3.1). These experiments followed the exact timeline of those 
of the CGRP assay (section 5.3.3) to align experimental results. Following the 48 h stimulation 
period (with NGF, TNFα or a combination of the two) samples were collected, the RNA 
extracted and amplified and cDNA measured on the Qubit as previously described (section 
5.3.4.3). Samples were run on the same pain-related custom made TaqMan 384-well PCR 
array microfluidic cards as for the CM experiments (section 5.3.4.4).  
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5.3.5.1 Data analysis  
mRNA transcripts were normalised to the expression of the housekeeping genes (18s, Ywhaz 
and Gapdh) using the ∆∆Ct method and data expressed as ∆∆Ct changes from the basal 
condition. 
5.3.6 IL-1β ELISA 
Levels of IL-1β secretion in mixed DRG neuronal/glia cultures, BMDM cultures or mixed DRG 
neuronal/glia + BMDM co-cultures in response to NGF (10 ng/mL, 48 h), TNFα (10 ng/mL, 48 
h) or NGF + TNFα (10 ng/mL, 48 h) were examined using a Mouse IL-1β ELISA kit (R&D Systems, 
DY401-05). A 96-well microplate was coated with 100 µL/well of the Mouse IL-1β Capture 
Antibody at a working concentration of 4 µg/mL, diluted in PBS without carrier protein. The 
plate was sealed and left to incubate overnight at RT. The plate was washed three times with 
400 µL of wash buffer and then blocked via the addition of 300 µL/well of Reagent Diluent for 
1 h at RT. The wash step described above was repeated. 100 µL of either standard (1000 
pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.25 pg/mL, 15.6 pg/mL or 0 pg/mL) 
or sample diluted in Reagent Diluent were added to the plate and incubated for 2 h at RT. The 
wash step was repeated. Subsequently, 100 µL/well of the Mouse IL-1β Detection Antibody, 
diluted to a working concentration of 500 ng/mL in Reagent Diluent, was added to the plate 
and incubated for 2 h at RT. The wash step was repeated. 100 µL/well of Streptavidin-HRP, 
diluted 1:40 in Reagent Diluent, was added to the plate and incubated for 20 min at RT, 
protected from direct sunlight. Following a final wash step, 100 µL of Substrate Solution was 
added to the plate and incubated for 20 min at RT (protected against direct sunlight). To stop 




5.3.6.1 Data Analysis for IL-1β ELISA Data 
The absorbance was read at 450 nm and 540 nm on a FLUOstar Omega microplate reader 
(BMG Labtech). Readings at 540 nm were subtracted from the readings at 450 nm to correct 
for optical imperfections in the plate. The absorbance values of the standards were used to 
plot a standard curve, from which absorbance values of experimental samples were 
interpolated to determine their concentrations.  
5.3.7 Calcium Imaging  
Following the culture and purification of adult mouse DRG neurones, purified DRG neuronal 
cultures were plated on Poly-L-lysine coated 13 mm coverslips placed in a 4 well plate 
incubated with growth-factor reduced matrigel as previously described (section 3.3.1.2). 
Initially, neurones were plated at a density of ~1500 cells/well in a small (10 µL) volume of 
B27 medium. Following a time period of 30 min to allow for the attachment of the purified 
DRG neurones, 500 µL BMDM-derived CM was added and allowed to incubate at 37 °C for 24 
h prior to calcium imaging. BMDM-derived CM was collected as previously described and the 
treatment groups remained the same (for CM experiments BMDM were used at a density of 
80K cells/well). 
Calcium imaging was performed as previously described (section 3.3.6). To determine if the 
CM was able to sensitise the purified DRG neurones, the response to capsaicin 50 nM was 
determined. Both capsaicin and KCl solutions were made up in the previously described 




Figure 37. Schematic displaying the timeline of the CM experiments and the associated calcium imaging protocol. 
5.3.7.1 Data Analysis for Calcium Imaging Experiments 
Images were extracted from the Easy Ratio Pro software as Tiff files and further image 
processing was undertaken using ImageJ Version 1.8. In order to generate traces of calcium 
signals from time lapse images, cell bodies of neurons were circled using the oval selection 
tool in ImageJ. Cell bodies were circled with minimal overlap where possible. To generate 
normalised data (as neurones show differences in their baseline fluorescence), the baseline 
period (at least 3 min) of fluorescence for each cell and changes from this baseline 







Where Ft is the fluorescence at time t and F0 is the fluorescence average over a baseline 
period. 
5.3.8 Statistical Analysis 
All statistical analysis was performed using GraphPad software (version 7.04). Prior to any 
statistical analysis taking place, the data were tested for normality using the Shapiro-Wilk 
normality test. Within this chapter, all data was analysed using the following statistical tests; 
Two-tailed t-tests, One-Way ANOVA, Two-Way ANOVA or LIMMA (for the TaqMan card data) 
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followed by post-hoc correction tests for multiple comparisons. In all instances, data are 
displayed as Mean ± SEM, n numbers and specific post-hoc correction tests used are reported 

















5.4.1 Direct Co-Culture Viability is Comparable to that of Mixed DRG Neuronal/Glia 
Cultures 
Following the culture of mixed DRG neuronal/glia and BMDM together, a number of methods 
were employed to determine that no significant detrimental effects (of macrophage presence 
on neuronal health) were occurring. The % of cell death was examined in a mixed DRG 
neuronal/glia culture vs a mixed DRG neuronal/glia + BMDM co-culture and analysed using a 
Two-Way ANOVA. A significant treatment effect was observed (F(2,12)=89.23, P<0.0001), 
with the positive control of staurosporine producing a significant increase in cell death (Figure 
38A, B and C).  In a naïve state, i.e. unstimulated, the co-culture showed no significant increase 
in cell death compared to mixed DRG neuronal/glia cultures (8.14 ± 2.39 % cell death in mixed 
DRG neuronal/glia cultures (n=3 biological replicates) to 22.42 ± 4.36 % cell death in mixed 
DRG neuronal/glia + BMDM co-cultures (n=3 biological replicates). In cultures where there 
had been a stimulation period with TNFα, no significant differences were observed, with 
10.08 ± 2.02 % cell death in the mixed DRG neuronal/glia cultures (n=3 biological replicates) 
and 11.87 ± 4.13 % cell death in the mixed DRG neuronal/glia + BMDM co-cultures (n=3 
biological replicates).  
Additionally, the expression levels of three housekeeping genes were examined; 18s, Ywhaz 
and Gapdh, to ensure that no unexpected changes were occurring at the transcriptional level. 
Using a Two-Way ANOVA, no significant culture type effect was observed (F(1, 18)=0.3075, 
P=0.5861). No significant changes in the mRNA levels of 18s, Ywhaz or Gapdh were detected 
between the mixed DRG neuronal/glia cultures and the mixed DRG neuronal/glia + BMDM 
co-culture groups (Figure 38D). In the mixed DRG neuronal/glia cultures, 18s, Ywhaz and 
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Gapdh displayed ΔΔCt values of 9.59 ± 1.64, 23.71 ± 2.12 and 17.01 ± 0.88 respectively (n=4 
biological replicates). In the mixed DRG neuronal/glia + BMDM co-cultures, 18s, Ywhaz and 
Gapdh displayed ΔΔCt values of 8.36 ± 1.04, 23.53 ± 1.66 and 16.48 ± 0.65 respectively (n=4 
biological replicates) (Figure 38D).  
It was important to determine if the neurones within the mixed DRG neuronal/glia + BMDM 
co-cultures showed significant functional differences compared to neurones of the mixed 
DRG neuronal/glia cultures. In terms of average neurite outgrowth, the co-culture system 
responded to NGF-stimulation (10 ng/mL) as expected, with 12 times increase in neurite 
outgrowth from 17.72 ± 2.62 µm (n=3 biological replicates,) in the untreated condition to 
220.2 ± 4.71 µm (n=3 biological replicates, One-Way ANOVA; F(3,8)=11.19, P=0.0104) 
following NGF (10 ng/mL) treatment (Figure 39B). This effect is comparable with the response 
of mixed DRG neuronal/glia cultures to NGF treatment (Figure 39A and B), which saw an 
increase in neurite outgrowth from 9.55 ± 5.39 µm to 184.7 ± 65.35 µm (n=3 biological 
replicates, One-Way ANOVA; F(3,8)=11.19, P=0.0229) following NGF 10 ng/mL treatment. 
Furthermore, the levels of CGRP release in response to NGF 100 ng/mL were examined using 
a Two-Way ANOVA (Figure 39C). A significant treatment effect was observed (F(1, 26)=82.73, 
P<0.0001). In co-cultures with BMDM added in at both 40K and 80K, a significant increase in 
stimulated CGRP release was observed following NGF treatment (Figure 39C) of between 4-5 
times the release in untreated conditions, from 698.8 ± 75.59 pg/mL to 3507 ± 223.9 pg/mL 
and 732.6 ± 53.18 pg/mL to 3143 ± 375.8 pg/mL respectively (n=4-6 biological replicates). The 
above data indicates that the mixed DRG neuronal/glia + BMDM co-culture remains viable 





Figure 38. Comparison of culture viability and health in mixed DRG neuronal/glia cultures or mixed DRG neuronal/glia + 
BMDM co-cultures. A) % of cell death measured using the LDH assay in mixed DRG neuronal/glia cultures (white bars) or (B) 
mixed DRG neuronal/glia + BMDM co-cultures (shaded bars) in response to TNFα (10 ng/mL, 48 h, hollow squares) or 
staurosporine (1 µM, 48 h, black triangles) as a positive control. C) Direct comparison of different treatment groups between 
mixed DRG neuronal/glia cultures (white bars, black circles) and mixed DRG neuronal/glia + BMDM co-cultures (shaded bars, 
hollow squares). Data displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data analysed 
using One-Way ANOVA followed by Tukey’s multiple comparisons test for (A-B) and Two-Way ANOVA followed by Sidak’s 
multiple comparisons test for (C). D) The basal expression level of 18s, Ywhaz or Gapdh in either mixed DRG neuronal/glia 
cultures (white bars, black circles) or mixed DRG neuronal/glia + BMDM co-cultures (shaded bars, hollow squares). Data 
displayed as Mean ± SEM, n=4 biological replicates. Data analysed using Two-Way ANOVA followed by Sidak’s multiple 
comparison test.  
Abbreviations: DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; LDH: lactate dehydrogenase; TNFα: 
tumour necrosis factor alpha; 18s: 18s ribosomal RNA; Ywhaz: tyrosine 3-monooxygenase/tryptophan 5 monooxygenase 





Figure 39. Co-culture response to NGF stimulation. A-B) Average neurite outgrowth in response to NGF (10 ng/mL, 24 h, 
hollow squares) in either mixed DRG neuronal/glia cultures (white bars) or mixed DRG neuronal/glia + BMDM co-cultures 
(shaded bars). C) High K+-evoked CGRP release in response to high concentration NGF stimulation (100 ng/mL, 48 h, hollow 
squares) in either a mixed DRG neuronal/glia cultures or mixed DRG neuronal/glia + BMDM, with BMDM added in at 40K/well 
or 80K/well. Data displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points) for neurite 
outgrowth experiments and n=4-6 biological replicates (displayed as individual data points) for CGRP release experiments. 
Data were analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test or Two-Way ANOVA followed by 
Sidak’s multiple comparisons test. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.  
Abbreviations: NGF: nerve growth factor; DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; CGRP: 




5.4.2 Stimulation of Co-cultures with TNFα, in the Presence of NGF, Results in a 
Potentiation of CGRP Release 
CGRP release has been shown to represent a pain-relevant read-out at the level of the sensory 
neurone (Schou et al., 2017). Therefore, CGRP levels in the co-culture system were examined 
to determine whether NGF and TNFα could synergistically contribute to pain states via CGRP 
release. The timeline used in the following experiments are outlined in Figure 40.  
The effect of different densities of BMDM, 20K, 40K or 80K on CGRP release in the 
presence/absence of TNFα (10 ng/mL), were examined. At a density of 20K BMDM (in co-
culture with 8K neurones), there was no significant effect on K+-evoked CGRP release between 
cultures which were stimulated with or without TNFα (10 ng/mL) (Figure 41A). However, 
BMDM at higher densities of 40K and 80K (in co-culture with 8K neurones), significantly 
increased K+-evoked CGRP release (Figure 41A). This was apparent in co-cultures which had 
been stimulated with TNFα for 48 h, with an average increase in CGRP release of 229.4 pg/mL 
(40K BMDM) and 245.5 pg/mL (80K BMDM) respectively (Figure 41A). Worth noting however, 
is the large variation of baselines seen in this co-culture system; most likely due to combining 
two primary cells together. Based on the above data set it was decided to use the highest 
density of BMDM of 80K for all future co-culture experiments.  
It has been shown that growing BMDM in GMCSF, as opposed to MCSF, can create BMDM 
with a different phenotypic profile (Na et al., 2016), an effect which may alter their response 
to subsequent stimulation (e.g. TNFα). Therefore, CGRP release following TNFα stimulation 
was further examined in co-cultures where BMDM had been differentiated either in the 
presence of MCSF or GMCSF using a Two-Way ANOVA.  No significant difference in the BMDM 
growth condition effect was seen (F(1,32)=0.2559, P=0.6164), however a significant 
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treatment effect was observed (F(1,32)=16.36, P=0.0003). There was no significant difference 
between cultures grown in MCSF and GMCSF in their response to TNFα stimulation (Figure 
41B). In MCSF grown cultures, an increase in CGRP release from 872.9 ± 43.73 pg/mL to 1061 
± 28.09 pg/mL (n=minimum 4 biological replicates) was observed following TNFα stimulation, 
compared to an increase in CGRP release from 829.3 ± 51.06 pg/mL to 1053 ± 71.1 pg/mL 
(n=minimum 4 biological replicates) in GMCSF grown cultures (Figure 41B). All subsequent 
BMDM cultures used in the co-culture system were therefore differentiated in MCSF to 
provide consistency with the previous chapter in this thesis. 
Following a 48 h stimulation period, CGRP release was triggered from mixed DRG 
neuronal/glia cultures or from mixed DRG neuronal/glia + BMDM co-cultures using three 
different challenges; K+ (25 mM), capsaicin (100 nM) or veratridine (31.25 µM). The above 
challenges were used to establish the mechanism by which an effect was produced. For 
example, if a strong effect was seen using veratridine but not capsaicin, it could be assumed 
that the mechanism responsible for producing said effect may involve voltage-gated sodium 
channel modulation.  
Throughout the forthcoming experiments, the effect of NGF was examined at a range of 
concentrations (0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL), whereas TNFα was kept at a 






Figure 40. Schematic demonstrating the timeline of all CGRP experiments conducted in the co-culture system. Mixed DRG 
neuronal/glia cultures were plated at desired density and left to settle overnight prior to the addition of BMDM at varying 
densities. The co-cultures were left for a further 24 h to allow the sensory neurones and BMDM to acclimatise to each other 
prior to stimulation with either NGF, TNFα or a combination of the two for 48 h. Following this stimulation period, CGRP 
release was triggered via either high K+, capsaicin or a veratridine challenge.  
Abbreviations: CGRP: calcitonin gene-related peptide; DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; 





Figure 41. Determining optimal conditions for the co-culture system (mixed DRG neuronal/glia + BMDM). A) CGRP release 
in the co-culture system with increasing densities of BMDM (grown in MCSF); 20K cells/well, 40K cells/well or 80K cells/well 
+/- TNFα (10 ng/mL, 48 h) stimulation. Each line represents data from the same culture. B) Effect on CGRP release when 
BMDM were grown in either MCSF or GMCSF +/- TNFα (10 ng/mL) stimulation. Data displayed as Mean ± SEM, n=minimum 
4 biological replicates (displayed as individual data points). Data were analysed using unpaired two-tailed t-tests for (A) and 
Two-Way ANOVA followed by Tukey’s multiple comparisons test (B). * P<0.05.  
Abbreviations: DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; TNFα: tumour necrosis factor alpha; 
CGRP: calcitonin gene-related peptide; MCSF: macrophage colony-stimulating factor; GMCSF: granulocyte-macrophage 







5.4.2.1 Potassium Evoked CGRP Release 
Application of high extracellular K+ solution results in the general depolarisation of mouse 
DRG neurones, triggering peptide secretion (Bost et al., 2017). The effect of NGF, TNFα or a 
combination of the two was examined using a Two-Way ANOVA. In both the mixed DRG 
neuronal/glia + BMDM co-cultures (Figure 42A) and the mixed DRG neuronal/glia cultures 
(Figure 42B), the concentration of NGF effect was significant (F(3,63)=10.02, P<0.0001 and 
F(3,61)=29.94, P<0.0001 respectively). NGF at a concentration of 10 ng/mL resulted in 
enhanced CGRP release (reaching significance at 10 ng/mL). The addition of TNFα (10 ng/mL) 
alone (i.e. with 0 ng/mL NGF) produced no significant changes in CGRP release in mixed DRG 
neuronal/glia + BMDM co-cultures (Figure 42A). Pre-treatment of co-cultures with TNFα (10 
ng/mL), in addition to NGF stimulation, showed no significant enhancement of NGF (10 
ng/mL)-induced potentiation of K+ evoked CGRP release (Figure 42A) (an increase from 1435 
± 371.6 pg/mL in the NGF alone group to 2233 ± 303.1 pg/mL in the combination group of 
NGF/TNFα, n=minimum 4 biological replicates).  
5.4.2.2 Capsaicin Evoked CGRP Release 
Capsaicin, an agonist of TRPV1, stimulates the release of neurotransmitters, including CGRP 
from sensory neurones expressing TRPV1 (Yang et al., 2018). This was of particular interest to 
us due to the previously discussed literature surrounding the TNFα regulation of TRPV1 
(Kochukov et al., 2009, Wang et al., 2018, Hensellek et al., 2007a). The effect of NGF, TNFα or 
a combination of the two was examined using a Two-Way ANOVA. In both the mixed DRG 
neuronal/glia + BMDM co-cultures (Figure 42C) and the mixed DRG neuronal/glia cultures 
(Figure 42D) the concentration of NGF effect was significant (F(3,40)=37.48, P<0.0001 and 
F(3,31)=85.35, P<0.0001 respectively). NGF at a concentration of 10 ng/mL resulted in 
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enhanced CGRP release in response to capsaicin challenge (reaching significance at 10 
ng/mL). The addition of TNFα (10 ng/mL) alone (i.e. with 0 ng/mL NGF) showed no significant 
increase in CGRP release in mixed DRG neuronal/glia co-cultures (Figure 42C), or in the mixed 
DRG neuronal/glia cultures (Figure 42D). In co-cultures it was found that the presence of TNFα 
effect was significant (F(1,40)=14.2, P=0.0005). Pre-treatment of co-cultures with TNFα (10 
ng/mL), in addition to NGF stimulation, produced a significant enhancement of NGF (10 
ng/mL)-induced potentiation of capsaicin evoked CGRP release (Figure 42C) (an increase from 
1957 ± 160.4 pg/mL in the NGF alone group to 2513 ± 307.9 pg/mL in the combination group, 
n=minimum 4 biological replicates). In the presence of BMDM, this effect was only apparent 
at the higher NGF concentration of 10 ng/mL (Figure 42C and D). For all other treatment 
groups within the co-culture system, no significant differences were observed (Figure 42C). In 
contrast to high K+ as a challenge, a significant difference in the mixed DRG neuronal/glia 
cultures was observed between NGF (1 ng/mL) alone and the combination group (NGF 1 
ng/mL + TNFα 10 ng/mL) (Figure 42D). No other significant differences were detected in the 
mixed DRG neuronal/glia cultures.  
5.4.2.3 Veratridine as a Challenge 
The last challenge used was veratridine 31.25 µM. Veratridine is a neurotoxin that acts by 
binding to a receptor site on voltage gated sodium channels (VGSC), thus inhibiting their 
activation and shifting the channel activation threshold toward a more negative membrane 
potential (Fekete et al., 2009). Veratridine has previously been shown to evoke CGRP release 
in capsaicin-sensitive nerves of the rat urinary bladder (Tramontana et al., 1992). TNFα has 
been reported to modulate VGSCs and affect primary sensory neurone excitability in rats, 
contributing to neuropathic and inflammatory pain states (Leo et al., 2015).  
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The effect of NGF, TNFα or a combination of the two was examined using a Two-Way ANOVA. 
It was found that, similar to both high K+ and capsaicin, in both the mixed DRG neuronal/glia 
+ BMDM co-cultures (Figure 42E) and the mixed DRG neuronal/glia cultures (Figure 42F) the 
concentration of NGF effect was significant (F(3,42)=55.64, P<0.0001 and F(3,24)=28.01, 
P<0.0001 respectively). NGF at a concentration of 10 ng/mL resulted in enhanced CGRP 
release in response to veratridine challenge (reaching significance at 10 ng/mL). The addition 
of TNFα (10 ng/mL) alone (i.e. with 0 ng/mL NGF) showed no significant increase in CGRP 
release in both types of culture (Figure 42E and F). In co-cultures it was found that the 
presence of TNFα effect was significant (F(1,42)=10.03, P=0.0029). Pre-treatment of co-
cultures with TNFα (10 ng/mL), in addition to NGF stimulation, produced a significant 
enhancement of NGF (10 ng/mL)-induced potentiation of veratridine evoked CGRP release 
(Figure 42E) (an increase from 902.9 ± 90.8 pg/mL to 1391 ± 207.7 pg/mL, n=minimum 4 
biological replicates). In agreement with previous data, this effect was only apparent in the 
presence of BMDM, and not in the mixed DRG neuronal/glia cultures and only at the higher 
NGF concentration of 10 ng/mL (Figure 42E and F).  
Overall, a consistent increase in the combination group (where both mediators were at 10 
ng/mL) compared to the NGF or TNFα alone groups (10 ng/mL) was observed across all three 
different challenges in the co-culture set-up (Figure 43). Therefore, when considering all data 
together, a potentiation of CGRP release can be observed in the co-culture when pre-
treatment with TNFα (10 ng/mL) is combined with NGF treatment (10 ng/mL) (Figure 44A) 
(1432 ± 184.5 pg/mL in the NGF (10 ng/mL) alone group to 2072 ± 188.5 pg/mL in the 
combination group, n=minimum of 12 biological replicates). This effect is however not 
observed in the mixed DRG neuronal glia cultures (Figure 44B), suggesting that the presence 
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of BMDM is crucial for this observed synergistic effect between NGF and TNFα. An important 
aspect to note is that BMDM themselves do not release CGRP, either basally or in response 
to NGF, TNFα or a combination of the two (Appendix Figure 2), therefore any increases in 






Figure 42. Effect of stimulus-evoked CGRP release in mixed DRG neuronal/glia + BMDM co-cultures vs mixed DRG 
neuronal/glia cultures. A) High K+ (25 mM)-evoked CGRP release in mixed DRG neuronal/glia + BMDM co-cultures (80K 
BMDM/well) in response to a range of NGF concentrations (0.1 ng/mL to 10 ng/mL), TNFα (10 ng/mL), combination of the 
two B) as above but in mixed DRG neuronal/glia cultures (no BMDM present). C)  Capsaicin (100 nM)-evoked CGRP release 
in mixed DRG neuronal/glia + BMDM co-cultures (80K BMDM/well) in response to a range of NGF concentrations (0.1 ng/mL 
to 10 ng/mL), TNFα (10 ng/mL), combination of the two D) as above but in mixed DRG neuronal/glia cultures (no BMDM 
present). E) Veratridine (31.25 µM)-evoked CGRP release in mixed DRG neuronal/glia + BMDM co-cultures (80K BMDM/well) 
in response to a range of NGF concentrations (0.1 ng/mL to 10 ng/mL), TNFα (10 ng/mL), combination of the two E) as above 
but in mixed DRG neuronal/glia cultures (no BMDM present). In all graphs displayed, white bars represent cultures with no 
TNFα whereas black bars represent cultures that have received TNFα (10 ng/mL). Data displayed as Mean ± SEM, n=minimum 
4 biological replicates. Data were analysed using Two-Way ANOVA followed by Sidak’s multiple comparisons test. * P<0.05, 
** P<0.01, *** P<0.001, **** P<0.0001.   
Abbreviations: CGRP: calcitonin gene-related peptide; DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; 




Figure 43. % of CGRP release in response to NGF alone (10 ng/mL), TNFα alone (10ng/mL) or a combination of the two in 
either mixed DRG neuronal/glia cultures or mixed DRG neuronal/glia + BMDM co-cultures. A-B) % of CGRP release 
following K+ (25 mM) C-D) capsaicin (100 nM) or E-F) veratridine (31.25 µM). Data displayed as individual data points, with 
each line representing a different culture.  
Abbreviations: CGRP: calcitonin gene-related peptide; DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; 







Figure 44. Combined effect of all stimuli (K+, capsaicin and veratridine) used to evoke CGRP release. CGRP release in A) 
mixed DRG neuronal/glia + BMDM co-cultures or B) mixed DRG neuronal/glia cultures.  Data displayed as Mean ± SEM, 
n=minimum of 12 biological replicates. Data were analysed using Two-Way ANOVA followed by Sidak’s multiple comparisons 
test. ** P<0.01, **** P<0.0001. 
Abbreviations: CGRP: calcitonin gene-related peptide; DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; 





5.4.3 TNFα-Stimulated BMDM-Derived Conditioned Medium Increases the Expression of 
Pain-Relevant Genes in Purified DRG Neuronal Cultures 
To help dissect the mechanism by which TNFα could modulate DRG sensory neurones, a set 
of CM experiments were performed to determine if any neuronal transcriptional changes 
were evoked by factor(s) secreted by TNFα-stimulated BMDM. CM was added both in the 
absence and presence of NGF 10 ng/mL to address the following questions: 
1) What is the effect of BMDM secreted factor(s) (+/- TNFα stimulation) on the 
transcription of pain-relevant genes in purified DRG neuronal cultures? 
2) Can adding NGF, in addition to CM, result in synergistic effects, regarding 
transcriptional modulation, driven by secreted factors from TNFα-activated 
macrophages? 
The effect of CM from TNFα-stimulated BMDM was examined using a Two-Way ANOVA, a 
significant treatment effect was found (F(3,132)=9.701, P<0.0001). Interestingly, CM from 
TNFα-stimulated BMDM significantly increased the average gene expression change of a 
panel of 45 pain-relevant genes (0.77 ± 0.21 ΔΔCt, n=3 biological replicates) when compared 
to cultures exposed to media only controls, +/- TNFα (Figure 45A and B) (-0.17 ± 0.18 ΔΔCt, 
n=3 biological replicates). No significant differences in the average gene expression change 
(of the 45-gene panel) evoked by CM of naïve BMDM, or media only controls (i.e. non BMDM 
CM, +/- TNFα) were observed (Figure 45B). Although the average difference in gene 
expression (of the 45-gene panel) evoked by CM from naïve BMDM was not significantly 
different from TNFα-stimulated BMDM, a trend for an increase was observed (0.33 ± 0.18 
ΔΔCt to 0.78 ± 0.21 ΔΔCt, n=3 biological replicates) (Figure 45B). 
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Figure 47 displays neuronal gene expression changes in purified DRG neuronal cultures 
treated with media only controls (+/- TNFα), naïve BMDM CM or TNFα-stimulated BMDM CM. 
Expression levels of Ccl2, Nos1 and Ccl3 all displayed significant differences following 
treatment with TNFα-stimulated BMDM CM compared to media only controls (Figure 47A, B 
and C). Of particular interest was the neuronal expression levels of Ccl2. A significant 
difference between the media only control group and the TNFα-stimulated BMDM CM 
(increase of 2.40 ± 0.49 ΔΔCt, n=3 biological replicates) was observed, but also between the 
naïve BMDM CM and the TNFα-stimulated BMDM groups (0.31 ± 0.18 ΔΔCt to 2.40 ± 0.49 
ΔΔCt, n=3 biological replicates) (Figure 47A). These findings suggest that the increase in 
neuronal Ccl2 expression is dependent on both the presence of BMDM and TNFα-stimulation. 
Expression levels of Atf3, Il-1β and Trpa1 all displayed a trend for an increase in neuronal 
expression following treatment with TNFα-stimulated BMDM CM (Figure 47D,E and F).  
The above data suggest that BMDM secreted factor(s), driven by TNFα-stimulation, are 
capable of affecting sensory neurone expression of pain-relevant genes. To investigate 
whether any additive or synergistic actions occur (between the TNFα-stimulated BMDM 
secreted factor(s) and NGF itself) the same experiment, examining gene expression, was 
performed but in the presence of NGF (i.e. NGF added to the purified DRG neurones at time 
of treatment with BMDM-derived CM). Using a Two-Way ANOVA, no significant treatment 
effect was observed (F(4,176)=1.275, P=0.2815), with concomitant NGF neuronal treatment 
displaying no significant differences in neuronal gene expression (of the 45-gene panel) were 





Figure 45. Gene expression changes in purified DRG 
neuronal cultures in response to treatment with CM 
from untreated or TNFα-stimulated BMDM (in absence 
of NGF). A) Heat map displaying the regulation of 45 pain-
related genes (normalised to three housekeeping genes 
(18s, Ywhaz and Gapdh) and relative to the media only 
control group) in response to CM from naïve or TNFα 10 
ng/mL treated BMDM (80K cells/well). Naïve and TNFα 
treated media (no BMDM) conditions were included as 
appropriate controls. Data represents the average ∆∆Ct 
value over 3 biological replicates. Genes which are 
upregulated are signified in red whereas genes which are 
downregulated are signified in green. B) Comparing the 
effect of BMDM-derived CM (stimulated +/- TNFα 10 
ng/mL) on expression changes in purified DRG neuronal 
cultures. Media only treatment groups (+/- TNFα) served 
as controls. Each data point represents the average ∆∆Ct 
value of an individual gene. Data displayed as Mean ± 
SEM, n= 3 biological replicates. Data were analysed using 
Two-Way ANOVA followed by Tukey’s multiple 
comparisons test. *P<0.05, ***P<0.001, ****P<0.0001. 
CM: conditioned medium. 
Abbreviations: DRG: dorsal root ganglia; CM: conditioned 
medium; TNFα: tumour necrosis factor alpha; BMDM: 
bone marrow-derived macrophages; NGF: nerve growth 
factor; 18s: 18s ribosomal RNA; Ywhaz: tyrosine 3-
monooxygenase/tryptophan 5 monooxygenase 
activation protein; Gapdh: glyceraldehyde 3-phosphate 
dehydrogenase; n.s: not significant; further details of all 




Figure 46.  Gene expression changes in purified DRG 
neuronal cultures in response to treatment with 
CM from untreated or TNFα-stimulated BMDM (in 
presence of NGF 10 ng/mL). A) Heat map displaying 
the regulation of 45 pain-related genes (normalised 
to three housekeeping genes (18s, Ywhaz and Gapdh 
and relative to the media only control group) in 
response to CM from naïve or TNFα 10 ng/mL 
treated BMDM (80K cells/well) with added NGF 10 
ng/mL in the purified DRG neuronal culture. Data 
represents the average ∆∆Ct value over 3 biological 
replicates. Genes which are upregulated are signified 
in red whereas genes which are downregulated are 
signified in green. B) Comparing the effect of BMDM-
derived CM (stimulated +/- TNFα 10 ng/mL), on 
expression changes in purified DRG neuronal 
cultures (also stimulated with NGF 10 ng/mL). Media 
only treatment groups (+/- TNFα, +NGF) served as 
controls. Each data point represents the average 
∆∆Ct value of an individual gene. Data displayed as 
Mean ± SEM, n= 3 biological replicates.  
Abbreviations: DRG: dorsal root ganglia; CM: 
conditioned medium; TNFα: tumour necrosis factor 
alpha; BMDM: bone marrow-derived macrophages; 
NGF: nerve growth factor; 18s: 18s ribosomal RNA; 
Ywhaz: tyrosine 3-monooxygenase/tryptophan 5 
monooxygenase activation protein; Gapdh: 
glyceraldehyde 3-phosphate dehydrogenase; n.s: not 
significant; further details of all genes examined can 
be found in the abbreviation list. 
 
 Figure 47. Transcriptional effect on individual genes following treatment of purified DRG neuronal cultures with 
BMDM derived CM (in absence of NGF). Genes displayed; A) Ccl2, B) Nos1, C) Ccl3, D) Atf3, E) Il-1β and F) Trpa1. Data 
displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data were analysed using 
LIMMA analysis and adjusted for multiple comparisons. * P<0.05.  
Abbreviations: DRG: dorsal root ganglia; BMDM: bone marrow-derived macrophages; CM: conditioned medium; NGF: 
nerve growth factor; TNFα: tumour necrosis factor; Ccl2: chemokine (C-C motif) ligand 2; Nos1: nitric oxide synthase; 
Ccl3: chemokine (C-C motif) ligand 3; Atf3: activating transcription factor 3; Il-1β: interleukin-1β; Trpa1: transient 









5.4.4 BMDM Co-Cultured with Mixed DRG Neuronal/Glia Cultures Display Enhanced 
Responsiveness to Stimuli 
For a complete picture, the transcriptional changes (of the same 45-gene panel) from 
direct co-cultures were also examined. In this instance, direct co-cultures (mixed DRG 
neuronal/glia cultures + BMDM) were compared with mixed DRG neuronal/glia cultures 
alone and BMDM cultures alone. All cultures were stimulated with NGF, TNFα or a 
combination of the two. A heat-map displaying the overall changes in genes from these 
cultures are shown in Figure 48. For clarity, the heat-map is divided into genes which are 
known to be expressed in BMDM and genes which are more associated with neuronal 
function. Genes shown to be upregulated are signified by the colour red, and genes 
shown to be downregulated are signified by the colour green. The heat-map shows that 
the co-culture system may drive higher expression of a number of genes (known to be 
expressed in BMDM) compared to either the mixed DRG neuronal/glia cultures or 
BMDM alone, for example, Ccl5, Il-1β and Tnf (Figure 48 and 49A, B and C). The latter 
suggesting that within the co-culture system, the presence of the neurones may be 
impacting BMDM response to pain-related stimuli. However, the fact that both cell 
types are adherent and therefore impossible to separate from each other in the RNA 
extraction process, makes it hard to definitively say which cell type is responsible for the 








Figure 48. Heat map displaying the regulation of 45 
pain-related genes in direct co-cultures. 
Transcriptional changes in response to NGF (0.1 
ng/mL, 10 ng/mL, 48 h), TNFα (10 ng/mL, 48 h), NGF 
(0.1 ng/mL, 48 h) + TNFα (10 ng/mL, 48 h) or NGF + 
TNFα (both at 10 ng/mL, 48 h) in mixed DRG 
neuronal/glia cultures, direct co-cultures (mixed 
DRG neuronal/glia + BMDM) or BMDM alone 
cultures. Data represents the average ∆∆Ct value 
over a number of biological replicates. n= minimum 
of 3 biological replicates across all groups except 
NGF 0.1 ng/mL and NGF 0.1 ng/mL + TNFα 10 ng/mL 
in the DRG mixed neuronal culture where n=2 
biological replicates.   
Abbreviations: DRG: dorsal root ganglia; NGF: nerve 
growth factor; TNFα: tumour necrosis factor alpha; 
BMDM: bone marrow-derived macrophages; 
further details of all genes examined can be found 




Figure 49. Transcriptional effect on individual genes in response to NGF and TNFα in BMDM alone cultures, mixed 
DRG neuronal/glia cultures or mixed DRG neuronal/glia + BMDM co-cultures. Genes displayed; A) Ccl5, B) Il-1β and 
C) Tnf. Data displayed as Mean ± SEM, n= minimum of 3 biological replicates. 
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor alpha; BMDM: bone marrow-derived 









5.4.5 Direct Co-cultures Display Enhanced IL-1β Secretion in Response to TNFα 
Stimulation 
The transcriptional data from section 5.4.4 highlighted BMDM-derived IL-1β as a 
potential inflammatory mediator which was being modulated by the presence of DRG 
sensory neurones. Therefore, the release of IL-1β at the cellular level was examined in 
these culture systems. Both mixed DRG neuronal/glia cultures and BMDM alone cultures 
showed no detectable release of IL-1β in response to NGF 10 ng/mL, TNFα 10 ng/mL or 
a combination of the two (Figure 50). However, in the co-culture set-up, not only was IL-
1β detectable in all groups, there was a significant increase in IL-1β (of almost 95 %) 
after TNFα 10 ng/mL treatment (60.7 ± 8.16 pg/mL, n=3 biological replicates, One-Way 
ANOVA; F(12,26)=37.48, P<0.0001), when compared to the untreated group (31.28 ± 
3.32 pg/mL, n=3 biological replicates). However, there was no detectable additive or 
synergistic actions occurring in the combination group of NGF and TNFα-stimulation 
(49.96 ± 3.31 pg/mL, n=3 biological replicates). The response from the combination 
group was almost identical to the IL-1β release triggered via NGF stimulation (49.72 ± 







Figure 50. IL-1β secretion in different culture set-ups. IL-1β secretion in BMDM alone cultures, mixed DRG 
neuronal/glia cultures or mixed DRG neuronal/glia + BMDM co-cultures in response to NGF (10 ng/mL, 48 h), TNFα 
(10 ng/mL, 48 h) or a combination of the two (10 ng/mL, 48 h). LPS (100 ng/mL) was used as a positive control. Data 
displayed as Mean ± SEM, n=3 biological replicates (displayed as individual data points). Data analysed using One-
Way ANOVA followed by Tukey’s multiple comparisons test. ** P<0.01. 
Abbreviations: IL-1β: interleukin-1β; BMDM: bone marrow-derived macrophages; DRG: dorsal root ganglia; NGF: 




5.4.6 Conditioned Medium from TNFα-Stimulated BMDM does not Acutely Regulate 
Sensory Neuronal Calcium Transients  
Given the observed effect of CM (from TNFα-stimulated BMDM) on DRG sensory 
neuronal gene expression, it was decided to investigate whether the same CM may 
acutely modulate calcium dynamics in sensory neurones. Calcium imaging was utilised 
to actively visualise and quantify neuronal activation in response to CM derived from 
BMDM (+/- TNFα-stimulation).  
On application of CM (from either naïve BMDM or TNFα-stimulated BMDM) to purified 
DRG neuronal cultures, we saw no evidence of increased cytosolic calcium over an acute 
period (Figure 51). The latter was true regardless of the presence of NGF in the purified 
DRG neuronal cultures (Figure 51A and B). Regarding the % of neurones responding to 
capsaicin, it was found that 14.19 ± 2.58 % of cells (n=399 neurones across 4-5 mice) 
responded in the media only condition (no BMDM media only control) (-NGF) condition 
compared to 13.36 ± 2.41 % of cells (n=499 neurones across 4-5 mice) in purified DRG 
neuronal cultures exposed to TNFα-stimulated BMDM CM (-NGF) group (Figure 51C). 
Likewise, no difference was detected in the magnitude of the capsaicin response (0.53 
± 0.09 ΔF/F and 0.52 ± 0.04 ΔF/F respectively) or the magnitude of the KCl response 
(0.53 ± 0.07 ΔF/F and 0.51 ± 0.05 ΔF/F respectively) in cultures exposed to CM from 
TNFα-stimulated BMDM (Figure 51E and F). On average > 90 % of neurones responded 
to KCl stimulation in all cultures tested (Figure 51D), confirming the viability of neurones 










Figure 51. Calcium signals in purified DRG neuronal cultures +/- NGF (10 ng/mL) following 24 h in culture with CM 
derived from BMDM treated with or without TNFα (10 ng/mL). A-B) Representative traces from coverslips displaying 
ΔF/F versus time, A) –NGF and B) +NGF. Each line represents the average values of all neurones on one coverslip. 
Capsaicin (50 nM) was applied for 3 min followed by a wash-out period and a final KCl (25 mM) stimulus to ensure 
cell viability. C-D) Quantification of % of responding cells to both C) capsaicin 50 nM or D) KCl 25 mM. E-F) The 
maximum response seen from E) capsaicin (50 nM) or F) KCl (25 mM) (calculated by taking the difference between 
the maximum capsaicin/KCl response recorded and the average of baseline ten frames pre-capsaicin/KCl stimulus.) 
Data displayed as Mean ± SEM, n=6858 neurones across 4-5 mice per group.  Untreated No BMDM –NGF (399 
neurones), TNFα No BMDM –NGF (348 neurones), Untreated 80K BMDM –NGF (456 neurones), TNFα 80K BMDM –
NGF (499 neurones), Untreated No BMDM +NGF (1281 neurones), TNFα No BMDM +NGF (1136 neurones), Untreated 
80K BMDM +NGF (1347 neurones), TNFα 80K BMDM +NGF (1392 neurones). Data points on graphs represent 
individual cover slips.  
Abbreviations: DRG: dorsal root ganglia; NGF: nerve growth factor; CM: conditioned medium; BMDM: bone marrow-
derived macrophages; TNFα: tumour necrosis factor; KCl: potassium chloride. 
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5.5 Discussion  
This chapter aimed to address two primary questions; does TNFα affect sensory neurone 
function indirectly via BMDM activation and could synergistic actions of NGF and TNFα 
be detected using a co-culture system between sensory neurones and BMDM.  
In the first instance, the focus was ensuring appropriate levels of viability within the co-
cultures. The data presented in this chapter suggests that the sensory DRG neurones 
function as expected in the presence of BMDM in terms of neurite outgrowth and CGRP 
release. We have shown that in the presence of TNFα, in both mixed DRG neuronal/glia 
cultures and mixed DRG neuronal/glia + BMDM co-cultures, the viability of the sensory 
DRG neurones are unaffected. The latter is in line with evidence in the literature which 
shows that rat neurone-macrophage co-culture viability is only reduced following 
LPS/IFNγ stimulation, and not TNFα stimulation (Massier et al., 2015). However, one 
study showed the addition of macrophages for 24 h to neurones caused rapid cell death, 
an effect only seen in the direct co-cultures and not in a conditioned medium set-up 
(Arantes et al., 2000). The difference between the above study and our results could be 
explained by the latter study using peritoneal macrophages, which may have a more 
activated phenotype, and looking at sympathetic neurones isolated from neo-natal 
mice.  
We found that levels of evoked-CGRP release from primary sensory neurones could be 
significantly potentiated when combining the two inflammatory mediators together 
(only observed at 10 ng/mL) in a direct co-culture set-up (mixed DRG neuronal/glia + 
BMDM). This effect was reproducible across all three challenges used to evoke CGRP 
release and only seen with the additional presence of BMDM in the co-culture system. 
228 
 
Previous work within the literature supports the ability of macrophages to stimulate 
CGRP release from sensory neurones (Massier et al., 2015), an effect which was seen as 
early as 1 h in neurone-macrophage co-cultures obtained from rats with antigen-
induced arthritis. Despite some evidence to suggest that invading macrophages may 
upregulate their own production of CGRP in response to pro-inflammatory stimuli, thus 
contributing to pain states (Ma and Quirion, 2006), we showed that BMDM were unable 
to produce CGRP themselves (including stimulation with TNFα).  
Future experiments could examine the effect of our co-culture system on release of 
other neuropeptides known to be involved in pain processing, for example substance P 
(Lisowska et al., 2016, Mashaghi et al., 2016, Teodoro et al., 2013, Sahbaie et al., 2009). 
A co-culture system comprised of pig DRG sensory neurones and skin keratinocytes 
demonstrated an increase in substance P release triggered by capsaicin stimulation 
(Pereira et al., 2010). Similar to our own experiments, the authors highlight that 
substance P was secreted exclusively by the neurones, an effect enhanced via the 
presence of keratinocytes. This provides further evidence for sensory neurone 
modulation via non-neuronal cell types. 
A number of genes in purified DRG neuronal cultures displayed an increase in expression 
following treatment with CM from TNFα treated BMDM. This effect was observed 
despite no effects of TNFα on sensory DRG neurones being detectable previously 
(section 3.4). This suggests that TNFα-stimulated BMDM can release factor(s) that can 
act directly on the sensory neurone itself. In this instance, intriguing changes were 
detected in the following neuronal genes; Ccl2, Nos1, Ccl3, Atf3, Il-1β and Trpa1.  
It has previously been shown that CCL2 can act as a key mediator in the communication 
between neurones and macrophages, enhancing regenerative capacity following a 
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peripheral nerve injury (Kwon et al., 2015). However, it has also been shown that CCL2 
and its receptor, CCR2, are upregulated in the DRG following chemotherapy-induced 
peripheral neuropathy, an effect which is correlated with mechanical hypersensitivity 
(Illias et al., 2018). Furthermore, the use of an anti-CCL2 antibody could successfully 
prevent the development of the described hypersensitivity (Illias et al., 2018). CCL2 is 
known to trigger CGRP release from cultured DRG neurones obtained from neonatal 
rats, an effect dependent on both phospholipase C and protein kinase C signalling (Qin 
et al., 2005b).  
NOS1 is one of three isoforms of nitric oxide (NO) synthase which produces NO, a 
messenger molecule with widespread affects throughout the body (Thomas et al., 
2008). NOS1 is expressed in central and peripheral neurones, in addition to other cell 
types, such as endothelial cells (Forstermann et al., 1994). NOS1 has been implicated in 
a myriad of physiological functions, including learning and memory, regulation of 
synaptic transmission and regulation of vascular tone in the periphery (Förstermann and 
Sessa, 2012). However, NO is also an important mediator in both chronic and acute 
inflammation (Laroux et al., 2000). For example, it has been shown that mice pre-treated 
with a selective NOS1 inhibitor failed to develop thermal hyperalgesia induced by 
intraplantar injection of CFA (Chen et al., 2010). The authors demonstrate that CFA-
induced increases in pro-inflammatory cytokines (e.g. Tnf and Il-1β) were prevented 
following the use of the NOS1 inhibitor, along with an increase in the expression of the 
anti-inflammatory cytokine, Il-10 (Chen et al., 2010). Additionally, NOS1 was 
upregulated in the spinal cords of mice exposed to a model of neuropathic pain (sciatic 
nerve ligation), while NOS1-KO mice showed a significant reduction in mechanical and 
thermal hyperalgesia compared to wildtype mice (Hervera et al., 2010). Interestingly, 
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recently NOS1 has also been linked with regulating macrophage phenotype, with NOS1 
deficiency in mice resulting in a switch from pro- to anti-inflammatory properties in 
macrophages (Blajszczak et al., 2017) and reduced pro-inflammatory NF-κB 
transcriptional activity (Baig et al., 2015). 
CCL3 (also known as macrophage inflammatory protein-1α) is a chemokine secreted by 
macrophages with various biological functions, primarily in the recruitment of 
inflammatory cells and maintenance of the effector immune response (Bhavsar et al., 
2014). However, its role in nociceptive processing is being increasingly recognised, with 
involvement in both acute and chronic inflammatory states (Llorián-Salvador et al., 
2016). Following remifentanil-induced hyperalgesia in rats, the expression of both CCL3 
and its receptor, CCR5, were significantly increased (at both the mRNA level and the 
protein level) in the DRG, when compared to the control saline group (Li et al., 2016b). 
Additionally, CCL3 has been shown to be upregulated following peripheral nerve injury 
in mice, an effect thought to be due to the epigenetic histone modification in infiltrating 
macrophages (Kiguchi et al., 2013). One proposed mechanism for CCL3-induced 
hyperalgesia has been the sensitisation of sensory neurone TRPV1 (Zhang et al., 2005a). 
The authors show, using immunohistochemistry, that CCR1 (an additional CCL3 
receptor) is co-expressed with TRPV1 in >85 % of small-diameter neurones within the 
DRG. They also show that pre-treatment with CCL3 enhanced calcium transients of DRG 
neurones in response to capsaicin and that an intraplantar injection of CCL3 in mice 
decreased their hot-plate response latency (Zhang et al., 2005a).  
TRPA1 is instrumental in the detection of noxious cold stimuli and involved in a number 
of chronic painful states, including inflammation, neuropathic pain and fibromyalgia (as 
reviewed by (Garrison and Stucky, 2011)). However, its regulation via mediators such as 
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TNFα is not well understood. TNFα treatment of odontoblast-like cells has been shown 
to result in an increase in Trpa1 expression, an effect which is dependent on p38 
activation (El Karim et al., 2015). Additionally, TNFα treatment of rat trigeminal sensory 
neurons resulted in an elevated surface TRPA1 content (Meng et al., 2016). However, 
one study demonstrated that despite TNFα enhancing Trpv1 expression in synoviocytes, 
TNFα was unable to modulate the expression of Trpa1 (Kochukov et al., 2009). 
Interestingly, despite the literature surrounding the TNFα effect on Trpv1 expression (as 
previously described), we were not able to replicate this finding.  
The data collected from the conditioned medium experiments, looking at transcriptional 
changes, support the hypothesis that TNFα is more likely to act indirectly via the BMDM 
than on the neurones themselves. This is particularly compelling due to the use of 
purified DRG neuronal cultures in these experiments. Figure 52 illustrates how this may 
occur. The hypothesis is that NGF added into the system could act on the neurones 
themselves, while TNFα could increase the release of other inflammatory molecules 
from macrophages. Thereby, the two inflammatory mediators would act together to 




Figure 52. Schematic demonstrating the possible indirect action of TNFα on sensory neurones. (Schematic courtesy 
of Prof. Stephen McMahon). TNFα, from a variety of sources, may act directly via TNFR1 on a non-neuronal cell type, 
for example, a macrophage, resulting in the release of numerous inflammatory mediators which can then directly act 
upon the sensory neurone itself.  These inflammatory mediators include H+, PGE2, Histamine, 5-HT, ATP, NGF and 
heat which act on their respective receptors residing on the sensory neurone terminal.   
Abbreviations: TNFα: tumour necrosis factor; TNFR1: tumour necrosis factor receptor 1; PGE2: Prostaglandin E2; 5-
HT: serotonin;  ATP: adenosine triphosphate; NGF: nerve growth factor; EPR: prostaglandin E2 receptor; 5-HTR: 
serotonin receptor; ASIC: acid sensing ion channel.  
In line with this, our data shows enhanced CGRP release when NGF and TNFα are used 
in combination and only in the presence of BMDM. However, when examining changes 
at the transcriptional level (experiments involving CM from TNFα-stimulated BMDM 
(+NGF)) we saw no further changes. One explanation for this finding could be that 
adding NGF at 10 ng/mL was saturating the system and therefore any further 
modulation with CM was undetectable.    
Although we saw a possible TNFα-driven effect on neurones (mediated via the CM 
released from TNFα stimulated BMDM) at the transcriptional level, this effect failed to 
translate into functional changes detected via calcium imaging. There are a number of 
reasons that this may have been the case. In our case we used 24 h as a time-point (24 
h of neuronal exposure to the CM), in order to stay as consistent as possible with 
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previous experiments. However, it may be that changes would be detectable at either a 
much more acute time point (e.g. minutes-hours) or a more chronic one (e.g. days). 
Alternatively, it is possible that calcium imaging is not sensitive enough to pick up subtle 
changes in neuronal function.  
One read-out that was not assessed following the addition of CM from BMDM on 
purified DRG neuronal cultures was that of neurite outgrowth. It has been shown that 
painful conditions, such as chronic low back pain caused by intervertebral disc 
degeneration, is associated with increased neurite outgrowth and increased CGRP 
expression via the release of nociceptive factors  (Krock et al., 2014), A recent study has 
shown that conditioned medium collected from neurone-peritoneal macrophage 
cultures treated with dibutyryl cyclic AMP for 24 h, stimulated robust neurite outgrowth 
activity when applied to adult DRG neurone cultures alone (Au - Yun et al., 2018). These 
findings highlight the crucial role that macrophages play in modulating sensory neurone 
behaviour and suggest a possible future assay to explore in the context of this project.  
Within this chapter, the emphasis has been on how the BMDM may be influencing 
neurones to produce changes which may be crucial to the generation and maintenance 
of pain states. However, it is important to note that the reverse may also be true, i.e. 
that neurones may influence the behaviour of the macrophages. Our co-culture data 
corroborates this idea, with macrophage-associated mediators appearing to be 
enhanced compared to macrophage or neuronal alone cultures (e.g. macrophage 
expressed gene transcripts and IL-1β release). In line with this, it has been shown that 
cerebral cortical neurones secrete TGF-β2, a factor that can significantly enhance the 
proliferation of macrophages (Dobbertin et al., 1997) and enteric neurones can secrete 
CSF1, a factor required for macrophage development (Muller et al., 2014). Furthermore, 
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it has recently been shown that CGRP reduced the mRNA levels of pro-IL-1β and 
subsequent secretion of IL-1β following LPS treatment by murine macrophages, as well 
as enhancing the expression of anti-inflammatory cytokines (e.g. IL-10) (Duan et al., 
2017). The above suggests that following macrophage infiltration at the site of injury, 
there is most likely extensive bidirectional crosstalk between neurones and 
macrophages, with each cell type capable of modulating the behaviour of the other.  
5.6 Summary of Chapter   
In summary, the data presented throughout this chapter displays the successful 
optimisation and use of a co-culture system between adult DRG sensory neurones and 
BMDM to assess pain-relevant changes. It was found that the presence of BMDM, 
greatly enhanced the capacity of TNFα to potentiate neuronal evoked-CGRP release. 
Furthermore, we show that the effects of TNFα (likely via BMDM) can further enhance 
NGF-sensitised CFRP release in co-cultures of sensory neurones and BMDM. In addition 
to the above, expression analysis data provides supporting evidence for the existence of 
























6. Investigating the Combined 
Individual Antagonism of  NGF and 




The previous chapters have presented and discussed results using in vitro methods. In 
this chapter, data will be presented using individual antagonists against NGF/TNFα in 
vivo. Appendix 1 displays the behavioural data obtained previously from chronic pain 
studies conducted at MedImmune wherein a bispecific molecule against NGF and TNFα 
was used.  The following in vivo behavioural data mirrors this study with the exception 
that individual antagonists against NGF and TNFα were used. The data in Appendix 1 has 
been included for clarity and comparative reasons between the two studies. 
Our data so far has investigated the relationship between DRG neurones and 
macrophages, and how this is modulated by NGF/TNFα, via a range of in vitro assays 
(Chapter 5). In vitro methods are fundamental to our understanding of basic biological 
processes; however, these are isolated systems that lack the presence of multiple other 
cell types and the corresponding complex environment that exists in vivo. Up to now, 
we have attempted to understand potential additive or synergistic effects following 
application of exogenous recombinant NGF or TNFα. In a disease state (such as chronic 
pain) these factors will be endogenously expressed (McMahon et al., 1995, Kidd and 
Urban, 2001), a scenario in which dual antagonism (of low concentrations of NGF or 
TNFα) provides synergistic pain relief. Thus, an alternative approach to understand the 
potential downstream mediators regulating the functional analgesic synergy (seen with 
antagonism of NGF and TNFα, Appendix Figure 1) would be to perform expression 
analysis of pain-relevant tissues in rodent models of chronic pain. The latter may lead to 
the discovery of genes which are specifically regulated by the dual antagonism of the 
NGF and TNFα signalling pathway.  
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Here, we investigate the effects of antagonising NGF or TNFα (both alone and in 
combination) on the expression of pain-relevant genes, in pain relevant tissues taken 
from two commonly used mouse models of chronic pain: 
1. Intra-articular CFA model of inflammatory joint pain, and 
2. Seltzer model (partial nerve ligation) of neuropathic pain 
Importantly, the dose of NGF/TNFα antagonists used throughout this chapter have been 
carefully chosen based on their capacity to drive functional synergy (in terms of 
analgesia, Appendix Figure 1). Therefore, by comparing gene expression changes 
between mice dosed with these combined concentrations of antagonists and mice who 
do not receive the dual antagonism, we may gain insight into molecular drivers behind 
the synergistic analgesia observed.  
6.1.1 Inflammatory Model of Pain- Intra-Articular Injection of Complete Freund’s 
Adjuvant  
CFA is composed of inactivated and dried Mycobacterium and is a common model used 
to mimic chronic inflammatory pain conditions, such as OA (Gregory et al., 2013). It is 
known to produce a persistent inflammatory state compared to other compounds, such 
as carrageenan, and is commonly used as a screening model to assess anti-inflammatory 
and analgesic drugs (Matson et al., 2007). Following CFA injection into the rat hind paw, 
the cardinal signs of inflammation occur (including redness, heat and swelling), followed 
by both allodynia and hyperalgesia, which can occur as early as 30 min after injection 
and persist for up to two weeks (Ren and Dubner, 1999). This time frame mimics the 
chronic pain experienced in humans closer than other models. CFA can be injected into 
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a number of anatomical sites including the paw and the tail; in our case CFA was injected 
into the knee joint to simulate the development of arthritis.  
In this model, levels of pain-related gene transcripts in L3, L4, L5 DRG and fat pad tissue 
(taken from the injected knee site) were analysed. L3, L4 and L5 DRG were chosen as it 
known that these DRGs innervate the knee (Aso et al., 2014). Additionally, it has been 
shown that neuronal changes, following an inflammatory insult, were primarily located 
in the L3 and L4 ganglia, with a smaller contribution from L5. This differs substantially 
from rats, where the L3 ganglia do not contribute at all (Rigaud et al., 2008).  
The fat pad tissue in the injected knee was collected due to the growing literature 
suggesting a crucial role for this tissue type in pain development, as described below. 
This tissue is an intracapsular, extrasynovial structure that fills the anterior knee 
compartment and is richly vascularised and innervated (Dragoo et al., 2012). The 
presence and distribution of substance P positive fibres within the fat pad of patients 
suffering from anterior knee pain syndrome suggest a role in nociceptive function 
(Bohnsack et al., 2005). It has been shown that the fat pad tissue from the knees of 
patients suffering with OA contained increased levels of pro-inflammatory cytokines 
(Ushiyama et al., 2003) and fatty acids such as palmitic acid, which are also known to 
have pro-inflammatory actions (Ioan-Facsinay and Kloppenburg, 2013). The fat pad of 
OA patients are infiltrated with high levels of immune cells, such as T cells and 
macrophages, the latter of which have been shown to be a mix of both pro- and anti-
inflammatory phenotypes (Klein-Wieringa et al., 2011). Additionally, the level of CGRP 
expression in the fat pad of OA patients are increased depending on the grade of OA and 
positively correlated with COX-2 expression (Aikawa et al., 2017).  A recent study 
showed that injection of NGF, into the fat pad tissue of healthy volunteers, resulted in 
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significantly reduced pressure pain thresholds (Munkholm and Arendt-Nielsen, 2017) 
and patients with anterior knee pain syndrome displayed a significantly higher 
expression of TNFα in the fat pad when compared to control subjects (Witonski et al., 
2010). The above studies point to a tissue in which pain-related signalling may be 
modulated via the antagonism of inflammatory mediators, such as NGF and TNFα.  
The levels of circulating cytokines in the plasma were also analysed due to reports of 
pro-inflammatory cytokines in the blood being associated with increased pain sensitivity 
and severity (Owens et al., 2018, Zu et al., 2016, Si et al., 2017). For example, a cross-
sectional study demonstrated that levels of TNFα and IL-6 were higher in blood samples 
from patients suffering with chronic lower back pain compared to healthy controls 
(Kraychete et al., 2010). Additionally, higher serum levels of the soluble receptors of 
TNFα were associated with increased symptoms of pain and stiffness, increased OA 
symptoms and worse knee radiographic scores (Penninx et al., 2004). This is in line with 
data that shows that enhanced serum levels of IL-6 and TNFα are associated with knee 
cartilage loss in older people suffering from OA (Stannus et al., 2010), as well as in 
synovial fluid from patients who had meniscectomies (leading to OA) (Larsson et al., 
2015). 
6.1.2 Neuropathic Model of Pain- Seltzer Model  
The Seltzer model involves a partial nerve injury whereby part of the sciatic nerve is 
unilaterally ligated. This model results in allodynia, thermal hyperalgesia and mechanical 
hyperalgesia, the effects of which can last for several months after the initial surgery 
(Seltzer et al., 1990). Similarly to the CFA model, L3, L4 and L5 DRG were collected for 
transcriptional analysis. We chose to examine the effect of NGF and TNFα antagonism 
in a model of neuropathic pain (in addition to studying an inflammatory model), due to 
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the difficulty in finding effective pharmacological treatments to control symptoms with 
this pain type (Teixeira, 2009). Therefore, discovering novel signalling pathways and 
interactions in this system may offer opportunities to unearth novel pain targets with 
improved efficacy compared to current treatments.  
In both models, collection of tissue samples occurred 1-day or 7-day post-vehicle/test 
compound administration. These time points were based on previous mouse model data 
which displayed a significant reversal in mechanical hypersensitivity in the dual 
NGF/TNFα antagonist group when compared to either antagonist alone (Appendix 
Figure 1). Gene panels for each time point and tissue type (DRG or fat pad tissue) were 
based on genes known to be relevant in pain signalling e.g. Trpv1 (Zhang and Wang, 
2017), as well as knowledge gained in our laboratory. Dawes and colleagues have 
previously shown time-dependent modulation of a range of genes in the knee fat pad 
tissue of rats injected with monosodium iodoacetate, including Nos2, CCL3, CXCL5 
(Dawes et al., 2013). Gene transcripts for both NGF and TNFα (along with their 
respective receptors) were also examined. Additionally, Itgam and Cd14 were chosen to 
assess the effect of blockade on non-neuronal cell type infiltration into DRG/fat pad 
tissue.  
6.2 Aims and Experimental Strategy 
The aims of this chapter are to test the hypotheses that: 
• Dual antagonism of NGF and TNFα results in a superior analgesia (compared to 
antagonising either factor alone) in both an inflammatory and neuropathic 
mouse model of chronic pain (to confirm previous findings, Appendix Figure 1) 
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• Dual antagonism of NGF and TNFα (at low doses which provide synergistic 
analgesia) normalise the expression of pain-related genes/levels of circulating 
cytokines in both an inflammatory and neuropathic mouse model of chronic 
pain 
The data presented below arises from the intra-articular CFA model of inflammatory 
joint pain and the Seltzer model of pain (PNL) in mice. Behavioural changes in response 
to the different antagonists (‘MEDI578’ (a human anti-NGF IgG), TNFRII-fc (recombinant 
Fc-tagged TNFRII, acting as a TNFα antagonist)) alone or in combination, are presented 
along with the subsequent analysis of any changes occurring at the transcriptional level 













I would like to extend my greatest gratitude to Jon Hatcher (Senior Research Scientist, 
MedImmune) who conducted the necessary surgeries and performed all behavioural 
testing presented throughout this chapter.  
All experiments were performed in accordance with the United Kingdom Home Office 
Animals (Scientific Procedures) Act (1986). Experiments were performed under Home 
Office Licence PPL 70/7994 (Development of Novel Analgesics) and in accordance with 
ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Mice were 
group housed and had food and water available ad libitum. 
6.3.1 Complete Freund’s Adjuvant Pain Model  
CFA injection and behavioural testing was carried out by Jon Hatcher from MedImmune, 
In Vivo Senior Research Scientist. A schematic representing the time course of this study 






Figure 53. Schematic displaying the experimental timeline of the effect of NGF/TNFα antagonism in the intra-
articular CFA model of inflammatory joint pain.   
Abbreviations: NGF: nerve growth factor; TNFα: tumour necrosis factor; CFA; complete Freund’s adjuvant; DRG: 
dorsal root ganglia; Ab: antibody. 
 
50 adult female C57BL/6 mice were used for this study.  Female mice were utilised in 
these experiments to allow for the mice to be group housed for a prolonged period of 
time (4-5 weeks in total).  It is known that female mice are less aggressive than male 
mice (Miczek et al., 2001) and therefore do not show the same level of aggressive 
behaviour towards each other, thus avoiding the need to isolate any of the mice.  
All mice underwent insertion of transponders (IPTT-300 Electronic ID, Plexx) for 
identification purposes 5 days prior to the start of the study. Transponders were 
implanted sub-cutaneously under general anaesthetic (isoflurane 3.5 %). Mechanical 
hypersensitivity was determined using a mouse incapacitance tester (Linton 
Instrumentation). Mice were placed in the incapacitance tester with their hind paws on 
separate sensors, and the body weight distribution calculated over a period of 4 secs. 
Data was expressed as ipsilateral and contralateral weight bearing measurements in 
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grams.  Following the establishment of baseline readings mice were divided into 2 
groups (of 40 in the CFA group and 10 in the vehicle group) with approximately equal 
ipsilateral/contralateral ratios.  For CFA injection, animals were anesthetised using 3 % 
isoflurane in oxygen.  The left knee was shaved, cleaned and the joint of each mouse 
injected with either CFA or mineral oil vehicle using a 25 g needle mounted on a 100 μl 
Hamilton syringe. Injections were made directly into the synovial space of the knee joint.  
Mice were re-tested for changes in mechanical hypersensitivity on day 6, 8 and 10 post-
injection, as described above, in order to confirm the development of mechanical 
hypersensitivity. Baseline readings were taken on day 10, from which the groups were 
further sub-divided into the final treatment groups (see below). Any mice showing an 
ipsilateral/contralateral ratio of greater than 80 % were classed as non-responders and 
removed from the study.  
The final treatment groups were as follows (described in section 6.3.1.1): 
• Group 1: Vehicle + CAT-251 0.01 mg/kg s.c. + PBS vehicle 10 ml/kg s.c. (n=10) 
• Group 2: CFA + CAT-251 0.01 mg/kg s.c. + PBS vehicle 10 ml/kg s.c. (n=9) 
• Group 3: CFA + CAT-251 0.01 mg/kg s.c. + TNFRII-fc 0.01 mg/kg s.c. (n=9) 
• Group 4: CFA + MEDI578 0.01 mg/kg s.c. + PBS vehicle 1 0ml/kg s.c. (n=9) 
• Group 5: CFA + MEDI578 0.01 mg/kg s.c. + TNFRII-fc 0.01 mg/kg s.c. (n=9) 
Mice were administered vehicle control or test compound on day 13 post CFA injection 
and were subsequently re-tested for changes in mechanical hypersensitivity at 4 h, 1 
day, 4 days and 7 days post dose.  Following testing on day 1 post dose approximately 
half of the mice were culled and DRGs (L3, L4 and L5) as well as the fat pad of the 
ipsilateral knee were removed for subsequent analysis. Plasma was also obtained from 
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these mice.  The remaining mice were culled following testing on day 7 and also 
underwent tissue removal as the first group. 
6.3.1.1 Details of Drugs Used Throughout Study 
CFA- 100 mg of dried mycobacterium tuberculosis (BD Biosciences; Batch number 
9138946) was suspended in 10 ml of light mineral oil (Sigma Aldrich, 330779-1L) to give 
a stock solution of 10 mg/ml and stored at 4 oC until required for use.  The solution was 
removed from the fridge and allowed to acclimatise to RT prior to use. The solution was 
shaken frequently to ensure thorough mixing. Used at a final concentration of 10 µg/µL. 
CAT251- (isotype control human IgG4 antibody, MedImmune) 0.5 ml of 0.1 mg/ml 
solution diluted 0.5:5.0 to give 0.01 mg/ml = 0.1 mg/kg.  This was then further diluted 
0.5:5.0 to give a solution of 0.001 mg/ml = 0.01 mg/kg.   
MEDI578- (anti-NGF human IgG4 antibody, MedImmune) Supplied as 50 mg/ml.  Used 
at a final concentration of 0.01 mg/kg, made up in PBS.  
TNFRII-fc- (recombinant Fc-tagged TNFRII, MedImmune) Supplied at 50 mg/ml. Used at 
a final concentration of 0.01 mg/kg, made up in PBS.  
6.3.1.2 Behavioural Data Analysis  
For the behavioural data, ipsilateral and contralateral readings were taken for each 
animal at each test time and ipsilateral/contralateral ratios calculated. PRISM was used 
for graphical and statistical analysis. Results were analysed using Two-Way ANOVA.  
Pairwise comparisons where appropriate were made using Tukey’s test.   
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6.3.2 Gene Expression Analysis in Response to Intra-Articular CFA 
6.3.2.1 RNA Isolation and cDNA Conversion 
Following collection, samples from both day 1 collection and day 7 collection were snap 
frozen on dry ice and stored at -80 ᵒC until subsequent analysis took place. On the day 
of experiment, samples were prevented from defrosting and kept on dry ice until RLT 
plus buffer + β-mercaptoethanol had been added, at which point they were transferred 
to wet ice. 
6.3.2.2 L3, L4, L5 DRG Samples 
DRG RNA was isolated using the RNeasy plus micro kit according to the manufacturer’s 
instructions. Samples were homogenised in 700 µL RLT plus buffer + β-mercaptoethanol, 
first using a 19 g needle, followed by a 25 g needle until the DRG tissue was visually 
dispersed completely. Following complete homogenisation, the lysate was centrifuged 
at full speed for 3 min (Eppendorf centrifuge 5424) before the resulting supernatant was 
collected and an equal volume of 70 % ethanol added. The subsequent steps, including 
quantification on the Agilent 2100 Bioanalyzer, followed the same process as outlined 
in section 3.3.4.  
Only samples with a RIN < than 7 were taken forward for further analysis. Based on this 
quantification 15 ng of RNA was reverse transcribed. cDNA samples were diluted 2-fold 
in RNase-free water and kept at 4 ᵒC until ready for use.  
6.3.2.3 Fat Pad Samples 
Fat pad RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, 74134) according to 
the manufacturer’s instructions. Samples were homogenised in 350 µL RLT plus buffer + 
β-mercaptoethanol, first using a 19 g needle, followed by a 25 g needle until the fat pad 
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tissue was visually dispersed completely. Following complete homogenisation, the 
lysate was centrifuged at full speed for 3 min (Eppendorf centrifuge 5424) before the 
resulting supernatant was collected. The homogenised lysate was transferred to a gDNA 
Eliminator spin column and centrifuged for 30 s at 8000 g (Eppendorf centrifuge 5424). 
The column was discarded and the flow through saved. An equal volume of 70 % ethanol 
was added, and the sample transferred to an RNeasy Mini spin column prior to being 
centrifuged for 15 s at 8000 g (Eppendorf centrifuge 5424). The sample was transferred 
to an RNeasy spin column, centrifuged for 15 s at 8000 g (Eppendorf centrifuge 5424) 
and the flow-through discarded. At each of the following steps the flow through was 
discarded. The column was washed with 700 µL RW1 buffer, centrifuged for 15 s at 8000 
g (Eppendorf centrifuge 5424), followed by 500 µL RPE buffer and centrifuged once 
more (same settings). Subsequently, 500 µL RPE buffer was added to the column and 
centrifuged for 2 min at 8000 g (Eppendorf centrifuge 5424) to further wash the 
membrane. At this point the column was transferred to a new collection tube and 
centrifuged at full speed for 1 min in order to fully air dry the membrane. Finally, the 
column was placed in a new 1.5 mL collection tube and 40 µL RNase-free water added 
directly to the centre of the membrane. To elute the RNA, the column was spun for a 
final time at 8000 g for 1 min (Eppendorf centrifuge 5424).  
Quantification and sample quality assessment of RNA was conducted as described above 
(section 6.3.2.2), with the exception that 25 ng of RNA was reverse transcribed.  
6.3.2.4 RT-qPCR 
Quantification of gene transcripts, for both DRG and fat pad cDNA samples, used the 
same TaqMan technology and protocol as previously described in section 3.3.4.2. Mouse 
gene transcripts analysed are listed below (Table 13, 14 and 15) and 18s used as the 
248 
 
housekeeping control gene. A blank sample of water was used as a negative control in 
all experiments. Where possible the assays selected were those recommended by 
Applied Biosystems and ones whose probes spanned an exon junction, and therefore 
would not detect any genomic DNA (denoted by _m1 within the catalogue numbers of 
Table 13, 14 and 15). For the fat pad samples, either leptin or adiponectin was quantified 
as a positive control to ensure that the correct tissue type was collected.  
6.3.2.5 Data Analysis 
mRNA transcripts were normalised to the expression of the housekeeping gene 18s 
using the ∆∆Ct method and data expressed as ∆∆Ct changes from the basal condition. 














Table 13. List of mouse gene transcripts and the associated catalogue reference number used for L3, L4 and L5 DRG 
tissue (following intra-articular CFA administration) day 1 and day 7. 
Gene Transcript 
Applied Biosystems Catalogue 
Number 
Vgf 














P2X Purinoceptor 4 
Mm00501787_m1 
Trpv1 




Integrin Alpha M 
Mm00434455_m1 
F2rl1 








Nerve Growth Factor Receptor 
Mm01219406_m1 
Ngf 
Nerve Growth Factor 
Mm00443039_m1 
Tnf 
Tumour Necrosis Factor 
Mm00443258_m1 
Calca 




Sodium Voltage-Gated Channel 
Alpha Subunit 10 
Mm00501467_m1 
Tnfrsf1a 




Tachykinin Precursor 1 
Mm01166996_m1 
Cd14 







Table 14. List of mouse gene transcripts and the associated catalogue reference number used for knee fat pad 
samples (following intra-articular CFA administration) at day 1. 
Gene Transcript 












C-X-C Motif Chemokine 5 
Mm00436451_g1 
Ccl3 
Chemokine (C-C Motif) Ligand 3 
Mm00441259_g1 
Ccl12 
Chemokine (C-C Motif) Ligand 12 
Mm01617100_m1 
Itgam 
Integrin Alpha M 
Mm00434455_m1 
Ngf 
Nerve Growth Factor 
Mm00443039_m1 
Tnf 








Colony Stimulating Factor 3 
Mm00438334_m1 
Cd14 
Cluster of Differentiation 14 
Mm00438094_g1 
Calca 




















Table 15. List of mouse gene transcripts and the associated catalogue reference number used for knee fat pad 
samples (following intra-articular CFA administration) at day 7. 
Gene Transcript 
Applied Biosystems Catalogue 
Number 
Ccl1 
Chemokine (C-C Motif) Ligand 1 
Mm00441236_m1 
Nos2 
Nitric Oxide Synthase 2 
Mm00440502_m1 
Ccl21 
Chemokine (C-C Motif) Ligand 21 
Mm03646971_gH 
Ngf 
Nerve Growth Factor 
Mm00443039_m1 
Tnf 
Tumour Necrosis Factor 
Mm00443258_m1 
Csf3 
Colony Stimulating Factor 3 
Mm00438334_m1 
Itgam 
Integrin Alpha M 
Mm00434455_m1 
Ccl5 
Chemokine (C-C Motif) Ligand 5 
Mm01302427_m1 
Cxcl5 
C-X-C Motif Chemokine 5 
Mm00436451_g1 
Ccl3 
































6.3.3 MSD® U-PLEX Platform for CFA Experimental Plasma Sample Analysis 
To measure the circulating levels of pain-relevant cytokines in each condition, MSD® U-
PLEX technology was utilised. The following cytokine protein levels, at day 1 and day 7, 
were collected and analysed from plasma samples; IL-6, TNFα, IL-1β, KC/GRO, MCP1, 
MIP-3α and GM-CSF (Finn et al., 2014). Briefly, plasma samples were collected in the 
following way; whole blood was collected in anticoagulant-treated tubes and mixed by 
inverting several times prior to being left for 30 mins at room temperature.  The samples 
were then centrifuged for 10 mins at 1000 g at 4 °C in order to deplete the number of 
platelets in the plasma sample.  The resulting plasma was transferred into clean 0.5 
eppendorfs and placed immediately on dry ice.  Plasma samples were stored at -80 °C 
until further processing occurred, and numerous freeze/thaw cycles actively avoided.  
The MSD assay was performed according to manufacturer’s instructions as previously 
described in section 4.3.4.  
6.3.4 Seltzer Pain Model 
Partial nerve ligation (PNL) surgeries and subsequent behavioural testing was carried 
out by Jon Hatcher from MedImmune, In Vivo Senior Research Scientist. A schematic 




Figure 54. Schematic displaying the experimental timeline of the effect of NGF/TNFα antagonism in a PNL model 
of neuropathic pain. PNL schematic modified from (Zhao et al., 2014). 
Abbreviations: PNL: partial nerve ligation; DRG: dorsal root ganglia.  
 
50 female C57BL/6 mice were used for the studies.  All mice underwent insertion of 
transponders (IPTT-300 Electronic ID, Plexx) for identification purposes at least 5 days 
before the start of the study.  Transponders were implanted sub-cutabeously under 
general anaesthetic (isoflurane, 3.5 %). Mechanical hyperalgesia was determined using 
an analgesiometer (Randall & Selitto 1957) (Ugo Basile).  An increasing force was applied 
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to the dorsal surface of each hind paw in turn until a withdrawal response was observed.  
The application of force was halted at this point and the weight in grams recorded.  Data 
was expressed as withdrawal threshold in grams for ipsilateral and contralateral paws.  
Following the establishment of baseline readings mice were divided into 2 groups with 
approximately equal ipsilateral/contralateral ratios which underwent surgery to 
partially ligate the sciatic nerve or served as sham operated controls.  Operated mice 
were anaesthetised with 3 %  isoflurane.  Following this approximately 1 cm of the left 
sciatic nerve was exposed by blunt dissection through an incision at the level of the mid-
thigh.  A suture (8/0 Virgin Silk: Ethicon) was then passed through the dorsal third of the 
nerve and tied tightly.  The incision was then closed using glue and the mice were 
allowed to recover for at least six days prior to commencement of testing.  Sham 
operated mice underwent the same protocol but following exposure of the nerve the 
mice were sutured and allowed to recover.  
Mice were tested for onset of hyperalgesia on days 7 and 10 post surgery. Any mice 
showing an ipsilateral/contralateral ratio of greater than 80 % were classed as non-
responders and removed from the study.  Following testing on day 10, mice were further 
sub-divided into groups. 
The final treatment groups were as follows; 
• Group 1: Sham operated + CAT-251 0.03 mg/kg s.c. + PBS vehicle 10 ml/kg s.c. 
(n=10) 
• Group 2: Nerve ligated + CAT-251 0.03 mg/kg s.c. + PBS vehicle 10 ml/kg s.c. (n=9) 




• Group 4: Nerve ligated + MEDI578 0.03 mg/kg s.c. + PBS vehicle 10 ml/kg s.c. 
(n=9) 
• Group 5: Nerve ligated + MEDI578 0.03 mg/kg s.c. + TNFRII-fc 0.01 mg/kg s.c. 
(n=9) 
Mice were administered PBS control or test molecules on day 13 and were re-tested for 
changes in mechanical hyperalgesia at 1 and 4 h post dose and also at 1, 4 and 7 days 
post dose.  Following testing on day 1 post dose approximately half of the mice were 
culled. DRGs (L3, L4 and L5) were removed for subsequent analysis. The remaining mice 
were culled following testing on day 7 and also underwent tissue removal as the first 
group. 
Details of drugs were as described in section 6.3.1.1, with the exceptions of CAT251 and 
MEDI578 being used at the higher dose of 0.03 mg/kg. Data analysis was performed as 
described in section 6.3.1.2. 
6.3.5 Gene Expression Analysis in Response to PNL 
Following the collection of L3, L4, L5 DRG from the above animals, samples were handled 
as for the intra-articular CFA model samples. RNA isolation, cDNA conversion and RT-
qPCR were performed as previously described in section 6.3.2. Gene transcripts 







Table 16. List of mouse gene transcripts and the associated catalogue reference number used for L3, L4, L5 DRG 
samples at day 1 and day 7 following PNL. 
Gene Transcript 









P2X Purinoceptor 4 
Mm00501787_m1 
Trpv1 




Integrin Alpha M 
Mm00434455_m1 
F2rl1 







Nerve Growth Factor Receptor 
Mm01219406_m1 
Ngf 





Tumour Necrosis Factor 
Mm00443258_m1 
Calca 




Sodium Voltage-Gated Channel 
Alpha Subunit 10 
Mm00501467_m1 
Tnfsf1a 




Tachykinin Precursor 1 
Mm01166996_m1 
Atf3 










6.3.6 Statistical Analysis 
All statistical analysis was performed using GraphPad software (version 7.04). Prior to 
any statistical analysis taking place, the data were tested for normality using the Shapiro-
Wilk normality test. Within this chapter, all data was analysed using the following 
statistical tests; One-Way ANOVA or Two-Way ANOVA followed by post-hoc correction 
tests for multiple comparisons. In all instances, data are displayed as Mean ± SEM, n 
numbers and specific post-hoc correction tests used are reported within the figure 












6.4 Results  
6.4.1 Behavioural Results from the CFA Model Support the Finding of a Superior 
Analgesic Effect when Antagonising NGF and TNFα Together in an 
Inflammatory Model of Joint Pain 
Results demonstrated a clear effect of administration of CFA 100 µg on the ipsilateral 
side, an effect which was evident throughout the 7-day period (Figure 55B and C). The 
effect of CFA was evident as early as 4 post-injection, with the weight bearing reduced 
from 7.53 ± 0.53 g to 4.89 ± 0.41 g (n=8-10 mice/group) (Figure 55B).  This effect was 
not present in the sham group or on the contralateral side (Figure 55A). The effect of 
treatment on reversal of mechanical hypersensitivity was examined using a Two-Way 
ANOVA. A significant treatment effect was present (F(4,284)=102.4, P<0.0001). When 
examining the ipsilateral/contralateral ratio, the administration of the isotype control, 
MEDI578 or TNFRII-fc failed to significantly reverse the mechanical hypersensitivity 
associated with CFA injection (Figure 55C). In the case of the combination treatment 
(ipsi/contra ratio: 82.04 ± 4.48, n=4-5 mice/group), a significant reversal from both the 
MEDI578 (ipsi/contra ratio: 43.3 ± 7.11, n=4-5 mice/group) and TNFRII-fc (ipsi/contra 
ratio: 40.17 ± 8.7, n=4-5 mice/group) alone treatment groups was observed. This effect 
was only observed at day 4 post-dosing with antagonists (Figure 55C). The reversal 
observed in the combination group at day 7 was no longer significant compared to the 
other treatment groups (MEDI578 ipsi/contra ratio: 54.76 ± 3.73, TNFRII-fc ipsi/contra 
ratio: 45.58 ± 4.84), displaying a ipsi/contra ratio of 67.36 ± 4.72 (n=4-5 mice/group) 




Figure 55. Effect of TNFRII-fc and 
MEDI578 on the reversal of intra-
articular CFA induced mechanical 
hypersensitivity. A) Effect of sham, 
CFA alone, CFA + TNFRII-fc, CFA + 
MEDI578 or CFA + TNFRII-fc + 
MEDI578 on contralateral weight 
bearing B) ipsilateral weight bearing 
or C) the ipsi/contra ratio at 4 h, 1 d, 4 
d, and 7 d post-vehicle/test 
compound administration. Data 
presented as Mean ± SEM, n= 8-10 
mice/group up to 1 d, n= 4-5 
mice/group for 4 d and 7 d. Data were 
analysed using Two-Way ANOVA 
followed by Tukey’s multiple 
comparisons test. ** P< 0.01 
compared to CFA alone, CFA + TNFRII-
fc and CFA + MEDI578.  
Abbreviations: CFA: complete 
Freund’s adjuvant; Ipsi: ipsilateral; 
Contra: contralateral.  
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6.4.2 Minimal Modulation at the Transcriptional Level Occurs Following CFA 
Administration in the L3, L4, L5 DRG 
CFA administration evoked limited DRG gene expression changes compared to sham-
operated mice at both day 1 and day 7 (Figure 56). The effect of CFA was examined using 
a Two-Way ANOVA; no overall significant CFA effect was observed (F(1,78)=3.245, 
P=0.0755). However, at day 1, a significant increase in Itgam was observed between the 
sham group and CFA only group, with an increase from -0.0025 ± 0.47 ΔΔCt (n=4 
mice/group) to 2.02 ± 0.36 ΔΔCt (n=4 mice/group) (Figure 56A). Amongst all other genes 
examined (at day 1) there was only a trend for an increase in the expression of Tnf, with 
an increase from 0.0 ± 0.21 ΔΔCt to 1.46 ± 0.22 ΔΔCt (n=4 mice/group) (Figure 56A). At 
the later time point of day 7, the above changes were no longer as evident, suggesting 
a possible resolution of earlier changes by this time point (Figure 56B).  
Administration of test compounds (MEDI578, TNFRII-fc or a combination of the two) 
following CFA administration, had no effect on the gene expression profile evoked by 
CFA administration alone (1-day post-test compound addition). This was true for both 
Ngf, Tnf, their respective receptors (Ntrk1, Ngfr, Tnfrsf1a) and Itgam (Figure 57A-F), the 
latter of which had displayed a significant increase from the sham group at day 1. Similar 
to day 1, at day 7, administration of test compounds following CFA administration, 
evoked no differential expression (compared to CFA alone) (Figure 58A-F). Data for all 




Figure 56. Transcriptional changes of DRG pain-relevant transcripts in response to intra-articular CFA 
administration. A) ∆∆CT values for both the sham (n=4 mice/group) and CFA group (n=4 mice/group) at day 1 and B) 
∆∆CT values for both the sham (n=6 mice/group) and CFA group (n=3 mice/group) at day 7. Data displayed as Mean 
± SEM. Individual data points represent individual mice. Data were analysed using Two-Way ANOVA followed by 
Sidak’s multiple comparisons test. ** P< 0.01.  
Abbreviations: DRG: dorsal root ganglia; CFA: complete Freund’s adjuvant; P2x4: P2x purinoceptor 4; Trpv1: transient 
receptor potential vanilloid 1; F2rl1: coagulation factor II receptor-like 1; Ntrk1: neurotrophin tyrosine kinase 1; Ngfr; 
nerve growth factor receptor; Calca:  calcitonin related polypeptide alpha; Scn10a: sodium voltage-gated channel 
alpha subunit 10; Tnfrsf1a: tumour necrosis factor receptor superfamily member 1a; Tac1: tachykinin precursor 1; 




Figure 57. DRG transcriptional 
changes 1-day post-vehicle or test 
compound administration in the 
mouse intra-articular CFA model. 
ΔΔCt values for A) Ngf B) Ntrk1 C) 
Ngfr D) Tnf E) Tnfrsf1a or F) Itgam 
expression. Data displayed as Mean 
± SEM, n=4 mice/group (displayed as 
individual data points). Data were 
analysed using One-Way ANOVA 
followed by Tukey’s multiple 
comparisons test. ** P<0.01, *** 
P<0.001 compared to sham group.  
Abbreviations: DRG: dorsal root 
ganglia; CFA: complete   Freund’s 
adjuvant; Ngf: nerve growth factor; 
Ntrk1: neurotrophic receptor 
tyrosine kinase 1; Ngfr: nerve growth 
factor receptor; Tnf: tumour necrosis 
factor; Tnfrsf1a: tumour necrosis 
factor receptor superfamily member 




Figure 58. DRG transcriptional 
changes 7-days post-vehicle or test 
compound administration in the 
mouse intra-articular CFA model. 
ΔΔCt values for A) Ngf B) Ntrk1 C) 
Ngfr D) Tnf E) Tnfrsf1a or F) Itgam 
expression. Data displayed as Mean 
± SEM, n=3-5 mice/group (displayed 
as individual data points). Data were 
analysed using One-Way ANOVA 
followed by Tukey’s multiple 
comparisons test.  
Abbreviations: DRG: dorsal root 
ganglia; CFA: complete   Freund’s 
adjuvant; Ngf: nerve growth factor; 
Ntrk1: neurotrophic receptor 
tyrosine kinase 1; Ngfr: nerve growth 
factor receptor; Tnf: tumour necrosis 
factor; Tnfrsf1a: tumour necrosis 
factor receptor superfamily member 
1a; Itgam: integrin subunit alpha M.
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6.4.3 Intra-articular CFA Administration Drives a Profound Inflammatory Response 
at Day 1 in the Knee Fat Pad 
In contrast to the DRG, CFA evoked marked changes in gene expression in the knee fat 
pad tissue when compared to sham-operated mice. The effect of CFA was examined 
using a Two-Way ANOVA; an overall CFA effect was observed (F(1,70)=62.95, P<0.0001). 
Significant increases in gene expression from the sham group were seen in Nos2 (0.0 ± 
0.25 ΔΔCt to 6.03 ± 0.85 ΔΔCt, n=4 mice/group), Cxcl5 (0.003 ± 0.29 ΔΔCt to 4.58 ± 0.80 
ΔΔCt, n=4 mice/group) and Ptgs2 (0.0 ± 0.42 ΔΔCt to 3.97 ± 0.84 ΔΔCt, n=4 mice/group) 
(Figure 59A). Similar to the DRG tissue, these changes appeared to be returning to their 
baseline levels at the day 7 timepoint (Figure 59B), with the above CFA-induced gene 
expression changes no longer reaching significance. One exception is the expression of 
Cd14. Our data indicates that there are higher levels of Cd14 following CFA 
administration at day 7 than at day 1 (1.87 ± 0.72 ΔΔCt (n=4 mice/group) to 6.59 ± 0.82 
ΔΔCt (n=2 mice/group). However, due to technical issues in the CFA alone group at the 
day 7 timepoint, the n number (2 mice) is too low to draw any further conclusions. 
Figure 60 displays all gene transcripts examined at day 1 in the knee fat pad. In terms of 
the test compound groups, both the TNFRII-fc and combination group behaved in a very 
similar manner to the CFA alone group. However, one effect of interest was seen in the 
MEDI578 (anti-NGF) group. Across an array of genes, we saw a consistent and 
reproducible increase in levels of expression in this group (Figure 60A-K, Table 17). These 
genes included Tnf, Ereg, Nos2, Areg, Ccl3, Itgam, Ptgs2 and Csf3. Individual ΔΔCt values 
for all groups are displayed in Table 17, and results for the MEDI578 group highlighted 
in red. In each case, combined dosing of MEDI578 with TNFRII-fc, appeared to prevent 
these MEDI578-induced gene expression increases from occurring (Figure 60A-K, Table 
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17). Additionally, this effect of MEDI578 was no longer present at day 7, possibly 
suggesting an initial acute mechanism of action, however further experiments will be 
needed to confirm this finding. There were no significant changes across the genes 
examined at day 7, data for individual genes can be found in Appendix Table 3. 
Table 17. ΔΔCt values of pain-relevant transcripts in the knee fat pad 1-day post vehicle or test compound 
administration in the intra-articular CFA model of joint pain. ΔΔCt values for each treatment group (CFA Only (n=4 
mice), CFA + TNFRII-fc (n=4 mice), CFA + MEDI578 (n=3 mice) and CFA + TNFRII-fc + MEDI578 (n=3 mice)) relative to 
the sham-operated mice. Data for the MEDI578 alone group are highlighted in red. 
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
Tnf 2.07 ± 0.62 2.28 ± 0.57 4.75 ± 0.16 1.62 ± 0.29 
Ereg 1.23 ± 1.11 0.99 ± 0.41 2.81 ± 0.37 0.41 ± 0.31 
Inos 6.03 ± 0.85 6.48 ± 0.34 10.21 ± 0.38 6.56 ± 0.56 
Areg 0.28 ± 0.57 0.32 ± 0.35 2.74 ± 0.78 0.18 ± 0.24 
Ccl3 2.33 ± 0.83 2.72 ± 0.87 6.72 ± 0.19 2.31 ± 0.59 
Itgam 0.87 ± 0.46 0.89 ± 0.34 2.95 ± 0.03 0.78 ± 0.46 
Ptgs2 3.97 ± 0.84 3.98 ± 0.62 7.42 ± 0.20 1.13 ± 0.61 
Csf3 2.26 ± 0.86 1.97 ± 0.39 4.65 ± 0.39 2.35 ± 0.41 
 
The levels of cytokines in the plasma of these test mice were examined using Two-Way 
ANOVA.  Although a significant treatment effect was observed for both TNFα and IL-6 
(F(4,33)=12.1, P<0.0001 and F(4,33)=4.4, P=0.0058 respectively), no changes were 
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observed when comparing the treatment groups with the CFA only group (Figure 61A 
and B). All other cytokines examined showed no significant differences across any of the 
groups at either time point, with levels of IL-1β being below the limits of detection 
(Appendix Figure 3). TNFα showed a significant increase from the sham group following 
CFA administration at day 1 (8.08 ± 1.12 pg/mL (n=4 mice/group) to 29.45 ± 5.13 pg/mL 
(n=4 mice/group), an effect which was unchanged by dosing with all test compounds 
(Figure 61A). A similar effect was seen at day 7 (6.39 ± 0.40 pg/mL (n=3 mice/group) to 
18.4 ± 2.37 pg/mL (n=3 mice/group)) (Figure 61A). Regarding IL-6 release, we did not 
detect a CFA-induced effect (when compared to sham). Treatment with test compounds 
did not affect CFA-induced levels of plasma IL-6 relative to the CFA only treated animals 
(Figure 61B). 
To summarise, in the DRG and knee fat pad tissue, we saw no evidence that antagonism 
of NGF or TNFα, or combined antagonism of NGF and TNFα (in animals dosed with 
MEDI578 and TNFRII-fc respectively) could differentially affect gene expression changes 
evoked by intra-articular CFA injection in mice (Figures 57, 58 and 60). Similarly, CFA-
evoked increases in plasma TNFα or IL-6 were unaffected by antagonism of NGF and 






Figure 59. Transcriptional changes of knee fat pad transcripts following intra-articular CFA administration. A) ∆∆CT 
values for both the sham (n=4 mice/group) and CFA group (n=4 mice/group) at day 1 and B) ∆∆CT values for both the 
sham (n=6 mice/group) and CFA group (n=2 mice/group) at day 7. Data displayed as Mean ± SEM. Individual data 
points represent individual mice. Data were analysed using Two-Way ANOVA followed by Sidak’s multiple 
comparisons test. **** P< 0.0001. 
Abbreviations: CFA: complete Freund’s adjuvant; Bdnf: brain-derived neurotrophic factor; Ccl1: chemokine (C-C motif) 
ligand 1; Nos2: nitrogen oxide synthase 2; Il-3: interleukin-3; Ccl21: chemokine (C-C motif) ligand 21; Ngf: nerve 
growth factor; Tnf: tumour necrosis factor; Csf3: colony-stimulating factor; Itgam: integrin subunit alpha M; Ccl5: 
chemokine (C-C) ligand 5; Cxcl5: chemokine (C-X-C motif) ligand 5; Calca: calcitonin related polypeptide alpha; Tac1: 
tachykinin precursor 1; Ccl3: chemokine (C-C motif) ligand 3; Cd14: cluster of differentiation 14. 
272 
 
Figure 60. Knee fat pad 
transcriptional changes 1-day post-
vehicle or test compound 
administration in the mouse intra-
articular CFA model. Genes 
displayed A) Ngf, B) Tnf, C) Ereg, D) 
Nos2, E) Areg, F) Cxcl5, G) Ccl3, H) 
Ccl12, I) Itgam, J) Ptgs2 and K) Csf3. 
Data displayed as Mean ± SEM, n=3-
4 mice/group (displayed as 
individual data points). Data were 
analysed using One-Way ANOVA 
followed by Tukey’s multiple 
comparisons test. * P< 0.05, ** 
P<0.01, *** P<0.001.  
Abbreviations: CFA: complete 
Freund’s adjuvant; Ngf: nerve 
growth factor; Tnf: tumour necrosis 
factor; Ereg: epiregulin; Nos2: 
nitrogen oxide synthase 2; Areg: 
amphiregulin; Cxcl5: Chemokine (C-
X-C motif) ligand 5; Ccl3: chemokine 
(C-C) ligand 3; Ccl12: chemokine (C-
C) ligand 12; Itgam: integrin subunit 
alpha M; Ptgs2: prostaglandin-
endoperoxide synthase 2; Csf3: 





Figure 61. Levels of TNFα and IL-6 in plasma following intra-articular CFA administration. A) Levels of TNFα release 
(pg/mL) or B) IL-6 release (pg/mL) in the sham group or following vehicle or test compound administration at both 
day 1 and day 7. Data displayed as Mean ± SEM, n=3-6 mice/group (displayed as individual data points). Data analysed 
using Two-Way ANOVA with Tukey’s multiple comparisons test. Lower limits of quantification (LLOQ) for these assays 
were 1.3 pg/mL (TNFα) and 4.8 pg/mL (IL-6).  













6.4.4 Behavioural Results from the Seltzer Model Support the Finding of a Superior 
Analgesic Effect when Antagonising NGF and TNFα Together  
Partial ligation of the sciatic nerve resulted in a profound mechanical hypersensitivity on 
the ipsilateral side (Figure 62B). The effect of treatment on reversal of mechanical 
hypersensitivity was examined using a Two-Way ANOVA. A significant treatment effect 
was present (F(4,284)=161.2, P<0.0001). This was clearly demonstrated when looking at 
the ipsilateral/contralateral ratio at day 7 (ipsi/contra ratio: from 107.5 ± 3.82 to 73.89 
± 4.31, n=9-10 mice/group) and day 10 post surgery (ipsi/contra ratio: 111 ± 2.21 to 70 
± 2.36, n=9-10 mice/group) (Figure 62C). This effect was not observed on the 
contralateral side (Figure 62A). The administration of a vehicle compound (CAT-251 
isotype control) had no effect on the reversal of mechanical hyperalgesia, as was the 
case for MEDI578 and TNFRII-fc by themselves (Figure 62B and C). However, combined 
dosing of MEDI578 and TNFRII-fc (at doses 0.03 mg/kg and 0.01 mg/kg respectively) 
reversed PNL-evoked mechanical hypersensitivity at 4 h (ipsi/contra ratio: 83 ± 2.55, 
n=9-10 mice/group), day 1 (89 ± 4, n=9-10 mice/group) and day 7 (82.91 ± 2.92, n=4-5 
mice/group) (Figure 62C) following administration of test compounds. However, as with 
the intra-articular CFA model of inflammatory joint pain, day 4 and day 7 represent the 
behavioural data from half the number of mice used at earlier time points due to tissue 




 Figure 62. Effect of TNFRII-fc and 
MEDI578 on the reversal of PNL 
induced mechanical hypersensitivity. 
A) Effect of sham, PNL alone, PNL+ 
TNFRII-fc, PNL + MEDI578 or PNL + 
TNFRII-fc + MEDI578 on contralateral 
weight bearing, B) ipsilateral weight 
bearing or C) the ipsi/contra ratio at 4 
h, 1 d, 4 d, and 7 d post-vehicle/test 
compound administration at day 13 
post surgery. Data presented as Mean 
± SEM, n= 9-10 mice/group up to 1 d, 
n= 4-5 mice/group for 4 d and 7 d. Data 
were analysed using Two-Way ANOVA 
followed by Tukey’s multiple 
comparisons test. ** P<0.01 compared 
to PNL surgery alone, PNL surgery + 
TNFRII-fc and PNL surgery alone + 
MEDI578. 
Abbreviations: PNL: partial nerve 




6.4.5 Partial Nerve Ligation Causes a Modest Upregulation of Several Genes in L3, L4 
and L5 DRG 
Following PNL, a significant effect of treatment was observed at day 1 (F(1,104)=14.29, 
P=0.0003). Several genes showed a trend for an increase in expression when compared 
to the sham surgery group at day 1 (Figure 63A). These included Il-6 (increase of 2.10 ± 
0.40 ΔΔCt, n=4 mice/group), Areg (increase of 1.13 ± 0.33 ΔΔCt, n=4 mice/group), F2rl1 
(increase of 1.63 ± 0.16 ΔΔCt, n=4 mice/group) and a significant increase in the 
expression of Atf3 (increase of 4.60 ± 1.82 ΔΔCt, n=4 mice/group) (Figure 63A). At day 
7, these changes were less prominent, and no genes displayed a significant change from 
the sham surgery group (Figure 63B).  
When looking at the effect of the test compounds on the above regulated genes at day 
1, there were no significant differences detected between the vehicle, MEDI578 alone, 
TNFRII-fc alone and the combination groups (Figure 64A, C, E). No significant differences 
between the test compounds were seen at day 7 (Figure 64B, D, F and H). The effects of 




Figure 63. Transcriptional changes of DRG pain-relevant transcripts in response to PNL. A) ∆∆CT values for both the 
sham (n=5 mice/group) and the PNL group (n=4 mice/group) at day 1 and B) ∆∆CT values for both the sham (n=5 
mice/group) and PNL group (n=5 mice/group) at day 7. Data displayed as Mean ± SEM. Individual data points 
represent individual mice. Data were analysed using Two-Way ANOVA followed by Sidak’s multiple comparisons test. 
**** P< 0.0001.  
Abbreviations: DRG: dorsal root ganglia; PNL: partial nerve ligation; Il-6: interleukin-6; Areg: amphiregulin; P2x4: P2x 
purinoceptor 4; Trpv1: transient receptor potential vanilloid 1; Itgam: integrin subunit alpha M; F2rl1: coagulation 
factor II receptor-like 1; Ntrk1: neurotrophic receptor tyrosine kinase 1; Ngfr: nerve growth factor receptor; Ngf: 
nerve growth factor; Tnf: tumour necrosis factor alpha; Calca: calcitonin related polypeptide alpha; Scn10a: sodium 
voltage-gated channel alpha subunit 10; Tnfrsf1a: tumour necrosis factor receptor superfamily member 1a; Tac1: 







Figure 64. DRG transcriptional changes 1-day or 7-day post-vehicle or test compound administration following PNL. 
Expression levels of Il-6 at A) day 1 and B) day 7, Areg at C) day 1 and D) day 7, F2rl1 at E) day 1 and F) day 7 and Atf3 
at G) day 1 and H) day 7. Data displayed as Mean ± SEM, n=3-5 mice/group (displayed as individual data points). Data 
were analysed using One-Way ANOVA followed by Tukey’s multiple comparisons test.  
Abbreviations: DRG: dorsal root ganglia; PNL: partial nerve ligation; Il-6: interleukin-6; Areg: amphiregulin; F2rl1: 





The principal aim of this chapter was to determine if NGF/TNFα antagonism in vivo could 
synergistically reduce behavioural read-outs of pain and/or the expression of pain-
relevant mediators/circulating cytokines. Two models of pain were used; the intra-
articular CFA model of inflammatory joint pain and the Seltzer model of neuropathic 
pain (PNL).  
Behavioural read-outs from both models (inflammatory and neuropathic) demonstrated 
a reversal in mechanical hypersensitivity following the combined blockade of NGF and 
TNFα compared to the blockade of each factor alone. This supports previous data 
collected using these models. The ability of the combination group to produce a superior 
analgesia compared to the individual components at the same dose could be a distinct 
advantage if this effect is translatable into humans. There are known adverse effects 
associated with both anti-NGF and anti-TNFα therapy in humans, including reports of 
osteonecrosis and rapidly progressive OA of the hip knee and shoulder  (Lane and Corr, 
2017) and development of infections, malignancies and cardiovascular effects (Atzeni et 
al., 2015) respectively. Therefore, a combination therapy which is efficacious at lower 
doses could substantially reduce these undesirable side effects. 
Intra-articular CFA administration evoked limited changes in the expression of pain 
transcripts in DRG at the earlier time pints of tissue collection (day 1). At the later time 
point (day 7) of tissue collection, the effect of intra-articular CFA on DRG gene expression 
was nearly non-existent. One DRG gene which was significantly induced by intra-
articular CFA (at the earlier timepoint of tissue collection) was Itgam. This molecule is 
commonly used as a marker for a range of cell types including monocytes, granulocytes, 
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neutrophils and macrophages (Yu et al., 2016). Its increase in expression following CFA 
administration may be indicative of non-neuronal cell type infiltration into the DRG 
compared to the sham group. In keeping with this, it has been shown that CFA injection 
into the hind paw of rats results in an increase of monocyte chemoattractant protein-1 
immunoreactivity in inflammatory cells within the DRG, suggesting an infiltration of non-
neuronal cell types (Jeon et al., 2008). Furthermore, CFA administration, in the hind paw 
of rats, has been shown to induce a 10-fold increase in the amount of perineuronal 
macrophages in the DRG, a finding which correlated with the level of mechanical 
hyperalgesia seen (Inglis et al., 2005a). Furthermore, the above infiltration was shown 
to be completely abolished with pre-treatment with etanercept (an anti-TNFα antibody), 
although etanercept application was shown to be ineffective if administered after 
inflammation onset. This is in line with our data which showed that despite the increase 
in Itgam expression following CFA administration, this increase was unaffected by any 
of the test compounds, including TNFRII-fc. The latter suggests that the mechanism by 
which the combination group produces superior analgesic responses is not via a 
mechanism which is preventing the infiltration of non-neuronal cells into the DRG.  
Although not significant, there was a trend for an increase in Tnf expression in the DRG 
tissue collected at day 1 following intra-articular CFA administration, suggesting that an 
inflammatory response is occurring. The above finding is corroborated by a study which 
analysed the level of gene expression across a number of pain-relevant genes in L3-L5 
rat DRG (Im et al., 2010). The authors found that across a number of rat OA knee pain 
models (MIA-induced, anterior cruciate ligament transection and surgical destabilisation 
of the medial meniscus) both Tnf and Il-1β were significantly upregulated. For example, 
following intra-articular injection of MIA in rats, Il-1β expression were increased more 
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than 20-fold and Tnf increased approximately 4-fold at the lumbar DRG level of 4/5 (Im 
et al., 2010). Interestingly, the same paper reported a significant down regulation of 
CGRP and substance P, an effect that we did not observe. This difference may be due to 
the use of small cohorts of mice in our case, or the use of the intra-articular CFA model 
as opposed to the pain models aforementioned. 
The lack of gene expression changes was somewhat unexpected due to their known 
involvement in pain states. Changes in DRG gene expression have previously been 
examined in the CFA model. One study examined the effect of intraplantar CFA 
administration in rats on DRG gene expression at day 4 post-injection (Chang et al., 
2010). Using microarrays, they were able to assay a large range of genes and showed 
that in general, genes associated with the immune and inflammatory response were 
down-regulated, whilst those associated with neuron growth and survival were 
enhanced (Chang et al., 2010). One of the main reasons we could not replicate the above 
findings could be that the CFA in our study was administered to the knee and not the 
plantar surface of the paw- as was the case in the study by Chang et al. It has previously 
been shown that a high dose of CFA into the hind paw results in multiple joints 
undergoing arthritic changes and causing systemic symptoms (Almarestani et al., 2011), 
therefore possibly producing a more widespread and perhaps a more profound 
response. Furthermore, a much broader range of genes were examined (by Chang et 
al.), while we focussed on a more limited panel of pain-related genes.  
Another reason why we may not be detecting any changes in gene expression at the 
level of the DRG may be due to an effect of dilution. An intra-articular injection into the 
knee of an inflammatory substance affects far fewer DRG neurones that those 
innervating skin (Cook et al., 2018a). One study used an intra-articular injection of Dil (a 
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fluorescent dye) to demonstrate that on average only 15.9 % of L4 DRG neurones were 
positively labelled (and thereby innervating the joint) (Miller et al., 2018), whereas an 
injection of True Blue dye into plantar surface of the paw in mice showed approximately 
60 % of DRG neurones were positively labelled (Rigaud et al., 2008). Additionally, when 
considering the ganglia as whole, only 10 % represent neurones, with the remainder 
being satellite glia cells and other non-neuronal cell types (Thakur et al., 2014). 
Therefore, important changes may be occurring to a small proportion of the cells in the 
DRG but remain undetected due to the large number of unaffected neurones and other 
cell types present within the whole DRG. As there was no effect on gene expression 
following intra-articular CFA administration, it is unsurprising that no further modulation 
was seen with any of the test compounds. One way to circumvent the above issue would 
be to incorporate a cell dye within the injection and then FACS sort the cells that were 
dye positive. This technique of using differential neuronal labelling has been previously 
shown to be successful in distinguishing damaged neurones from intact neurones 
(Reinhold et al., 2015).  
Compared to the data from the DRG, several significant changes were apparent in the 
fat pad tissue, confirming the presence of an inflammatory reaction post-CFA 
administration. The most highly regulated genes in the fat pad (post-CFA administration) 
were identified at the earlier collection time point (day 1), with increases seen in Nos2, 
Cxcl5 and Ptgs2 expression. Both Nos2 and Cxcl5 have been shown to be highly up-
regulated in the rat knee fat pad three days following monosodium iodoacetate (Dawes 
et al., 2013). The same dataset showed that the most highly up-regulated gene in this 
model (day 3) was Ereg. Ereg encodes for the protein epiregulin; a protein that belongs 
to the Epidermal Growth Factor family of peptide hormones. EREG is known to 
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contribute to a variety of physiological processes, including inflammation, wound 
healing and tissue repair via binding to the EGF receptor (EGFR) (Riese and Cullum, 
2014). A recent study showed that blockade of EGFR signalling resulted in strongly 
reduced nociceptive behaviour in mouse models of both inflammatory and chronic pain. 
Additionally, the authors demonstrate that EREG application to sensory neurones 
resulted in potentiation of capsaicin-induced calcium influx (Martin et al., 2017). In line 
with the above evidence, single nucleotide polymorphisms (SNPs) in the gene loci 
encoding for EGFR and EREG have been shown to be associated with risk of chronic pain 
conditions, for example, temporomandibular disorder (Diatchenko, 2014). Although not 
significant, our dataset also showed a trend for an increase in the expression of Ereg in 
the knee fat pad (day 1). Dawes et al. may have observed a stronger increase in the 
levels of Ereg, either due to the different pain model used (MIA opposed to CFA) or due 
to the limited number of mice used in our study. Furthermore, the increase in Ptgs2 
expression is in line with research showing that that macrophage-dependent 
inflammation is significantly reduced in adipose tissue of Ptgs2-deficient mice (Ghoshal 
et al., 2011).  
Most of the gene expression changes detected in the knee fat pad (post-CFA) at day 1 in 
our dataset were reduced at day 7, suggesting an acute response. Interestingly, at day 
7, Cd14 was more highly expressed than at day 1. Cd14 encodes the protein CD14; a cell 
surface marker primarily expressed by macrophages, and to a lesser extent neutrophils 
and dendritic cells (Ziegler-Heitbrock and Ulevitch, 1993). One study, which would 
support the temporal changes in Cd14 expression that we observed, showed an initial 
neutrophil accumulation into the articular space of the knee subsequent to intra-
articular CFA administration in rats, followed by an infiltration of macrophages observed 
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at the later time point of 5 days (Chung et al., 2016). Using flow cytometry methods, 
macrophages, T cells and mast cells have all been shown to be present within arthritic 
knee joints in their activated state (Klein-Wieringa et al., 2016) further adding to the pro-
inflammatory environment.  
At day 1 in the fat pad tissue, MEDI578 alone further enhanced CFA-induced increases 
in the expression of a number of pain-relevant genes; Tnf, Nos2, Areg, Ccl3, Itgam, Ptgs2 
and Csf3. This effect was only observed 1-day post-MEDI578 administration and was lost 
by 7-days post-administration. Furthermore, the apparent potentiating effect of 
MEDI578 on these CFA-induced genes appeared to be negated by co-administration of 
TNFRII-fc. One potential explanation for this effect may be that the expression levels of 
several pro-inflammatory genes are upregulated to compensate for the blockade of NGF 
signalling. By day 7, the system may have ‘re-adjusted’ and therefore this compensation 
is no longer required. This issue of compensation by alternative inflammatory mediators 
has been highlighted in the use of chemokine and chemokine receptor blockade in 
treating chronic synovial inflammation (Haringman and Tak, 2004). The above data 
would need to be repeated in a larger cohort of mice to determine if this is a 
reproducible effect.  
Relative to sham, intra-articular CFA administration drove an increase in plasma levels 
of TNFα. It is known that CFA administration can induce a range of pro-inflammatory 
cytokines in synovial fluid and blood (Finn et al., 2014). Similarly to TNFα, IL-6 is a 
pleiotropic inflammatory cytokine with increasing evidence to suggest a crucial role in 
pain states. Following tissue injury, IL-6 is known to be upregulated, an effect which is 
positively correlated with pain intensity (Wang et al., 2009). Intra-articular injection of 
IL-6 in rats causes a gradual increase in the responses of C-fibres supplying the knee joint 
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in response to innocuous and noxious rotation (Brenn et al., 2007) and mice that lack its 
signal transducing receptor (gp130), specifically in nociceptors, showed significantly 
reduced levels of inflammatory and tumour-induced pain (Andratsch et al., 2009). The 
use of anti-IL-6 antibodies have been shown to be effective analgesics. For example, in 
a model of experimental autoimmune encephalomyelitis (EAE), the use of the anti-IL-6 
receptor antibody MR16-1 could prevent the increase in sensitivity to pain in EAE mice, 
as measured via the von Frey test (Serizawa et al., 2018). Additionally, the use of the 
anti-IL-6 receptor antibody, tocilizumab, in patients with neuromyelitis optica 
(characterised in part by nerve pain) displayed a significant improvement in neuropathic 
pain scores following a year of treatment (Araki et al., 2014). The increase in plasma 
TNFα and IL-6 plasma levels that we observe most likely reflects the leakage of cytokines 
from the inflamed joint, therefore suggesting an ongoing state of inflammation at the 
site of pain.  
Despite the detectable increase in TNFα (post-CFA administration), there was no 
significant effect of NGF or TNFα blockade (or combination of the two) on the enhanced 
TNFα plasma levels. This indicates that this cytokine is therefore unlikely to be 
contributing to the observed analgesia in Figure 55. Doses of NGF and TNFα antagonists 
(MEDI578 and TNFRII-fc respectively) used in this study were deliberately kept low (0.01 
mg/kg and 0.03 mg/kg), to enable the detection of their efficacy only when used in 
combination. Therefore, it is not surprising that the raised TNFα plasma level is not 
reduced following treatment with TNFRII-fc. The data does however suggest that the 
mechanism of analgesia observed (driven by the combination of the two antagonists) is 
unlikely to be dependent on TNFα protein levels.  
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One explanation for a lack of effect seen from any of the treatment groups (MEDI578, 
TNFRII-fc or a combination of the two) post-CFA administration could be the collection 
of tissue at the wrong timepoint. Retrospectively, the behavioural effects of intra-
articular CFA were significant at day-4 post-CFA injection, with only a trend for reversal 
in mechanical hypersensitivity observed at day 1 and day 7 (post-CFA injection) (Figure 
51). Therefore, future studies could collect tissue at day-4 post-CFA administration and 
re-examine if there are any changes (either at the transcriptional level or in circulating 
cytokines) which correlate with the analgesia observed when MEDI578 and TNFRII-fc are 
dosed together.  
Similarly to the intra-articular CFA model of inflammatory joint pain, L3, L4 and L5 DRG 
from mice that had received a PNL of the sciatic nerve showed limited changes across 
several genes at both time points investigated. However, a recent study reported that 
within the L4 DRG (7 day post injury), 75 genes were upregulated and 131 were 
downregulated in a neuropathic pain model (Chen et al., 2017a), changes which have 
been shown to produce effects for up to 30 days (Uttam et al., 2018). Additionally, one 
study used laser-capture microdissection to separate out injured neurons from the 
whole DRG ganglia and thereby demonstrated the regulation of several novel transcripts 
(Berta et al., 2017). The primary differences between the above studies and our own, 
which may account for the differences observed, was the use of a spinal nerve ligation 
model and our relatively narrow selection of analysed genes.  
One gene that did show an increase in expression was Atf3. ATF3 is considered a reliable 
marker of neuronal damage and therefore confirmed that an injury had occurred. In a 
model of joint pain, Atf3 was highly induced, primarily showing co-localisation with 
CGRP and IB4, displaying its specificity for peptidergic neurones (Nascimento et al., 
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2011). Atf3 is also upregulated in models of neuropathic pain, with a significant level of 
Atf3 induction following spinal nerve ligation in rats (Thacker et al., 2009). It has been 
shown that transcription factors, such as ATF3, orchestrate the extensive transcriptional 
changes in neurones following an injury and induce important changes such as the 
altered regulation of ion channels (Costigan et al., 2009). 
A further consideration when examining the in vivo data is the use of TNFRII-fc as an 
antagonist for TNFα signalling. It is known that this decoy receptor is capable of not only 
binding to TNFα but also lymphotoxin (also known as TNFβ) (Mpofu et al., 2005). Similar 
to TNFα, lymphotoxin can exist in a soluble homotrimer and is known to bind to TNFR1 
and TNFR2, in addition to the herpesvirus entry mediator receptor (Calmon-Hamaty et 
al., 2011).  High levels of lymphotoxin gene expression in the synovium of RA patients, 
measured using RT-PCR, have been reported to correlate with the degree of 
inflammation and patient pain scores compared to healthy controls (O’Rourke et al., 
2008).  Furthermore, one study reported a patient suffering with RA who was resistant 
to repeated high doses of infliximab, obtaining no clinical benefit. However, when the 
patient was treated with etanercept (blocking both lymphotoxin and TNFα) the patient 
went into clinical remission of the disease (Buch et al., 2004). Although the above study 
describes the situation for just one individual patient, it highlights the potential role of 
lymphotoxin in a disease where pain is a hallmark symptom. Therefore, future work 
could examine the potential role of lymphotoxin in the superior analgesia observed with 
the bispecific blocker.  
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6.6 Summary of Chapter 
The behavioural data shown in this chapter demonstrates the previously observed 
superior analgesia (Appendix Figure 1) when antagonising NGF and TNFα at the same 
time in two models of pain; the intra-articular CFA model of inflammatory pain and the 
Seltzer model of neuropathic pain (PNL). Our data shows an increase in the expression 
levels of Itgam and Cd14, suggesting an infiltration of non-neuronal cell types in pain-
relevant tissue types and further supporting our in vitro co-culture work. However, we 
have been unable to show changes in the expression level of se 
 
veral pain-related genes in DRG/knee fat pad or cytokine plasma levels that reflect the 
behavioural changes triggered by the blockade of NGF together with TNFα. These data 
would suggest that the mechanism by which superior analgesia occurring may not be 
via regulation of transcriptional changes (in the genes examined) or circulating TNFα or 































This PhD project has attempted to dissect the mechanisms by which a dual blocker 
directed against both NGF and TNFα demonstrates superior analgesic properties (in a 
number of pain models) compared to the blockade of either factor alone. To address 
this question, the effects of NGF and TNFα, either alone or in combination, were 
assessed using a variety of in vitro techniques in adult mouse sensory DRG neurones 
cultures, murine BMDM cultures or a co-culture system of the two. Additionally, in vivo 
experiments were used to assess the combined individual antagonism of NGF and TNFα.  
We have shown that in our hands, NGF and TNFα display distinct effects on different cell 
types; NGF acts directly upon sensory DRG neurones whereas TNFα has a profound 
effect on BMDMs. We have shown that pre-treatment of neurones with NGF can 
enhance stimuli-evoked CGRP release, whereas TNFα requires the presence of BMDM 
(in a co-culture set-up). In the co-culture we have shown that the presence of BMDM, in 
conjunction with TNFα treatment, can significantly potentiate the CGRP release 
observed with NGF (over and above the NGF effect alone). Furthermore, conditioned 
medium derived from TNFα-stimulated BMDM showed modulation of purified neurones 
at the transcriptional level. These experiments suggest a likely indirect action of TNFα 
on sensory DRG neurones. This finding is contrary to some reports within the literature 
(previously described in section 3.1.2). However, our data is in line with other literature 
reporting an indirect action of TNFα. For example, mirror-image pain has been shown to 
be mediated by NGF produced from TNFα-activated satellite glia following PNI in rats 
(Cheng et al., 2014). Finally, in mouse models of chronic pain, combined blockade of NGF 
and TNFα failed to prevent increases in mRNA levels of genes indicative of non-neuronal 
cell infiltration in the knee fat pad tissue and possibly the DRG. 
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This thesis demonstrates that TNFα does not appear to have a direct action upon 
sensory DRG neurones when studied in highly purified cultures. Our work has showed 
that purified neuronal cultures do express low levels of the TNFα receptor, Tnfrsf1a, 
however, it may be possible that in order for TNFα to exert a direct effect on sensory 
neurones, an initial insult is required resulting in an upregulation of functional TNFα 
receptors. Therefore, future experiments could include culturing purified DRG neuronal 
cultures that have been extracted from mice which have undergone a partial nerve 
ligation or CFA injection and then assessing their response to TNFα stimulation.   
Additionally, this project has focussed on the TNFα signalling mediated via the TNFR1 
receptor, however, TNFα also exerts its actions via the TNFR2 receptor. Although 
evidence in the literature suggests that TNFα exerts the majority of its effect via the 
TNFR1 receptor, future work could examine if TNFR2 contributes in any way to pain-
relevant signalling e.g. determine levels of TNFR2 in purified DRG neuronal cultures and 
if this is altered following treatment with NGF/TNFα. This thesis has presented some 
intriguing data, however, as with all scientific work, there are a number of caveats to 
consider. One such caveat is the use of BMDM in the co-culture set-up. BMDM were 
used as the most quiescent form of macrophage and therefore deemed the most 
suitable for assaying a response to a range of treatments. However, in vivo, in response 
to a painful stimulus, the macrophages which are infiltrating the DRG are likely to have 
a distinct phenotype compared to the BMDM used in our model, possibly altering the 
response (Komori et al., 2011). Therefore, future work could use the CGRP paradigm to 
assess the co-culture response when using either peritoneal macrophages or activated 
peritoneal macrophages (in place of BMDM) to further investigate the above. A further 
caveat to consider is the architecture of the co-culture set-up.  Our model may closely 
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resemble changes occurring at the level of the DRG following a painful stimulus (i.e. 
infiltration of non-neuronal cell types), however, it may not resemble the environment 
at the peripheral site of injury (Dubin and Patapoutian, 2010). Additionally, in vivo, there 
are numerous other cell types involved in pain-relevant signalling pathways than merely 
the neurones and macrophages. Therefore, when drawing conclusions from the data 
presented in this thesis it is important to recognise that this multi-cellular environment 
was not recapitulated in vitro, for example, no satellite glial cells were present. In line 
with this, it may be that the TNFα-driven BMDM effects observed (e.g. increases in 
mRNA levels of pro-inflammatory cytokines, chemokines) require an additional cell type 
in order to impact the neurone, an effect that we would be missing in our current co-
culture system.  
In a broader context, a further consideration of our work is the use of rodents. The ability 
to be able to translate basic scientific research into therapies which could be effective 
at the clinical level is a key issue in the drug discovery process (Rezaee and Abdollahi, 
2017). This is an area where many previous drugs have failed. For example, NK1 
(substance P) receptor antagonists failed to exhibit efficacy in clinical trials as an 
analgesic, despite promising results in preclinical animal studies (Hill, 2000). It has also 
been shown that there is a low correlation between gene expression changes in human 
patients who have experienced burns or trauma and the corresponding mouse model 
(Burkhardt and Zlotnik, 2013). Additionally, differences between mouse and human 
nociceptors have been identified, with the co-expression of Trpv1 with TrkA found to be 
present in a much larger population of neurones in humans compared to mice (Rostock 
et al., 2017). The above highlights the need to be cautious when interpreting the data 
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collected and the need to progress the work within this thesis into higher order of 
species to confirm our findings.  
Our work highlights the importance of cross-talk between sensory neurones and non-
neuronal cell types in driving changes at the level of the nociceptor that could impact 
the development and maintenance of pain states. We have focussed on the role of 
BMDM in the above process. However, future work could utilise the co-culture set-up 
we have used in this PhD project to investigate the effect of other non-neuronal cell 
types on sensory neurone function, or to assess the interaction between nociceptors 
and multiple non-neuronal cell types to better simulate an in vivo environment. In line 
with this, the use of in vivo calcium imaging could be harnessed to study the effect of 
NGF/TNFα application on nociceptor activation within the DRG. Additionally, the effect 
of NGF/TNFα blockade on nociceptor activation following an injury or insult (i.e. PNL, 
CFA injection) could be assessed. This technique would limit the potential caveats 
associated with cellular extractions (for in vitro studies), take into account the 
complication of intact cellular networks and has previously been used to characterise 
the response of large populations of sensory neurones to a variety of innocuous and 
noxious stimuli (Chisholm et al., 2018).  
In conclusion, this thesis proposes that the mechanism(s) by which the combined 
individual blockade (of NGF and TNFα) regulates analgesia is not simply by an inhibition 
of non-neuronal cell type infiltration into pain-relevant tissue types, but more likely to 
be dependent on a combined dampening of neuronal sensitisation evoked by the TNFα-
induced macrophage secretome and the direct activity of NGF at nociceptors.  Thus, the 
interaction between NGF and TNFα signalling may significantly contribute to the 
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Appendix Figure 1. Historical data showing the successful reversal of mechanical hypersensitivity in A) an intra-articular CFA model of inflammatory joint pain or B) in a neuropathic pain model 
(PNL) when using a dual blocker against NGF and TNFα. Data displayed as Mean ± SEM, n=9-10 mice/group. Data analysed using Two-Way ANOVA followed by Bonferroni’s multiple comparisons 
test. * P<0.05, *** P<0.001 vs CAT251 control.  




Appendix Figure 2. Potassium (25 mM)-evoked CGRP release from BMDM primed with NGF (10 ng/mL, 48 h), TNFα 
(10 ng/mL, 48 h) or a combination of the two (10 ng/mL, 48 h). Potassium-evoked DRG sensory neuronal CGRP 
release in cultures with NGF (100 ng/mL, 48 h) is included as a comparison. Lower limit of quantification in this assay 
is typically < 10 pg/mL. 
Legend: CGRP: calcitonin gene-related peptide; BMDM: bone-marrow derived macrophages; NGF: nerve growth 










Appendix Table 18. DRG transcriptional changes 1-day post-vehicle or test compound administration in the mouse 
intra-articular CFA model. ΔΔCt values for each treatment group (CFA Only (n=4 mice), CFA + TNFRII-fc (n=4 mice), 
CFA + MEDI578 (n=4 mice) and CFA + TNFRII-fc + MEDI578 (n=4 mice)) relative to the sham-operated mice. Data 
displayed as Mean ± SEM.  
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
P2x4 0.38 ± 0.17 0.69 ± 0.22 0.2 ± 0.41 0.89 ± 0.07 
Trpv1 0.32 ± 0.30 1.7 ± 0.26 1.23 ± 0.43 1.33 ± 0.30 
F2rl1 -1.21 ± 0.78 0.14 ± 0.37 -0.65 ± 0.52 0.42 ± 0.10 
Calca 0.05 ± 0.44 1.48 ± 0.28 1.1 ± 0.27 0.85 ± 0.18 
Scn10a 0.06 ± 0.39 1.33 ± 0.46 0.94 ± 0.55 0.47 ± 0.19 
Tac1 0.1 ± 0.28 1.09 ± 0.32 0.62 ± 0.27 0.26 ± 0.09 











Appendix Table 2. DRG transcriptional changes 7-days post-vehicle or test compound administration in the mouse 
intra-articular CFA model.  ΔΔCt values for each treatment group (CFA Only (n=3 mice), CFA + TNFRII-fc (n=5 mice), 
CFA + MEDI578 (n=5 mice) and CFA + TNFRII-fc + MEDI578 (n=5 mice)) relative to the sham-operated mice. Data 
displayed as Mean ± SEM.  
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
P2x4 0.57 ± 0.84 0.29 ± 0.34 -0.46 ± 0.27 -0.31 ± 0.47 
Trpv1 -0.45 ± 0.83 0.20 ± 0.52 -0.71 ± 0.46 -0.41 ± 0.79 
F2rl1 -0.14 ± 0.50 -0.59 ± 0.50 -0.77 ± 0.42 0.10 ± 0.76 
Calca -0.15 ± 0.66 -0.01 ± 0.32 -0.37 ± 0.44 -0.12 ± 0.55 
Scn10a -0.49 ± 0.65 -0.13 ± 0.31 -0.10 ± 0.58 -0.43 ± 0.77 
Tac1 -0.49 ± 0.35 0.07 ± 0.27 -0.40 ± 0.39 -0.44 ± 0.39 











Appendix Table 3. Knee fat pad transcriptional changes 7-days post-vehicle or test compound administration in the 
mouse intra-articular CFA model. ΔΔCt values for each treatment group (CFA Only (n=2 mice), CFA + TNFRII-fc (n=5 
mice), CFA + MEDI578 (n=5 mice) and CFA + TNFRII-fc + MEDI578 (n=5 mice)) relative to the sham-operated mice. 
Data displayed as Mean ± SEM. 
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
Ngf 0.52 ± 0.04 0.88 ± 0.29 0.95 ± 0.39 1.14 ± 0.22 
Tnf 1.50 ± 1.21 2.72 ± 0.78 2.29 ± 0.75 3.53 ± 0.35 
Cxcl5 3.27 ± 0.91  4.9 ± 0.66 3. 16 ± 0.49 5.31 ± 0.17 
Ccl3 0.81 ± 1.19 2.35 ± 1.15 2.13 ± 1.02 3.75 ± 0.79 
Ccl1 -0.92 ± 1.15 0.66 ± 0.83 0.23 ± 0.26 1.56 ± 0.40 
Itgam 1.32 ± 0.1 2.04 ± 0.54 1.34 ± 0.46 2.33 ± 0.22 
Csf3 1.21 ± 0.85 3.25 ± 0.86 1.58 ± 0.77 3.98 ± 0.24 
Nos2 4.23 ± 1.04 5.86 ± 1.06 4.62 ± 0.84 6.89 ± 0.45 
Ccl21 -0.21 ± 0.77 -1.22 ± 0.70 -0.73 ± 0.84 -0.46 ± 1.12 










Appendix Figure 3. Levels of plasma cytokines following intra-articular CFA administration. Plasma levels of A) 
GMCSF (pg/mL), B) IL-1β (pg/mL), C) KC/GRO (pg/mL), D) MCP-1 (pg/mL) and E) MIP-3α in the sham group or following 
vehicle or test compound administration at both day 1 and day 7. Data displayed as Mean ± SEM, n=3-6 mice/group 
(displayed as individual data points). Data were analysed using Two-Way ANOVA with Tukey’s multiple comparisons 
test. Lower limits of quantification (LLOQ) for these assays were 0.16 pg/mL (GMCSF), 3.1 pg/mL (IL-1β), 4.8 pg/mL 
(KC/GRO), 1.4 pg/mL (MCP-1) and 0.1 pg/mL (MIP-3α).  
Legend: CFA: complete Freund’s adjuvant; GMCSF: granulocyte-macrophage colony-stimulating factor; IL-1β: 
interleukin-1β; KC/GRO: keratinocyte chemoattractant/growth-regulated oncogene; MCP-1: monocyte 




Appendix Table 4. DRG transcriptional changes following 1-day post-vehicle or test compound administration 
following PNL. ΔΔCt values for each treatment group (PNL Only (n=4 mice), PNL + TNFRII-fc (n=4 mice), PNL + MEDI578 
(n=4 mice) and PNL + TNFRII-fc + MEDI578 (n=5 mice)) relative to the sham-operated mice. Data displayed as Mean 
± SEM. 
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
P2x4 0.25 ± 0.72 0.09 ± 0.38 -0.44 ± 0.22 -0.46 ± 0.27 
Trpv1 0.29 ± 0.22 0.55 ± 0.23 -0.14 ± 0.39 -0.21 ± 0.54 
Calca 0.02 ± 0.24 0.19 ± 0.27 -0.22 ± 0.29 -0.61 ± 0.26 
Ngf 0.41 ± 0.05 0.4 ± 0.4 0.55 ± 0.38 0.54 ± 0.24 
Ntrk1 -0.22 ± 0.15 0.15 ± 0.50 -0.11 ± 0.19 -0.92 ± 0.45 
Ngfr 0.52 ± 0.16 0.92 ± 0.48 0.67 ± 0.39 0.04 ± 0.59 
Tnf -0.25 ± 0.59 -0.44 ± 0.28 -0.16 ± 0.24 0.26 ± 0.48 
Tnfrsf1a 0.11 ± 0.10 0.09 ± 0.32 -0.19 ± 0.14 0.05 ± 0.33 
Scn10a 0.04 ± 0.14 0.67 ± 0.49 -0.03 ± 0.17 -0.69 ± 0.58 
Itgam -0.43 ± 0.34 -0.12 ± 0.38 -0.34 ± 0.26 -0.46 ± 0.2 







Appendix Table 5. DRG transcriptional changes following 7-day post-vehicle or test compound administration 
following PNL. ΔΔCt values for each treatment group (PNL Only (n=5 mice), PNL + TNFRII-fc (n=5 mice), PNL + MEDI578 
(n=5 mice) and PNL + TNFRII-fc + MEDI578 (n=5 mice)) relative to the sham-operated mice. Data displayed as Mean 
± SEM. 
Gene 
Change from Sham Group (ΔΔCt) 







fc + MEDI578 
P2x4 0.4 ± 0.29 0.17 ± 0.12 -0.26 ± 0.3 -0.18 ± 0.26 
Trpv1 -0.19 ± 0.37 -0.11 ± 0.34 -0.40 ± 0.29 0.51 ± 0.37 
Calca -0.20 ± 0.24 -0.05 ± 0.15 -0.33 ± 0.23 0.24 ± 0.3  
Ngf 0.292 ± 0.28 0.5 ± 0.13  0.21 ± 0.21 0.63 ± 0.18 
Ntrk1 -0.54 ± 0.27 -0.36 ± 0.24 -0.76 ± 0.28 0.10 ± 0.37 
Ngfr 0.08 ± 0.30 -0.05 ± 0.28 -0.20 ± 0.28 0.68 ± 0.43 
Tnf 0.72 ± 0.27 0.46 ± 0.35 -0.92 ± 0.29 -0.22 ± 0.37 
Tnfrsf1a 0.73 ± 0.15 0.40 ± 0.20 0.19 ± 0.22 0.78 ± 0.25 
Scn10a -0.87 ± 0.32 -0.63 ± 0.12  -0.98 ± 0.24  0.19 ± 0.44 
Itgam 0.58 ± 0.22 0.05 ± 0.17  -0.08 ± 0.34 0.48 ± 0.28 
Tac1 -0.06 ± 0.22 -0.01 ± 0.17 -0.34 ± 0.27 0.18 ± 0.19 
 
 
 
